WO2014136918A1 - 酸素吸収性医療用多層容器及びバイオ医薬の保存方法 - Google Patents
酸素吸収性医療用多層容器及びバイオ医薬の保存方法 Download PDFInfo
- Publication number
- WO2014136918A1 WO2014136918A1 PCT/JP2014/055877 JP2014055877W WO2014136918A1 WO 2014136918 A1 WO2014136918 A1 WO 2014136918A1 JP 2014055877 W JP2014055877 W JP 2014055877W WO 2014136918 A1 WO2014136918 A1 WO 2014136918A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxygen
- group
- layer
- absorbing
- acid
- Prior art date
Links
- WFIPYAYPAQPNDO-UHFFFAOYSA-N O=C(c(cc1)ccc1C(OCc1ccc(CCCC2)c2c1)=O)OCc1cc(CCCC2)c2cc1 Chemical compound O=C(c(cc1)ccc1C(OCc1ccc(CCCC2)c2c1)=O)OCc1cc(CCCC2)c2cc1 WFIPYAYPAQPNDO-UHFFFAOYSA-N 0.000 description 1
- HSAKUOGQSHUPMI-UHFFFAOYSA-N O=C(c(cccc1)c1C(OCc1ccc(CCCC2)c2c1)=O)OCc1ccc(CCCC2)c2c1 Chemical compound O=C(c(cccc1)c1C(OCc1ccc(CCCC2)c2c1)=O)OCc1ccc(CCCC2)c2c1 HSAKUOGQSHUPMI-UHFFFAOYSA-N 0.000 description 1
- BVQAUIGTGPJCFB-UHFFFAOYSA-N O=C(c1cc(C(OCc2cc(CCCC3)c3cc2)=O)ccc1)OCc1cc(CCCC2)c2cc1 Chemical compound O=C(c1cc(C(OCc2cc(CCCC3)c3cc2)=O)ccc1)OCc1cc(CCCC2)c2cc1 BVQAUIGTGPJCFB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/18—Layered products comprising a layer of synthetic resin characterised by the use of special additives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/34—Layered products comprising a layer of synthetic resin comprising polyamides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/36—Layered products comprising a layer of synthetic resin comprising polyesters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D11/00—Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of plastics material
- B65D11/20—Details of walls made of plastics material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2250/00—Layers arrangement
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2250/00—Layers arrangement
- B32B2250/02—2 layers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2250/00—Layers arrangement
- B32B2250/05—5 or more layers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/40—Properties of the layers or laminate having particular optical properties
- B32B2307/412—Transparent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/50—Properties of the layers or laminate having particular mechanical properties
- B32B2307/54—Yield strength; Tensile strength
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/724—Permeability to gases, adsorption
- B32B2307/7242—Non-permeable
- B32B2307/7244—Oxygen barrier
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2439/00—Containers; Receptacles
- B32B2439/80—Medical packaging
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2553/00—Packaging equipment or accessories not otherwise provided for
Definitions
- oxygen absorber Prevents oxygen oxidation of various products that are easily altered or deteriorated by the influence of oxygen, such as food, beverages, pharmaceuticals, and cosmetics, and removes oxygen in the package that contains them for the purpose of long-term storage.
- the oxygen absorber to be used is used.
- an oxygen absorbent containing iron powder as a main reaction agent is generally used from the viewpoint of oxygen absorption capacity, ease of handling, and safety.
- this iron-based oxygen absorbent is sensitive to a metal detector, it has been difficult to use the metal detector for foreign object inspection.
- the package which enclosed the iron-type oxygen absorber has a possibility of ignition, it cannot be heated with a microwave oven.
- water is essential for the oxidation reaction of iron powder, the effect of oxygen absorption could only be exhibited if the material to be preserved was a high moisture type.
- an oxygen absorbing layer that is a thermoplastic resin layer that has been added to provide a function to absorb oxygen in the container in addition to the function of preventing oxygen permeation from the outside, such as extrusion lamination, co-extrusion lamination, and dry lamination. It is manufactured using a known manufacturing method. However, this is also a problem that it can not be detected by metal detectors used for detecting foreign substances such as food, it can not be heated with a microwave oven, and the object to be stored only exhibits high moisture content have. Furthermore, there is a problem that the internal visibility is insufficient due to the problem of opacity.
- an oxygen absorbent having an organic substance as a reaction main agent is desired.
- an oxygen absorbent containing an organic substance as a main reaction agent an oxygen absorbent containing ascorbic acid as a main agent is known (see Patent Document 2).
- an oxygen-absorbing resin composition that does not require moisture for oxygen absorption
- an oxygen-absorbing resin composition comprising a resin having a carbon-carbon unsaturated bond and a transition metal catalyst is known (see Patent Document 5). .
- injection molding injection molding
- machine parts automobile parts, electrical / electronic parts, food / medicine containers, etc. because it can produce molded bodies having complicated shapes and has high productivity.
- various plastic containers have been widely used as packaging containers because they have advantages such as light weight, transparency and easy moldability.
- a typical plastic container for example, in a container such as a beverage, an injection molded body in which a screw shape is formed on a cap so that a lid can be sufficiently tightened is frequently used.
- Patent Literature a prefilled syringe with an improved oxygen barrier property, which has an innermost layer and an outermost layer made of a polyolefin-based resin, and an intermediate layer made of a resin composition having an excellent oxygen barrier property, is presented (Patent Literature). 8).
- examples of medical containers include artificial kidney hemodialyzers (dialyzers).
- dialyzers For the housing of the dialyzer, polystyrene or polycarbonate is used as a transparent plastic that allows the contents to be clearly seen. However, in order to avoid damage due to dropping or other impact, polycarbonate having good impact resistance is more preferred (See Patent Document 10).
- Patent Document 2 has the problems that the oxygen absorption performance is low in the first place, and only the high moisture content of the object to be preserved exhibits the effect, and is relatively expensive.
- Patent Document 3 since the resin composition of patent document 3 expresses an oxygen absorption function by containing a transition metal catalyst and oxidizing a xylylene group-containing polyamide resin, the polymer chain due to oxidative degradation of the resin after oxygen absorption. There is a problem that cutting occurs and the strength of the packaging container itself is reduced. Furthermore, this resin composition has a problem that oxygen absorption performance is still insufficient, and the object to be preserved exhibits only an effect of high moisture. Further, Patent Document 4 describes a method for improving delamination, but the effect is limited. Furthermore, this resin composition has a problem that oxygen absorption performance is still insufficient, and the object to be preserved exhibits only an effect of high moisture.
- the oxygen-absorbing resin composition of Patent Document 5 generates a low molecular weight organic compound that becomes an odor component by breaking the polymer chain accompanying the oxidation of the resin in the same manner as described above, and generates odor after oxygen absorption. There's a problem.
- composition of Patent Document 6 needs to use a special material containing a cyclohexene functional group, and this material still has a problem that it is relatively easy to generate an odor.
- the medical container made of polyester resin of Patent Document 7 has relatively excellent oxygen barrier property, the oxygen barrier property is insufficient to completely block oxygen, and the polyolefin resin Compared to a container made of, the water vapor barrier property is also inferior. Moreover, this polyester resin does not have oxygen absorption performance. Therefore, when oxygen enters the container from the outside, or oxygen remains in the head space existing above the contents of the container, there is a problem that the chemical solution in the container cannot be prevented from deteriorating. is there.
- the resin composition of Patent Document 9 has a problem that, as in Patent Documents 3 and 4 described above, a decrease in strength occurs due to oxidative degradation of the resin after oxidative absorption, and the strength of the packaging container itself decreases. Yes. Furthermore, this resin composition has a problem that oxygen absorption performance is still insufficient, and the object to be preserved exhibits only an effect of high moisture.
- the housing of the dialyzer disclosed in Patent Document 10 has excellent transparency and impact resistance, but polycarbonate is insufficient in oxygen barrier property and water vapor barrier property to be applied to a container for storing and storing a chemical solution. There is a problem in terms of long-term storage of the contents.
- the medical container made of polyester resin of Patent Document 7 still has insufficient oxygen barrier properties to completely block oxygen, and compared with a container made of polyolefin resin. Inferior to water vapor barrier. Moreover, this polyester resin does not have oxygen absorption performance. Therefore, when oxygen enters the container from the outside, or oxygen remains in the head space existing above the contents of the container, there is a problem that the chemical solution in the container cannot be prevented from deteriorating. there were.
- the prefilled syringe of Patent Document 8 has insufficient oxygen barrier properties to completely block oxygen.
- middle layer does not have oxygen absorption performance. Therefore, when oxygen enters the container from the outside, or oxygen remains in the head space existing above the contents of the container, there is a problem that the chemical solution in the container cannot be prevented from deteriorating. there were.
- the conventional gas barrier multilayer container and medical multilayer container as described above have sufficient basic performance such as oxygen barrier property, water vapor barrier property, chemical adsorption property, and container durability. Rather, there are several points to improve for preserving biopharmaceuticals. Improvement is demanded from the viewpoint of storage stability of chemicals.
- the medical container made of polyester resin of Patent Document 7 has insufficient oxygen barrier property to completely block oxygen, and is inferior to water vapor barrier property as compared with a container made of polyolefin resin. .
- this polyester resin does not have oxygen absorption performance. Therefore, when oxygen enters the container from the outside, or oxygen remains in the head space existing above the contents of the container, there is a problem that the chemical solution in the container cannot be prevented from deteriorating. is there.
- the prefilled syringe of Patent Document 8 has insufficient oxygen barrier properties to completely block oxygen.
- middle layer does not have oxygen absorption performance. Therefore, when oxygen enters the container from the outside, or oxygen remains in the head space existing above the contents of the container, there is a problem that the chemical solution in the container cannot be prevented from deteriorating. is there.
- the resin composition of Patent Document 9 has a problem that strength reduction due to oxidative degradation of the resin occurs after oxygen absorption, and the strength of the packaging container itself decreases. Further, this resin composition has a problem that the oxygen absorption performance is still insufficient, and the object to be preserved exhibits only an effect of high moisture.
- the present invention has been made in view of the above circumstances, and its purpose is to have excellent oxygen barrier properties, maintain strength even during long-term storage, ensure content visibility, and reduce the amount of impurities eluted.
- the object is to provide an oxygen-absorbing medical multilayer container.
- Another object of the present invention is to provide an oxygen-absorbing medical multilayer container that has excellent oxygen barrier properties and water vapor barrier properties, maintains strength even during long-term storage, and has a small amount of impurity elution.
- Still another object of the present invention is to provide an oxygen-absorbing medical multilayer container that has excellent oxygen barrier properties, maintains strength even during long-term storage, has a small amount of impurity elution, and has excellent interlayer adhesion. There is.
- Still another object of the present invention is to have excellent oxygen barrier properties, preferably excellent water vapor barrier performance, maintain strength even during long-term storage, and remarkably produce low molecular weight compounds after oxygen absorption.
- the object is to provide a suppressed oxygen-absorbing prefilled syringe.
- Still another object of the present invention is to prevent oxidative degradation of biopharmaceuticals during storage, to protect biopharmaceuticals from external impacts over a long period of time, to prevent contamination of biopharmaceuticals, and to preserve
- An object of the present invention is to provide a method for preserving a biopharmaceutical that can suppress a decrease in the efficacy of the biopharmaceutical later.
- a first resin layer containing a thermoplastic resin As a result of diligent investigations, the present inventors have found that a first resin layer containing a thermoplastic resin, an oxygen absorbing layer containing a predetermined oxygen-absorbing composition, and a second resin containing a thermoplastic resin.
- the present inventors have found that an oxygen-absorbing medical multilayer container having at least three layers with a resin layer in this order can solve the above-mentioned problems.
- the present invention is as follows. ⁇ 1> At least three layers of a first resin layer containing the thermoplastic resin (b1), an oxygen absorbing layer containing the oxygen-absorbing composition, and a second resin layer containing the thermoplastic resin (b2) are formed.
- An oxygen-absorbing medical multilayer container in order An oxygen-absorbing medical multilayer container, wherein the oxygen-absorbing composition contains at least one compound having a tetralin ring represented by the following general formula (1), a transition metal catalyst, and a thermoplastic resin (a).
- R 1 to R 12 each independently represents a hydrogen atom or a monovalent substituent, and the monovalent substituent includes a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, Heterocyclic group, cyano group, hydroxy group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, thiol group, alkylthio group, arylthio group, heterocyclic thio group, imide And at least one selected from the group consisting of a substituent represented by the following general formula (1a) and a substituent represented by the following general formula (1b), and these further have a substituent.
- R each independently represents a monovalent substituent, and the monovalent substituent includes a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, Aryl group, heterocyclic group, cyano group, hydroxy group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, thiol group, alkylthio group, arylthio group, heterocyclic thio
- R each independently represents a monovalent substituent, and the monovalent substituent includes a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, Aryl group, heterocyclic group, cyano group, hydroxy group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, thiol group, alkylthio group, arylthio group, heterocyclic
- W is a bond or a divalent organic group
- the divalent organic group is an aromatic hydrocarbon group, a saturated or unsaturated alicyclic hydrocarbon group, a linear or branched saturated or unsaturated group.
- Saturated fat Group hydrocarbon group and heterocyclic group at least selected from the group consisting of —C ( ⁇ O) —, —OC ( ⁇ O) —, —N (H) C ( ⁇ O) —, and any combination thereof.
- ⁇ 5> The tetralin ring represented by the general formula (1) with respect to the total amount of the compound having the tetralin ring represented by the general formula (1) and the thermoplastic resin (a) in the oxygen-absorbing composition.
- ⁇ 6> The oxygen-absorbing medicine according to any one of ⁇ 1> to ⁇ 5>, wherein the transition metal catalyst includes at least one transition metal selected from the group consisting of manganese, iron, cobalt, nickel, and copper. Multi-layer container.
- the amount of the transition metal catalyst is 100 parts by mass of the total amount of the compound having a tetralin ring represented by the general formula (1) and the thermoplastic resin (a).
- the oxygen-absorbing composition thermoplastic resin (a) is at least one selected from the group consisting of polyolefins, polyesters, polyamides, ethylene-vinyl alcohol copolymers, plant-derived resins, and chlorine-based resins.
- thermoplastic resin (b1) is a polyolefin (PO1), The oxygen-absorbing medical multilayer container according to any one of ⁇ 1> to ⁇ 8>, wherein the thermoplastic resin (b2) is a polyolefin (PO2).
- thermoplastic resin (b1) is polyester (PES1), The oxygen-absorbing medical multilayer container according to any one of ⁇ 1> to ⁇ 8>, wherein the thermoplastic resin (b2) is polyester (PES2).
- the dicarboxylic acid unit is terephthalic acid, isophthalic acid, 1,3-naphthalenedicarboxylic acid, 1,4-naphthalenedicarboxylic acid, A unit derived from one or more dicarboxylic acids selected from the group consisting of 1,5-naphthalenedicarboxylic acid, 2,6-naphthalenedicarboxylic acid, 2,7-naphthalenedicarboxylic acid, and ester-forming derivatives thereof.
- the oxygen-absorbing medical multi-layer container is an oxygen-absorbing prefilled syringe in which a medicine is accommodated in a sealed state in advance, and the sealed state can be released in use to dispense the medicine.
- the oxygen-absorbing medical multilayer container according to any one of to ⁇ 8>.
- ⁇ 13> A method for storing a biopharmaceutical, wherein the biopharmaceutical is stored in the oxygen-absorbing medical multilayer container according to any one of ⁇ 1> to ⁇ 12>.
- the oxygen-absorbing medicine has excellent oxygen absorption performance, has excellent oxygen barrier performance, maintains strength even during long-term storage, ensures content visibility, and has a small amount of impurity elution.
- a multi-layer container can be provided.
- an oxygen-absorbing multilayer medical container having excellent water vapor barrier properties and an oxygen-absorbing multilayer medical multilayer container that is insensitive to a metal detector are also realized.
- the oxygen-absorbing medical treatment has excellent water vapor barrier properties, excellent oxygen-absorbing performance, has excellent oxygen-barrier performance, maintains strength even during long-term storage, and has a small amount of impurity elution.
- a multi-layer container can be provided.
- an oxygen-absorbing multilayer injection molded article that is excellent in visibility inside the container and is insensitive to a metal detector can be realized.
- an oxygen-absorbing medical multilayer having excellent oxygen-barrier performance having excellent oxygen-absorbing performance, maintaining strength even during long-term storage, having a small amount of impurity elution, and having excellent interlayer adhesion A container can be provided.
- an oxygen-absorbing multilayer injection molded article that is excellent in visibility inside the container and is insensitive to a metal detector can be realized.
- the present invention has an excellent oxygen barrier property, preferably also has an excellent water vapor barrier performance, maintains strength even during long-term storage, and remarkably suppresses the generation of low molecular weight compounds after oxygen absorption.
- An oxygen-absorbing prefilled syringe can be provided.
- the oxygen absorption prefilled syringe which is excellent in the visibility inside a container and is insensitive to a metal detector is also implement
- oxidative degradation of a biopharmaceutical during storage can be prevented, the biopharmaceutical can be protected from external impacts over a long period of time, contamination of the biopharmaceutical can be suppressed, It is possible to provide a method for preserving a biopharmaceutical that can suppress a decrease in the drug efficacy.
- the biopharmaceutical being stored can be sufficiently visually recognized, and a storage method that is insensitive to a metal detector is also realized.
- the present embodiment a mode for carrying out the present invention (hereinafter simply referred to as “the present embodiment”) will be described in detail.
- the following embodiments are examples for explaining the present invention, and are not intended to limit the present invention to the following contents.
- the present invention can be implemented with appropriate modifications within the scope of the gist thereof.
- the oxygen-absorbing medical multilayer container of this embodiment includes a first resin layer (layer B) containing a thermoplastic resin (b), an oxygen-absorbing layer (layer A) containing an oxygen-absorbing composition, An oxygen-absorbing medical multilayer container having at least three layers in this order with a second resin layer (layer B) containing a thermoplastic resin (b),
- the oxygen-absorbing composition contains at least one compound having a tetralin ring represented by the following general formula (1), a transition metal catalyst, and a thermoplastic resin (a).
- R 1 to R 12 each independently represents a hydrogen atom or a monovalent substituent, and the monovalent substituent includes a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, Heterocyclic group, cyano group, hydroxy group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, thiol group, alkylthio group, arylthio group, heterocyclic thio group, imide And at least one selected from the group consisting of a substituent represented by the following general formula (1a) and a substituent represented by the following general formula (1b), and these further have a substituent.
- R each independently represents a monovalent substituent, and the monovalent substituent includes a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, Aryl group, heterocyclic group, cyano group, hydroxy group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, thiol group, alkylthio group, arylthio group, heterocyclic thio
- R each independently represents a monovalent substituent, and the monovalent substituent includes a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, Aryl group, heterocyclic group, cyano group, hydroxy group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, thiol group, alkylthio group, arylthio group, heterocyclic
- W is a bond or a divalent organic group
- the divalent organic group is an aromatic hydrocarbon group, a saturated or unsaturated alicyclic hydrocarbon group, a linear or branched saturated or unsaturated group.
- Saturated fat Group hydrocarbon group and heterocyclic group at least selected from the group consisting of —C ( ⁇ O) —, —OC ( ⁇ O) —, —N (H) C ( ⁇ O) —, and any combination thereof.
- M represents an integer of 0 to 4
- n represents an integer of 0 to 7
- p represents an integer of 0 to 8
- q represents an integer of 0 to 3.
- the oxygen-absorbing medical multilayer container of the present embodiment can be used as, for example, a medical container for storing content articles (stored objects).
- a medical container for storing content articles (stored objects).
- This oxygen-absorbing medical multi-layer container can absorb oxygen regardless of the presence or absence of moisture in the object to be stored, and furthermore, since there is no odor generation after oxygen absorption, it can be used for various pharmaceuticals and medical products. .
- the oxygen-absorbing medical multilayer container of the present embodiment is particularly useful for storing pharmaceuticals, biopharmaceuticals, medical products and the like that are required to be stored under a low oxygen concentration.
- the oxygen-absorbing medical multilayer container of the present embodiment includes a first resin layer (layer B) containing at least the thermoplastic resin (b), an oxygen-absorbing layer (layer A) made of an oxygen-absorbing composition, It has at least three layers in this order with the second resin layer (layer B) containing at least the thermoplastic resin (b).
- the oxygen-absorbing medical multilayer container of the present embodiment absorbs oxygen in the container, and if there is little oxygen that permeates or enters the container wall from the outside of the container, the oxygen-absorbing medical multilayer container also has this permeated or invading oxygen. It is possible to prevent alteration or the like due to oxygen of the content article (preservation object) to be absorbed and stored.
- the layer configuration in the oxygen-absorbing medical multilayer container of the present embodiment is the number of oxygen-absorbing layers (layer A) and resin layers (layer B)
- the type is not particularly limited.
- the oxygen-absorbing medical multilayer container of the present embodiment may include an arbitrary layer such as an adhesive layer (layer AD) as necessary.
- layer AD adhesive layer
- B1 / AD / B2 / A / B2 / AD / B1 The seven-layer structure may be used.
- the oxygen-absorbing layer (layer A) of the oxygen-absorbing medical multilayer container of the present embodiment includes at least a compound having a tetralin ring represented by the general formula (1) (hereinafter also simply referred to as “tetralin compound”). It is a layer containing an oxygen-absorbing composition containing one type, a transition metal catalyst, and a thermoplastic resin (a).
- examples of the monovalent substituent represented by R 1 to R 12 include a halogen atom (for example, chlorine atom, bromine atom, iodine atom), an alkyl group (preferably having 1 to 15 carbon atoms, More preferably, a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a tert-butyl group, an n-octyl group, or 2-ethylhexyl.
- a halogen atom for example, chlorine atom, bromine atom, iodine atom
- an alkyl group preferably having 1 to 15 carbon atoms, More preferably, a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, an n-propyl group, an is
- alkenyl group preferably a linear, branched or cyclic alkenyl group having 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, for example, vinyl group, allyl group
- alkynyl group preferably an alkynyl group having 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, such as an ethynyl group or a propargyl group
- an aryl group preferably An aryl group having 6 to 16 carbon atoms, more preferably 6 to 10 carbon atoms, such as a phenyl group or a naphthyl group, or a heterocyclic group (preferably having 1 to 12 carbon atoms, more preferably 2 to 2 carbon atoms).
- Monovalent groups obtained by removing one hydrogen atom from 6 5-membered or 6-membered aromatic or non-aromatic heterocyclic compounds such as 1-pyrazolyl, 1-imidazolyl, 2 -Furyl group), cyano group, hydroxy group, carboxyl group, ester group, amide group, nitro group, alkoxy group (preferably a linear or branched group having 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms) Or cyclic alkoxy groups such as methoxy group and ethoxy group), aryloxy groups (preferably having 6 to 12 carbon atoms, more preferably 6 to 8 carbon atoms, such as phenoxy group)
- An acyl group (including a formyl group, preferably an alkylcarbonyl group having 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, preferably 7 to 12 carbon atoms, more preferably 7 to 9 carbon atoms.
- Arylcarbonyl groups such as acetyl, pivaloyl and benzoyl
- amino groups preferably having 1 to 10 carbon atoms, more preferably having 1 to 6 carbon atoms, preferably having 6 to 6 carbon atoms).
- an anilino group having 6 to 8 carbon atoms preferably a heterocyclic amino group having 1 to 12 carbon atoms, more preferably 2 to 6 carbon atoms, such as an amino group, a methylamino group, an anilino group
- a thiol group an alkylthio group (preferably an alkylthio group having 1 to 10 carbon atoms, more preferably an alkylthio group having 1 to 6 carbon atoms, such as a methylthio group or an ethylthio group), aryl A thio group (preferably an arylthio group having 6 to 12 carbon atoms, more preferably an arylthio group having 6 to 8 carbon atoms, such as a phenyl
- At least one hydrogen atom is bonded to the benzyl position of the tetralin ring.
- an excellent oxygen absorption ability and the like can be expressed by the action of a hydrogen atom bonded to the benzyl position of the tetralin ring and a transition metal catalyst described later.
- Examples of the compound in which at least one hydrogen atom is bonded to the benzyl position of the tetralin ring include, for example, any one of R 1 , R 4 , R 9 and R 12 in the general formula (1) is a hydrogen atom. The compound etc. which are are mentioned.
- the hydrogen atom is a substituent T (wherein the substituent T is the same as that described for the monovalent substituent R above). It may be further substituted with the same meaning. Specific examples thereof include an alkyl group substituted with a hydroxy group (eg, hydroxyethyl group), an alkyl group substituted with an alkoxy group (eg, methoxyethyl group), and an alkyl group substituted with an aryl group (eg, benzyl).
- a hydroxy group eg, hydroxyethyl group
- an alkyl group substituted with an alkoxy group eg, methoxyethyl group
- an alkyl group substituted with an aryl group eg, benzyl
- an alkyl group substituted with a primary or secondary amino group eg, aminoethyl group
- an aryl group substituted with an alkyl group eg, p-tolyl group
- an aryl substituted with an alkyl group examples thereof include, but are not particularly limited to, an oxy group (for example, 2-methylphenoxy group).
- the carbon number described above does not include the carbon number of the substituent T.
- a benzyl group is regarded as a C 1 alkyl group substituted with a phenyl group, and is not regarded as a C 7 alkyl group substituted with a phenyl group.
- Two of the monovalent substituents R 1 to R 12 may be bonded to form a ring. Specific examples thereof include compounds in which two of R 1 to R 12 are condensed to form a 5- to 8-membered ring.
- the ring here may be any known ring structure and is not particularly limited, but is preferably an aromatic ring, aliphatic ring or heterocycle having 4 to 7 carbon atoms (more preferably , Cyclohexane ring, cycloheptane ring, acid anhydride ring (for example, succinic anhydride ring, glutaric anhydride ring, adipic anhydride ring, etc.), benzene ring, bicyclo ring, etc.). ).
- the compound having a tetralin ring represented by the general formula (1) is at least one of R 1 to R 12 .
- One is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a hydroxy group, a carboxyl group, a substituted or unsubstituted ester group, an alkoxy group, an acyl group, a substituted or unsubstituted amide group, and a substituted or unsubstituted group.
- substituted imide groups hereinafter also simply referred to as “substituent group S”
- substituent group S there are substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, hydroxy groups, carboxyl groups, alkoxy groups, substituted or unsubstituted ester groups, and substituted or unsubstituted amide groups. More preferred.
- R 1 to R 8 each independently represents a monovalent substituent, and the monovalent substituent has the same meaning as R 1 to R 12 described above, provided that Two or more of R 1 to R 8 are not bonded to form a ring.
- R 1 to R 8 are one selected from the substituent group S described above, and the other R 1 to R 8 are hydrogen atoms. More preferably, two of R 1 to R 8 are one selected from the substituent group S, and more preferably 6 of R 1 to R 8 are hydrogen atoms.
- various isomers are included.
- the structural isomers are represented by the following general formulas:
- tetralin derivatives represented by (1-2) to (1-15) can be generated, the introduction position (substitution position) of the substituent is not particularly limited.
- n represents an integer of 0 to 3
- each R independently represents a hydrogen atom or a monovalent substituent, and the monovalent substituent is an aromatic hydrocarbon group, saturated or It is at least one selected from the group consisting of an unsaturated alicyclic hydrocarbon group, a linear or branched saturated or unsaturated aliphatic hydrocarbon group, and an acyl group.
- examples of the aromatic hydrocarbon group include, but are not limited to, a phenyl group, a tolyl group, a xylyl group, a naphthyl group, an anthracenyl group, a phenanthryl group, a biphenyl group, and a fluorenyl group.
- examples of the alicyclic hydrocarbon group include a cycloalkyl group such as a cyclohexyl group and a cyclopentyl group, and a cycloalkenyl group, but are not particularly limited thereto.
- Examples of the aliphatic hydrocarbon group include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-hexyl, and n-octyl.
- Linear, branched alkyl groups such as 2-ethylhexyl group, n-decyl group, lauryl group, stearyl group, palmityl group, etc., ethenyl group, propenyl group, butenyl group, octenyl group, nonadecenyl group, pentacosenyl group
- alkenyl groups such as groups, but are not limited thereto.
- Examples of the acyl group include, but are not limited to, an acetyl group, a pivaloyl group, and a benzoyl group.
- substituents may further have a substituent, and specific examples thereof include, for example, halogen, alkoxy group, hydroxy group, carboxyl group, carboalkoxy group, amino group, acyl group, thio group (for example, alkylthio group). , Phenylthio group, tolylthio group, pyridylthio group, etc.), amino group (for example, unsubstituted amino group, methylamino group, dimethylamino group, phenylamino group, etc.), cyano group, nitro group and the like.
- substituent include, for example, halogen, alkoxy group, hydroxy group, carboxyl group, carboalkoxy group, amino group, acyl group, thio group (for example, alkylthio group). , Phenylthio group, tolylthio group, pyridylthio group, etc.), amino group (for example, unsubstituted amino group, methyl
- preferred second embodiments of the compound having a tetralin ring represented by the above general formula (1) include those having structures represented by the following general formulas (2-1) to (2-5). It is done.
- R 1 ⁇ R 8 each independently represents a hydrogen atom or a monovalent substituent
- R 1 a monovalent substituent R 1 ⁇ R 8 is as described in the general formula (1)
- arc a is the number of carbon atoms of the substituted or unsubstituted is an aromatic ring of 4 to 7, heterocyclic or acid anhydride ring.
- the arc A is preferably an aromatic ring, an aliphatic ring or a hetero ring having 4 to 7 carbon atoms. Specific examples thereof include benzene ring, cyclopentane ring, cyclohexane ring, cycloheptane ring, acid anhydride ring (succinic acid anhydride ring, glutaric acid anhydride ring, adipic acid anhydride ring) and the like.
- a preferred third embodiment of the compound having a tetralin ring represented by the above general formula (1) includes those having two or more carbonyl groups.
- Examples of the third embodiment having two or more carbonyl groups include monovalent substitution in which two or more of R 1 to R 12 in the general formula (1) are represented by the following general formula (2) It is preferably a group.
- R 1 to R 12 each independently represents a hydrogen atom or a monovalent substituent, and the monovalent substituents R 1 to R 12 have the same meanings as described above.
- R 1 to R 12 are not bonded to form a ring.
- X is one selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, an alkoxy group, a monoalkylamino group, and a dialkylamino group, and the plurality of Xs are the same. May be different or different.
- R 1 to R 12 are the following requirements (A) to (C):
- A) One or more monovalent substituents represented by the above general formula (2) are bonded to the aromatic ring of the tetralin ring, and the aliphatic ring of the tetralin ring is represented by the above general formula (2).
- One or more monovalent substituents are bonded.
- B) Two or more monovalent substituents represented by the general formula (2) are bonded to the aromatic ring of the tetralin ring.
- C Two or more monovalent substituents represented by the general formula (2) are bonded to the aliphatic ring of the tetralin ring. Those satisfying any of these are more preferable.
- X is preferably an alkoxy group represented by an —O—Z group or a monoalkylamino group represented by an NH—Z group.
- -Z represents an aromatic hydrocarbon group having 1 to 10 carbon atoms, a saturated or unsaturated alicyclic hydrocarbon group, or a linear or branched saturated or unsaturated aliphatic hydrocarbon group. It is more preferable that
- substituent R mentioned above description here is abbreviate
- n represents an integer of 0 to 3.
- n represents an integer of 0 to 7.
- n represents an integer of 0 to 7.
- n represents an integer of 0 to 7.
- a preferred fourth embodiment of the compound having a tetralin ring represented by the general formula (1) includes those having two or more tetralin rings.
- the upper limit of the tetralin ring is preferably 12 or less, and preferably 3 or less from the viewpoint of availability.
- the number of tetralin rings is more preferably 2 from the viewpoint of the balance between oxygen absorption performance and heat resistance and availability.
- a compound represented by any one selected from the group consisting of the following general formulas (4-1) to (4-6) is preferable.
- each R independently represents a monovalent substituent, and the monovalent substituent R has the same meaning as R 1 to R 12 described above.
- M represents 0 to 7, and n represents 0.
- p represents an integer of 0-4
- q represents an integer of 0-6, and one or more hydrogen atoms are bonded to the benzylic position of the tetralin ring
- X represents an aromatic hydrocarbon group, saturated or Represents a divalent group containing at least one group selected from the group consisting of an unsaturated alicyclic hydrocarbon group, a linear or branched saturated or unsaturated aliphatic hydrocarbon group and a heterocyclic group.
- Y represents an ester group or an amide group
- t represents an integer of 0 to 6.
- Examples of the substituent represented by R in the general formulas (4-1) to (4-6) include those exemplified as R 1 to R 12 in the above.
- a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a hydroxy group, a carboxyl group, an ester group, an alkoxy group, an acyl group, an amide group, and an imide group are preferable, a hydrogen atom, a substituted group Or an unsubstituted alkyl group, a substituted or unsubstituted aryl group, an alkoxy group, an ester group and an acyl group are more preferred, and a hydrogen atom, an unsubstituted alkyl group, an alkoxy group and an ester group are more preferred.
- the molecular weight of the compounds represented by the general formulas (4-1) to (4-6) is preferably 276 to 1000, more preferably 300 to 800, and still more preferably 350 to 600.
- a molecular weight of 276 or more is preferable because loss due to volatilization during use can be suppressed as compared with a molecular weight of less than 276.
- the proportion of the tetralin ring portion in the compound is higher than that when the molecular weight exceeds 1000, and the amount of oxygen absorbed per unit mass of the compound is preferably increased.
- the compounds represented by the general formulas (4-1) to (4-6) have a high boiling point and a low vapor pressure at the temperature at the time of use because loss due to volatilization at the time of use can be suppressed.
- the compound is an oxygen-absorbing composition to be described later, the vapor pressure at the kneading temperature with the thermoplastic resin is lower, and the higher the 3% weight loss temperature, the more loss due to volatilization during the production of the oxygen-absorbing composition. Since it can suppress, it is preferable.
- the 3% weight loss temperature is preferably 150 ° C or higher, more preferably 200 ° C or higher, and further preferably 250 ° C or higher.
- those having a hydrogen atom may be further substituted with the above group, for example, an alkyl group substituted with a hydroxy group (for example, a hydroxyethyl group), an alkyl substituted with an alkoxy group Group (eg, methoxyethyl group), alkyl group substituted with aryl group (eg, benzyl group), aryl group substituted with alkyl (eg, p-tolyl group), aryloxy group substituted with alkyl group ( Examples thereof include, but are not limited to, 2-methylphenoxy group.
- the carbon number mentioned above shall not include the carbon number of the further substituent.
- a benzyl group is regarded as a C 1 alkyl group substituted with a phenyl group, and is not regarded as a C 7 alkyl group substituted with a phenyl group.
- the substituent of tetralin having a substituent may have a plurality of substituents. Moreover, it is not always necessary to use a single substance, and two or more kinds may be mixed and used.
- X represents an aromatic hydrocarbon group, a saturated or unsaturated alicyclic hydrocarbon group, a linear or branched saturated or unsaturated aliphatic hydrocarbon group.
- n represents an integer of 1 to 10.
- n represents an integer of 0 to 8.
- n represents an integer of 1 to 8.
- n represents an integer of 1 to 8.
- n represents an integer of 1 to 10.
- the method for producing the compounds represented by the general formulas (4-1) to (4-6) is not limited at all, and can be produced by a known method.
- a transesterification reaction between an ester of a polycarboxylic acid having two or more carboxyl groups and a compound having a hydroxy group and a tetralin ring, a polyol having two or more hydroxy groups, and a compound having a carboxyl group and a tetralin ring are preferably exemplified.
- the tetralin ring has two or more tetralin rings, and at least one of the tetralin rings has a hydrogen atom bonded to its benzylic position. And compounds having two or more imide bonds.
- Such a compound is preferably, for example, at least one selected from the group consisting of the following general formulas (4-34) to (4-37).
- each R independently represents a monovalent substituent, and the monovalent substituent R has the same meaning as R 1 to R 12 described above.
- M is an integer from 0 to 6
- n is an integer from 0 to 3
- p is an integer from 0 to 7
- q is an integer from 0 to 2
- r is an integer from 0 to 4
- s is an integer from 0 to 5
- X represents a divalent substituent
- the divalent substituent is aromatic. It is at least one selected from the group consisting of a hydrocarbon group, a saturated or unsaturated alicyclic hydrocarbon group, a linear or branched saturated or unsaturated aliphatic hydrocarbon group, and a heterocyclic group.
- the molecular weight of the compounds represented by the general formulas (4-34) to (4-37) is not particularly limited, but is preferably 414 to 1000, more preferably 430 to 800, and still more preferably 450 to 600.
- the molecular weight is 414 or more, loss due to volatilization during use can be further suppressed.
- the molecular weight is 1000 or less, the oxygen absorption capacity is further improved.
- the compounds represented by the general formulas (4-34) to (4-37) those having a high boiling point and a low vapor pressure at the temperature during use are preferable because loss due to volatilization during use can be further suppressed. These compounds preferably have a low vapor pressure at the kneading temperature with the thermoplastic resin. Moreover, as these compounds, 3% weight loss temperature is so preferable that it is high. The 3% weight loss temperature is not particularly limited, but is preferably 150 ° C or higher, more preferably 200 ° C or higher, still more preferably 250 ° C or higher, and still more preferably 270 ° C or higher.
- the method for producing the compounds represented by the general formulas (4-34) to (4-37) is not particularly limited, and can be produced by, for example, a known method. For example, it can be obtained by reacting a diamine compound and an acid anhydride compound.
- All of the compounds having a tetralin ring represented by the general formula (1) described above have hydrogen at the benzyl position of the tetralin ring, and when used in combination with a transition metal catalyst described later, the hydrogen at the benzyl position is pulled. By pulling out, it exhibits excellent oxygen absorption ability.
- the oxygen-absorbing composition is one in which an increase in odor intensity after oxygen absorption is suppressed.
- the following oxidation reaction mechanism is assumed. That is, in the compound having a tetralin ring represented by the general formula (1), hydrogen at the benzyl position of the tetralin ring is first extracted to generate a radical, and then the benzyl position is obtained by the reaction between the radical and oxygen. It is considered that the carbon of this is oxidized to form a hydroxy group or a ketone group.
- the oxygen-absorbing composition the molecular chain of the oxygen-absorbing main agent is not broken by the oxidation reaction as in the prior art, and the structure of the compound that is the oxygen-absorbing main agent is maintained. It is presumed that the organic compound is hardly formed after oxygen absorption, and as a result, the increase in odor intensity after oxygen absorption is suppressed. Also from these viewpoints, in a compound having a tetralin ring, the larger the number of tetralin rings, the better. As a result, the number of reaction points with oxygen increases, and the oxygen absorbing ability is further improved. Further, the hydrogen at the benzyl position of the tetralin ring described above may be present on at least one tetralin ring.
- the molecular weight of the compound having a tetralin ring represented by the general formula (1) described above can be appropriately adjusted according to desired properties and substituents R 1 to R 12 to be introduced, and is not particularly limited. From the viewpoint of suppressing loss due to volatilization during use and increasing the amount of oxygen absorbed per unit mass of the compound, the molecular weight is preferably 190 to 1500, more preferably 210 to 1200, and even more preferably 250 to 1000. It is.
- the compound which has a tetralin ring represented by General formula (1) mentioned above can be used individually by 1 type or in combination of 2 or more types.
- the compounds having a tetralin ring represented by the general formula (1) those having a high boiling point, that is, a low vapor pressure at the temperature during use, are preferably used from the viewpoint of suppressing loss due to volatilization during use.
- a lower vapor pressure at the kneading temperature with the thermoplastic resin (a) is preferable because loss due to volatilization during production of the oxygen-absorbing composition can be suppressed.
- a 3% weight loss temperature can be adopted as an index of loss due to volatilization. That is, the compound preferably has a 3% weight loss temperature of 100 ° C or higher, more preferably 150 ° C or higher, and still more preferably 200 ° C or higher.
- the upper limit value of the 3% weight reduction temperature is not particularly limited.
- Compound having tetralin ring represented by general formula (1) with respect to total amount of compound having tetralin ring represented by general formula (1) and thermoplastic resin (a) described later in oxygen-absorbing composition The ratio is preferably 1 to 30% by mass, more preferably 1.5 to 25% by mass, and still more preferably 2 to 20% by mass.
- the transition metal catalyst used in the oxygen-absorbing composition can be appropriately selected from known ones as long as it can function as a catalyst for the oxidation reaction of the compound having a tetralin ring. It is not limited.
- transition metal catalysts include, for example, organic acid salts, halides, phosphates, phosphites, hypophosphites, nitrates, sulfates, oxides and hydroxides of transition metals.
- examples of the transition metal contained in the transition metal catalyst include, but are not limited to, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, ruthenium, and rhodium. Among these, manganese, iron, cobalt, nickel, and copper are preferable.
- organic acids examples include acetic acid, propionic acid, octanoic acid, lauric acid, stearic acid, acetylacetone, dimethyldithiocarbamic acid, palmitic acid, 2-ethylhexanoic acid, neodecanoic acid, linoleic acid, toluic acid, oleic acid, Examples include capric acid and naphthenic acid, but are not limited thereto.
- the transition metal catalyst is preferably a combination of these transition metals and an organic acid, the transition metal is manganese, iron, cobalt, nickel or copper, and the organic acid is acetic acid, stearic acid, 2-ethylhexanoic acid, olein A combination that is an acid or naphthenic acid is more preferred.
- a transition metal catalyst can be used individually by 1 type or in combination of 2 or more types.
- the mixture of the compound and the transition metal catalyst is processed into a powder, granule, pellet or other small piece by applying a known granulation method or molding method, and a thermoplastic resin. It can also be mixed with (a) to form layer A.
- the carrier material can be appropriately selected from those known in the art. Specific examples thereof include, for example, synthetic calcium silicate, slaked lime, activated carbon, zeolite, pearlite, diatomaceous earth, activated clay, silica, kaolin, talc, bentonite, activated alumina, gypsum, silica alumina, calcium silicate, magnesium oxide, graphite. , Powders of carbon black, aluminum hydroxide, iron oxide and the like are mentioned, but not limited thereto. Among these, synthetic calcium silicate, diatomaceous earth, silica, and activated carbon are preferably used. In addition, a carrier substance can be used individually by 1 type or in combination of 2 or more types.
- thermoplastic resin (a) a well-known thing can be used suitably, although it does not specifically limit, For example, low density polyethylene, medium density polyethylene, high density polyethylene, linear low density polyethylene, linear ultra-low Random or block copolymer of ⁇ -olefins such as density polyethylene, polypropylene, poly-1-butene, poly-4-methyl-1-pentene, or ethylene, propylene, 1-butene, 4-methyl-1-pentene Polyolefins such as maleic anhydride grafted polyethylene and maleic anhydride grafted polypropylene, etc .; ethylene-vinyl acetate copolymer, ethylene-vinyl alcohol copolymer, ethylene-vinyl chloride copolymer, ethylene- (meth) Acrylic acid copolymer and its ionic cross-linked product ), Ethylene-vinyl compound copolymers such as ethylene-methyl methacrylate copolymer; styrene resins such as
- polyester used in the oxygen-absorbing composition examples include, for example, one kind selected from a polyhydric carboxylic acid containing dicarboxylic acid and one or more kinds selected from these ester-forming derivatives and a polyhydric alcohol containing glycol. Or what consists of 2 or more types, what consists of hydroxycarboxylic acid and these ester-forming derivatives, what consists of cyclic ester, etc. are mentioned.
- the ethylene terephthalate-based thermoplastic polyester is composed of ethylene terephthalate units in the majority of ester repeating units, generally 70 mol% or more, and has a glass transition point (Tg) of 50 to 90 ° C. and a melting point (Tm) of 200 to 275.
- the oxygen-absorbing composition may further contain a radical generator and a photoinitiator as necessary in order to promote the oxygen absorption reaction.
- a radical generator include various N-hydroxyimide compounds such as N-hydroxysuccinimide, N-hydroxymaleimide, N, N′-dihydroxycyclohexanetetracarboxylic acid diimide, and N-hydroxyphthalimide.
- thermoplastic resin layer (layer B) The thermoplastic resin layer (layer B) of the oxygen-absorbing medical multilayer body of the present embodiment is a layer containing a thermoplastic resin (b).
- the content of the thermoplastic resin (b) in the layer B can be appropriately set and is not particularly limited, but is preferably 70 to 100% by mass, more preferably 80 to 100% by mass with respect to the total amount of the layer B. More preferably, it is 90 to 100% by mass.
- the adhesive layer preferably contains a thermoplastic resin having adhesiveness.
- a thermoplastic resin having adhesiveness for example, an acid modification in which a polyolefin resin such as polyethylene or polypropylene is modified with an unsaturated carboxylic acid such as acrylic acid, methacrylic acid, maleic acid, maleic anhydride, fumaric acid, itaconic acid, etc.
- the thickness of the adhesive layer is not particularly limited, but is preferably 2 to 100 ⁇ m, more preferably 5 to 90 ⁇ m, and still more preferably from the viewpoint of ensuring molding processability while exhibiting practical adhesive strength. Is 10 to 80 ⁇ m.
- the material constituting the layer B is injected from the injection cylinder, then the material constituting the layer A is injected from another injection cylinder simultaneously with the material constituting the layer B, and then the material constituting the layer B
- a multilayer injection molded body having a three-layer structure B / A / B can be manufactured.
- the material constituting the layer B is injected, then the material constituting the layer A is injected alone, and finally the necessary amount of the material constituting the layer B is injected to fill the cavity.
- a multilayer injection molded article having the structure B / A / B / A / B can be produced.
- a multilayer molded body can be obtained by a compression molding method.
- an oxygen-absorbing composition is provided in a thermoplastic resin melt, and the molten mass is made into a male mold. While supplying, it compresses with a female type
- a multilayer molded body can be obtained by an extrusion blow molding method.
- a cylindrical parison using an extrusion blow device comprising a plurality of extruders and a cylindrical die.
- the parison is extruded into a tube shape, the parison is sandwiched between molds, the parison lower part is pinched off and fused, and blown by high-pressure air or the like before being cooled, to expand the parison
- a multilayer molded body can be obtained.
- the usage mode of the oxygen-absorbing medical multilayer container of the present embodiment is not particularly limited, and can be used in various applications and forms.
- Preferred examples of usage include, but are not particularly limited to, vials, ampoules, prefilled syringes, vacuum blood collection tubes, and the like.
- preferred usage modes will be described in detail.
- the oxygen-absorbing medical multilayer container of this embodiment can be used as a vial.
- a vial is composed of a bottle, a rubber stopper, and a cap. After filling the bottle with a chemical solution, the vial is sealed with a rubber stopper, and the cap is tightened from above to seal the inside of the bottle.
- the oxygen-absorbing medical multilayer container of this embodiment can be used for the bottle portion of this vial.
- the material constituting the layer B is injected from the injection cylinder, then the material constituting the layer A is injected from another injection cylinder simultaneously with the material constituting the layer B, and then the material constituting the layer B
- a multilayer injection molded body having a three-layer structure B / A / B can be manufactured. Furthermore, by first injecting the material constituting the layer B, then injecting the material constituting the layer A alone, and finally injecting the necessary amount of the material constituting the layer B to fill the mold cavity, A multilayer injection molded article having a five-layer structure B / A / B / A / B can be produced.
- the material constituting the layer B1 is injected from the injection cylinder, then the material constituting the layer B2 is injected from another injection cylinder at the same time as the material constituting the layer B1, and then the layer A is constituted.
- the five-layer structure B1 / B2 / A / B2 / B1 A multilayer injection molded article can be produced.
- the multilayer injection molded body obtained by the above method is fitted in a final shape mold (blow mold) while being heated to some extent, and air is blown and inflated into the mold. It can be formed into a bottle shape by closely contacting and solidifying by cooling.
- the oxygen-absorbing medical multilayer container of the present embodiment can be used as an ampoule.
- an ampoule is composed of a small container having a narrow neck, and the container is hermetically sealed by filling the container with a chemical solution and then sealing the tip of the neck.
- the oxygen-absorbing medical multilayer container of this embodiment can be used for this ampoule (small container).
- injection blow molding, extrusion blow molding and the like are suitable.
- the oxygen-absorbing medical multilayer container of the present embodiment can be used as a barrel of a prefilled syringe.
- the shape of a general prefilled syringe barrel is a male luer taper nozzle to which an injection needle can be connected, a shoulder portion is formed from the nozzle base end to the cylindrical portion, and a flange is formed at the base end of the cylindrical portion. .
- the nozzle is sealed with a cap, and a gasket connected with a plunger is inserted into the cylindrical portion.
- the oxygen-absorbing medical multilayer container of this embodiment can be used for this barrel.
- an injection molding method is suitable. Specifically, first, a certain amount of material constituting the layer B is injected into the cavity of the injection mold, then a certain amount of material constituting the layer A is injected, and a certain amount of material constituting the layer B is again injected.
- a barrel can be manufactured as a multilayer injection molded article.
- the barrel and the joint may be molded as an integral part, or may be joined separately.
- the method is not particularly limited, and a known method can be adopted.
- the resin at the tip of the joint may be heated to a molten state and sandwiched with pliers or the like to be fused.
- the oxygen-absorbing medical multilayer container of the present embodiment can be used as a vacuum blood collection tube.
- the vacuum blood collection tube is composed of a tubular body and a stopper.
- the oxygen-absorbing medical multilayer container of this embodiment can be used for this tubular body.
- the material to be stored (filled material) filled in the oxygen-absorbing medical multilayer container of the present embodiment is not particularly limited.
- vitamins such as vitamin A, vitamin B2, vitamin B12, vitamin C, vitamin D, vitamin E, and vitamin K
- alkaloids such as atropine
- hormones such as adrenaline and insulin
- sugars such as glucose and maltose
- ceftriaxone Any natural product or compound such as antibiotics such as cephalosporin and cyclosporine, and benzodiazepines such as oxazolam, flunitrazepam, clothiazepam and clobazam can be filled.
- the oxygen-absorbing medical multilayer container of the present embodiment when filled with these natural products and compounds, has a small amount of adsorption of these natural products and compounds, and can suppress alteration due to oxidation, Further, transpiration of a solvent (for example, water) can be suppressed.
- a solvent for example, water
- thermoplastic resin (b1) is polyolefin (PO1)
- thermoplastic resin (b2) is polyolefin (PO2). It can be said that.
- the content article is a liquid such as an aqueous injection
- the decrease in strength due to oxidation or the like is extremely small, and the strength of the oxygen absorption layer is maintained even during long-term use, so that an oxygen-absorbing medical multilayer container that hardly causes delamination can be realized. Therefore, the oxygen-absorbing medical multilayer container of the present invention is particularly useful for storing pharmaceuticals, biopharmaceuticals, medical products and the like that are required to be stored under low oxygen concentration.
- the oxygen-absorbing layer (layer A) of the oxygen-absorbing medical multilayer container of the present embodiment includes at least a compound having a tetralin ring represented by the general formula (1) (hereinafter also simply referred to as “tetralin compound”). It is a layer containing an oxygen-absorbing composition containing one type, a transition metal catalyst, and a thermoplastic resin (a).
- Transition metal catalyst described in the first embodiment can be appropriately used.
- the resin layer (layer B; first resin layer, second resin layer) contains polyolefin (PO1, PO2).
- polystyrene resin examples include those shown for the thermoplastic resin suitably used in the layer B of the oxygen-absorbing multilayer body of the second embodiment described above.
- ring-opening polymers of cycloolefins such as norbornene or tetracyclododecene or derivatives thereof, and hydrogenated products thereof, and cycloolefins such as norbornene, tetracyclododecene or derivatives thereof, and molecules by polymerization with ethylene or propylene.
- a resin that is a copolymer in which a cyclopentyl residue or a substituted cyclopentyl residue is inserted into the chain is more preferable.
- Thermoplastic tetracyclododecene resins include ring-opening polymers of tetracyclododecene monomers, hydrogenated products thereof, addition polymers of tetracyclododecene monomers, tetracyclododecene monomers. And addition polymers of monomers and olefins.
- Thermoplastic norbornene resins are described in, for example, JP-A-03-014882, JP-A-03-122137, JP-A-04-063807, and the like.
- the polyolefin (PO1) and the polyolefin (PO2) may be the same type or different types.
- a cycloolefin polymer which is a polymer obtained by ring-opening polymerization of norbornene and hydrogenation.
- a cycloolefin copolymer that is a copolymer using borns such as norbornene and ethylene as raw materials and a copolymer using tetracyclododecene and olefins such as ethylene as raw materials is particularly preferable.
- Such COPs and COCs are described in, for example, Japanese Patent Application Laid-Open Nos. 05-317411 and 05-300939.
- COP is commercially available, for example, as “Zeonex (registered trademark)” or “ZEONOR (registered trademark)” manufactured by Nippon Zeon Co., Ltd., or as “Daikyo Resin CZ (registered trademark)” manufactured by Daikyo Seiko Co., Ltd.
- COC is commercially available, for example, as “Apel (registered trademark)” manufactured by Mitsui Chemicals, Inc.
- COP and COC show chemical properties such as heat resistance and light resistance and chemical resistance as a polyolefin resin, and physical properties such as mechanical properties, melting, flow properties, and dimensional accuracy are the same as those of amorphous resins. It is a particularly preferable material because of its characteristics.
- first resin layer and the second resin layer may further contain a thermoplastic resin other than polyolefin.
- a thermoplastic resin for example, a thermoplastic resin other than the polyolefin used in the layer A described above can be used.
- the other thermoplastic resin is preferably at least one selected from the group consisting of polyester, polyamide, ethylene-vinyl alcohol copolymer, plant-derived resin and chlorine-based resin.
- the thermoplastic resin used in the layer B of this embodiment is preferably contained in an amount of 50 to 100% by mass, more preferably 70 to 100% by mass, and still more preferably 90 to 100% by mass with respect to the total amount of the layer B. is there.
- the layers B of the oxygen-absorbing medical multilayer container of the present embodiment may be the same as or different from each other.
- the thickness of the layer B can be appropriately determined according to the application and desired performance, and is not particularly limited, but includes a drop resistance required for the multilayer body, etc. From the viewpoint of securing various physical properties such as strength and flexibility, the thickness is preferably 5 to 1000 ⁇ m, more preferably 10 to 800 ⁇ m, and still more preferably 20 to 500 ⁇ m.
- the layer B of the oxygen-absorbing medical multilayer container of the present embodiment may contain various additives known in the art in addition to the thermoplastic resin.
- optional components include desiccants, coloring pigments such as titanium oxide, dyes, antioxidants, slip agents, antistatic agents, plasticizers, stabilizers, additives such as lubricants, calcium carbonate, clay, mica, Examples thereof include fillers such as silica, deodorants and the like, but are not particularly limited thereto.
- the oxygen-absorbing medical multilayer body of this embodiment may further include an optional layer in addition to the above-described oxygen-absorbing layer (layer A) and resin layer (layer B) depending on the desired performance and the like.
- an optional layer include an adhesive layer, a metal foil, a metal vapor deposition layer, and an organic-inorganic film.
- other layers described in the first embodiment can be appropriately used.
- the thickness of the oxygen-absorbing medical multilayer container of the present embodiment is not particularly limited, but is 500 to 5000 ⁇ m from the viewpoint of enhancing oxygen absorption performance and ensuring various physical properties such as flexibility required for the injection molded article. Is more preferably 700 to 4000 ⁇ m, still more preferably 800 to 3000 ⁇ m.
- the oxygen-absorbing medical multilayer container of the present embodiment By using the oxygen-absorbing medical multilayer container of the present embodiment as a part of the components of the sealing container, the oxygen in the container is absorbed and little oxygen permeates or penetrates the container wall from the outside of the container. In some cases, however, this permeating or penetrating oxygen can be absorbed to prevent alteration of the stored content item (stored object) due to oxygen.
- the injection molded body of this embodiment may itself be molded into a container shape. Moreover, it can also shape
- the oxygen-absorbing medical multilayer container of the present embodiment exhibits oxygen absorption performance, it is preferably a storage container such as an ampoule, a vial, or a prefilled syringe.
- the material to be stored (filled material) filled in the oxygen-absorbing medical multilayer container of the present embodiment is not particularly limited.
- the details of the object to be stored are the same as those described in the first embodiment, and a duplicate description thereof is omitted here.
- thermoplastic resin (b1) is polyester (PES1)
- thermoplastic resin (b2) is polyester (PES2).
- the oxygen-absorbing medical multilayer container of the present invention is particularly useful for storing pharmaceuticals, biopharmaceuticals, medical products and the like that are required to be stored under a low oxygen concentration.
- the oxygen-absorbing medical multilayer container of the present embodiment absorbs oxygen in the container, and if there is little oxygen that permeates or enters the container wall from the outside of the container, the oxygen-absorbing medical multilayer container also has this permeated or invading oxygen. It is possible to prevent alteration or the like due to oxygen of the content article (preservation object) to be absorbed and stored.
- the layer structure in the oxygen-absorbing medical multilayer container of this embodiment is a resin layer (layer B) containing an oxygen-absorbing layer (layer A) and polyester.
- Number and type are not particularly limited.
- the oxygen-absorbing medical multilayer container of the present embodiment may include an arbitrary layer such as an adhesive layer (layer AD) as necessary.
- layer AD adhesive layer
- B1 / AD / B2 / A / B2 / AD / B1 The seven-layer structure may be used.
- the oxygen-absorbing layer (layer A) of the oxygen-absorbing medical multilayer container of the present embodiment includes at least a compound having a tetralin ring represented by the general formula (1) (hereinafter also simply referred to as “tetralin compound”). It is a layer containing an oxygen-absorbing composition containing one type, a transition metal catalyst, and a thermoplastic resin.
- the transition metal catalyst used in the oxygen-absorbing composition of the present embodiment is appropriately selected from known ones as long as it can function as a catalyst for the oxidation reaction of the compound having a tetralin ring.
- the transition metal catalyst the transition metal catalyst described in the first embodiment can be appropriately used.
- the compound, the transition metal catalyst, and the thermoplastic resin (a) can be mixed by a known method. However, preferably, the compound can be kneaded by an extruder to absorb oxygen with a good dispersion state. It can be used as a sex composition.
- the oxygen-absorbing composition of the present embodiment contains a thermoplastic resin.
- the content of the compound and the transition metal catalyst in the oxygen-absorbing composition is not particularly limited.
- the compound and the transition metal catalyst may be contained in the thermoplastic resin as they are, or the compound and the transition metal catalyst may be contained in the thermoplastic resin in a state of being supported on the above-described carrier material.
- the thermoplastic resin (a) the thermoplastic resin (a) described in the first embodiment can be appropriately used.
- the resin layer (Layer B) is a layer containing polyester (PES1, PES2).
- polyester (PES1, PES2) used in the layer B of the oxygen-absorbing multilayer body of this embodiment include one or more selected from polycarboxylic acids including dicarboxylic acids and ester-forming derivatives thereof. And those composed of one or more selected from polyhydric alcohols including glycols; those composed of hydroxycarboxylic acids and their ester-forming derivatives; those composed of cyclic esters.
- the polyester PES1 and the polyester PES2 may be of the same type or different types.
- dicarboxylic acids include oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, decanedicarboxylic acid, dodecanedicarboxylic acid, tetradecanedicarboxylic acid, hexadecanedicarboxylic acid 1,3-cyclobutanedicarboxylic acid, 1,3-cyclopentanedicarboxylic acid, 1,2-cyclohexanedicarboxylic acid, 1,3-cyclohexanedicarboxylic acid, 1,4-cyclohexanedicarboxylic acid, 2,5-norbornanedicarboxylic acid, Saturated aliphatic dicarboxylic acids exemplified by dimer acids and the like or ester-forming derivatives thereof, unsaturated aliphatic dicarboxylic acids exemplified by fumaric acid
- Aromatic dicarboxylic acids or their ester-forming derivatives 5-sodium sulfoisophthalic acid, 2-sodium sulfoterephthalic acid, 5-lithium sulfoisophthalic acid, 2-lithium sulfoterephthalic acid, 5-potassium sulfoisophthalic acid, 2- Exemplified by potassium sulfoterephthalic acid Genus sulfonate group-containing aromatic dicarboxylic acid or lower alkyl ester derivatives thereof, and the like.
- polyesters include terephthalic acid, isophthalic acid, 1,3-naphthalenedicarboxylic acid, 1,4-naphthalenedicarboxylic acid, 1,5-naphthalenedicarboxylic acid, 2,6-naphthalenedicarboxylic acid, 2,7 -It is more preferable to have units derived from one or more dicarboxylic acids selected from the group consisting of naphthalenedicarboxylic acids and their ester-forming derivatives. In addition, you may copolymerize another dicarboxylic acid as needed.
- the total amount of the above repeating units is preferably 70 mol%, more preferably 90 mol% or more of the dicarboxylic acid unit of the polyester.
- polycarboxylic acids other than these dicarboxylic acids include ethanetricarboxylic acid, propanetricarboxylic acid, butanetetracarboxylic acid, pyromellitic acid, trimellitic acid, trimesic acid, 3,4,3 ′, 4′-biphenyl. Examples thereof include tetracarboxylic acid and ester-forming derivatives thereof.
- glycols include ethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, diethylene glycol, triethylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, and 2,3-butylene glycol.
- 1,4-butylene glycol 1,5-pentanediol, neopentyl glycol, 1,6-hexanediol, 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,2 -Cyclohexanedimethanol, 1,3-cyclohexanedimethanol, 1,4-cyclohexanedimethanol, 1,4-cyclohexanediethanol, 1,10-decamethylene glycol, 1,12-dodecanediol, polyethylene glycol Aliphatic glycols exemplified by polytrimethylene glycol and polytetramethylene glycol, hydroquinone, 4,4′-dihydroxybisphenol, 1,4-bis ( ⁇ -hydroxyethoxy) benzene, 1,4-bis ( ⁇ -hydroxyethoxyphenyl) sulfone, bis (p-hydroxyphenyl) ether
- glycols ethylene glycol, 1,3-propylene glycol, 1,4-butylene glycol, and 1,4-cyclohexanedimethanol are preferably used as the main components.
- polyhydric alcohols other than these glycols include trimethylolmethane, trimethylolethane, trimethylolpropane, pentaerythritol, glycerol, hexanetriol, and the like.
- hydroxycarboxylic acid examples include lactic acid, citric acid, malic acid, tartaric acid, hydroxyacetic acid, 3-hydroxybutyric acid, p-hydroxybenzoic acid, p- (2-hydroxyethoxy) benzoic acid, 4-hydroxycyclohexanecarboxylic acid. Or ester-forming derivatives thereof.
- cyclic ester examples include ⁇ -caprolactone, ⁇ -propiolactone, ⁇ -methyl- ⁇ -propiolactone, ⁇ -valerolactone, glycolide, lactide and the like.
- ester-forming derivatives include these alkyl esters, acid chlorides, acid anhydrides and the like.
- a polyester in which the main acid component is terephthalic acid or an ester-forming derivative thereof or naphthalenedicarboxylic acid or an ester-forming derivative thereof, and the main glycol component is alkylene glycol is preferable.
- dicarboxylic acid units of the polyester preferably 70 mol% or more, more preferably 80 mol% or more, and even more preferably 90 mol% or more are units derived from terephthalic acid.
- Such a polyester is preferably a linear polyester.
- the above-mentioned polyester whose main glycol component is alkylene glycol is preferably a polyester containing 70 mol% or more of alkylene glycol in total with respect to all glycol components, more preferably a polyester containing 80 mol% or more. More preferably, it is a polyester containing 90 mol% or more.
- the alkylene glycol here may contain a substituent or an alicyclic structure in the molecular chain.
- polyester used for the layer B of the oxygen-absorbing multilayer body of the present embodiment include polyglycolic acid obtained by polycondensation of glycolic acid or methyl glycolate or ring-opening polycondensation of glycolide.
- the polyglycolic acid may be one in which other components such as lactide are copolymerized.
- the polyester-containing resin layer (layer B) may further contain a thermoplastic resin other than the polyester.
- a thermoplastic resin for example, a thermoplastic resin other than polyester used in the layer A described above can be used.
- the other thermoplastic resin is preferably at least one selected from the group consisting of polyolefin, polyamide, ethylene-vinyl alcohol copolymer, plant-derived resin, and chlorine-based resin.
- the thermoplastic resin used in the layer B of this embodiment is preferably contained in an amount of 50 to 100% by mass, more preferably 70 to 100% by mass, and still more preferably 90 to 100% by mass with respect to the total amount of the layer B. is there.
- the layers B of the oxygen-absorbing medical multilayer container of the present embodiment may be the same as or different from each other. Further, in the oxygen-absorbing medical multilayer container of the present embodiment, the thickness of the layer B can be appropriately determined according to the application and desired performance, and is not particularly limited, but is a drop required for the medical multilayer container. From the viewpoint of ensuring strength such as resistance and various physical properties such as flexibility, the thickness is preferably 5 to 1000 ⁇ m, more preferably 10 to 800 ⁇ m, and still more preferably 20 to 500 ⁇ m.
- the layer B of the oxygen-absorbing medical multilayer container of the present embodiment may contain various additives known in the art in addition to the above-described polyester and thermoplastic resin.
- optional components include desiccants, coloring pigments such as titanium oxide, dyes, antioxidants, slip agents, antistatic agents, plasticizers, stabilizers, additives such as lubricants, calcium carbonate, clay, mica, Examples thereof include fillers such as silica, deodorants and the like, but are not particularly limited thereto.
- the oxygen-absorbing medical multilayer body of this embodiment further includes an optional layer in addition to the above-described oxygen-absorbing layer (layer A) and polyester-containing resin layer (layer B) depending on the desired performance and the like. May be included.
- an arbitrary layer include an adhesive layer, a metal vapor deposition layer, and an organic-inorganic film.
- the other layers of the first embodiment described above can be used as appropriate.
- transparent vapor deposition films such as a silica and an alumina, are preferable.
- the manufacturing method of the oxygen-absorbing medical multilayer container of the present embodiment is not particularly limited, and a known method can be applied depending on the properties of various materials, the target shape, and the like.
- Various injection molding methods can be applied to produce an oxygen-absorbing medical multilayer container. Note that the details of the general injection molding of the multilayer body are the same as those described in the first embodiment, and a duplicate description is omitted here.
- the thickness of the oxygen-absorbing medical multilayer container of the present embodiment is not particularly limited, but is preferably 500 to 5000 ⁇ m from the viewpoint of enhancing oxygen absorption performance and ensuring various physical properties required for the medical container.
- the thickness is preferably 700 to 4000 ⁇ m, more preferably 800 to 3000 ⁇ m.
- the oxygen-absorbing medical multilayer container of the present embodiment By using the oxygen-absorbing medical multilayer container of the present embodiment as a part of the components of the sealing container, the oxygen in the container is absorbed and little oxygen permeates or penetrates the container wall from the outside of the container. In some cases, however, this permeating or penetrating oxygen can be absorbed to prevent alteration of the stored content item (stored object) due to oxygen.
- the injection molded body of this embodiment may itself be molded into a container shape. Moreover, it can also shape
- the oxygen-absorbing medical multilayer container of the present embodiment exhibits oxygen absorption performance, it is preferably a storage container such as an ampoule, a vial, or a prefilled syringe.
- the usage mode of the oxygen-absorbing medical multilayer container of the present embodiment is not particularly limited, and can be used in various applications and forms.
- Preferred examples of usage include, but are not particularly limited to, vials, ampoules, prefilled syringes, vacuum blood collection tubes, and the like.
- the details of the vial, the ampule, the prefilled syringe, and the vacuum blood collection tube are the same as those described in the first embodiment, and a duplicate description is omitted here.
- the material to be stored (filled material) filled in the oxygen-absorbing medical multilayer container of the present embodiment is not particularly limited.
- the details of the object to be stored are the same as those described in the first embodiment, and a duplicate description thereof is omitted here.
- the oxygen-absorbing prefilled syringe of the present embodiment is an oxygen-absorbing prefilled syringe that contains a medicine in a sealed state in advance and can release the sealed state when used to release the medicine.
- the prefilled syringe has a first resin layer containing at least a thermoplastic resin (b1), an oxygen absorbing layer containing an oxygen-absorbing composition, and a second resin layer containing at least a thermoplastic resin (b2). Having at least three layers in this order,
- the oxygen-absorbing composition contains at least one compound having a tetralin ring represented by the following general formula (1), a transition metal catalyst, and a thermoplastic resin (a). It is an oxygen-absorbing prefilled syringe.
- the oxygen-absorbing medical multilayer container previously stores the drug in a sealed state, and releases the sealed state before use to extract the drug. It can also be referred to as an oxygen-absorbing prefilled syringe that can be made.
- the oxygen-absorbing prefilled syringe of this embodiment includes a first resin layer (layer B) containing at least a thermoplastic resin (b1), an oxygen absorbing layer (layer A) containing an oxygen-absorbing composition, and a heat It has at least three layers in this order with the second resin layer (layer B) containing at least the plastic resin (b2).
- the oxygen-absorbing prefilled syringe of the present embodiment absorbs oxygen in the container, and also absorbs this permeating or penetrating oxygen when there is little oxygen that permeates or penetrates the container wall from the outside of the container. Thus, it is possible to prevent alteration or the like due to oxygen of the content item to be stored (material to be stored).
- the oxygen-absorbing prefilled syringe of the present embodiment is composed of at least a barrel for filling a chemical solution, a joint for joining an injection needle to one end of the barrel, and a plunger for pushing out the chemical solution at the time of use.
- a syringe (syringe) configured to store a medicine in a barrel in advance in a sealed state, and to open the tip side of the barrel and attach an injection needle during use is exemplified.
- the barrel can be an oxygen-absorbing laminate having at least three layers of the first resin layer, the oxygen absorption layer, and the second resin layer.
- the thickness of the container of the barrel of the prefilled syringe can be appropriately set according to the purpose and size of use, and is not particularly limited. In general, from the viewpoint of long-term storage stability of the chemical solution, moldability, and operability of the syringe, the thickness is preferably about 0.5 to 20 mm, more preferably about 0.5 to 5 mm. Moreover, even if thickness is uniform, what changed thickness may be sufficient. Further, another gas barrier film or a light shielding film may be further formed on the barrel surface for the purpose of long-term storage stability. These arbitrary films and methods for forming them are described in, for example, Japanese Patent Application Laid-Open No. 2004-323058.
- the oxygen-absorbing layer (layer A) of the oxygen-absorbing medical multilayer container of the present embodiment includes at least one compound having a tetralin ring represented by the general formula (1), a transition metal catalyst, and a thermoplastic resin ( It is a layer containing an oxygen-absorbing composition containing a).
- This oxygen-absorbing composition can remarkably suppress the formation of low molecular weight compounds after oxygen absorption. Although the reason is not clear, for example, the following oxidation reaction mechanism is assumed.
- the oxygen-absorbing composition of this embodiment contains a thermoplastic resin (a).
- the content of the compound and the transition metal catalyst in the oxygen-absorbing composition is not particularly limited.
- the compound and the transition metal catalyst are contained as they are in the thermoplastic resin (a)
- the compound and the transition metal catalyst are contained in the thermoplastic resin (a) in a state where they are supported on the carrier material described above. May be.
- the thermoplastic resin (a) the thermoplastic resin (a) described in the first embodiment can be appropriately used.
- the first resin layer and the second resin layer (layer B) of the oxygen-absorbing prefilled syringe of this embodiment are layers containing a thermoplastic resin (b).
- the content of the thermoplastic resin (b) in each layer B can be appropriately set and is not particularly limited, but is preferably 70 to 100% by mass, more preferably 80 to 100% by mass with respect to the total amount of the layer B. More preferably, it is 90 to 100% by mass.
- the oxygen-absorbing prefilled syringe of this embodiment may have three or more layers B.
- the configuration of the plurality of layers B may be the same as or different from each other.
- the thickness of the layer B can be appropriately determined according to the application and desired performance, and is not particularly limited, but strength such as drop resistance required as a prefilled syringe From the viewpoint of securing various physical properties such as flexibility and flexibility, the thickness is preferably 5 to 1000 ⁇ m, more preferably 10 to 800 ⁇ m, and still more preferably 20 to 500 ⁇ m.
- thermoplastic resin can be used as the thermoplastic resin (b) of layer B of the oxygen-absorbing prefilled syringe of the present embodiment, and is not particularly limited. For example, it may be the same as or different from the thermoplastic resin (a) used in the layer A described above.
- the layer B of this embodiment preferably contains at least one thermoplastic resin selected from the group consisting of polyolefin, polyester, polyamide, ethylene-vinyl alcohol copolymer, plant-derived resin, and chlorine-based resin.
- the thermoplastic resin (b) used in the layer B of the present embodiment is preferably contained in an amount of 50 to 100% by mass, more preferably 70 to 100% by mass, and still more preferably 90 to 100%, based on the total amount of the layer B. % By mass.
- thermoplastic resin (b) for the polyolefins, polyesters, polyamides, ethylene-vinyl alcohol copolymers, plant-derived resins, and chlorine-based resins mentioned as the thermoplastic resin (b) that can be used for the layer B, the thermoplastic resins that can be used for the layer A Each of those exemplified as (a) can be used.
- the layer B of the oxygen-absorbing prefilled syringe of the present embodiment may contain various additives known in the art in addition to the thermoplastic resin.
- optional components include desiccants, coloring pigments such as titanium oxide, dyes, antioxidants, slip agents, antistatic agents, plasticizers, stabilizers, additives such as lubricants, calcium carbonate, clay, mica, Examples thereof include fillers such as silica, deodorants and the like, but are not particularly limited thereto.
- the oxygen-absorbing prefilled syringe of the present embodiment may further include an optional layer in addition to the above-described oxygen absorbing layer (layer A) and resin layer (layer B) depending on the desired performance and the like.
- an arbitrary layer include an adhesive layer, a metal vapor deposition layer, and an organic-inorganic film.
- the adhesive layer preferably contains a thermoplastic resin having adhesiveness.
- a thermoplastic resin having adhesiveness for example, an acid modification in which a polyolefin resin such as polyethylene or polypropylene is modified with an unsaturated carboxylic acid such as acrylic acid, methacrylic acid, maleic acid, maleic anhydride, fumaric acid, itaconic acid, etc.
- the thickness of the adhesive layer is not particularly limited, but is preferably 2 to 100 ⁇ m, more preferably 5 to 90 ⁇ m, and still more preferably from the viewpoint of ensuring molding processability while exhibiting practical adhesive strength. Is 10 to 80 ⁇ m.
- a metal vapor deposition layer or an organic-inorganic film on one surface of the layer B described above.
- a metal vapor deposition layer In order to ensure the content visibility, transparent vapor deposition films, such as a silica and an alumina, are preferable.
- the method for forming a vapor deposition film include physical vapor deposition methods such as vacuum vapor deposition, sputtering, and ion plating, and chemical vapor deposition methods such as PECVD, but are not particularly limited and are publicly known. This method is applicable.
- the thickness of the deposited film is preferably 5 to 500 nm, more preferably 5 to 200 nm, from the viewpoint of gas barrier properties.
- the organic-inorganic film layer is not particularly limited, but a silica-polyvinyl alcohol hybrid film produced by a sol-gel method or the like is preferable.
- the thickness of the coating film is preferably 100 nm to 50 ⁇ m, more preferably 1 to 15 ⁇ m, from the viewpoint of gas barrier properties.
- the shape of a general prefilled syringe barrel is a male luer taper nozzle to which an injection needle can be connected, a shoulder portion is formed from the nozzle base end to the cylindrical portion, and a flange is formed at the base end of the cylindrical portion. .
- the nozzle is sealed with a cap, and a gasket connected with a plunger is inserted into the cylindrical portion.
- a certain amount of resin constituting the layer B is injected into the cavity from a gate provided at the nozzle tip of the barrel barrel, and then a certain amount of the resin constituting the layer A is injected.
- the resin constituting the layer B injected earlier is cooled by the cavity and the wall surface of the core mold to form a skin layer, and the resin constituting the layer A becomes the core layer and is formed between the skin layers.
- a barrel can be manufactured as a multilayer injection molded article.
- the injection amount of the resin constituting the layer B to be injected first is preferably adjusted so that the layer A is formed closer to the base end of the cylindrical portion than the planned insertion position of the gasket to be inserted into the barrel. .
- the barrier property of the barrel is further ensured.
- the injection amount of the resin constituting the layer A is adjusted so as to be formed closer to the nozzle tip than the cap sealing planned position.
- a known method can be applied to the above-described method for producing the oxygen-absorbing laminate, and is not particularly limited.
- Various injection molding methods can be applied to produce an oxygen-absorbing medical multilayer container. Note that the details of the general injection molding of the multilayer body are the same as those described in the first embodiment, and a duplicate description is omitted here.
- the material to be stored (filled material) filled in the oxygen-absorbing prefilled syringe of the present embodiment is not particularly limited as long as it is a chemical such as a chemical solution.
- vitamins such as vitamin A, vitamin B2, vitamin B12, vitamin C, vitamin D, vitamin E, and vitamin K, alkaloids such as atropine, hormones such as adrenaline and insulin, sugars such as glucose and maltose, ceftriaxone Any natural product or compound such as antibiotics such as cephalosporin and cyclosporine, and benzodiazepines such as oxazolam, flunitrazepam, clothiazepam and clobazam can be filled.
- the oxygen-absorbing prefilled syringe of this embodiment when filled with these natural products and compounds, has a small amount of adsorption of these natural products and compounds, can suppress alteration due to oxidation, It is also possible to suppress transpiration (for example, moisture).
- the biopharmaceutical storage method of the present embodiment includes a biopharmaceutical, an oxygen-absorbing medical multilayer container comprising an oxygen-absorbing layer containing an oxygen-absorbing composition and a resin layer containing a thermoplastic resin (b).
- a biopharmaceutical storage method comprising a).
- This biopharmaceutical storage method can also be referred to as a biopharmaceutical storage method in which the biopharmaceutical is stored in the oxygen-absorbing medical multilayer container of any of the first to fourth embodiments.
- the biopharmaceutical storage method of the present embodiment uses the above-described oxygen-absorbing medical multilayer container as a biopharmaceutical storage container.
- the oxygen in the container is absorbed, and there is a small amount of oxygen that permeates or enters the container wall from the outside of the container, the permeated or invading oxygen is also absorbed and stored. It is possible to prevent deterioration of the preserved material) due to oxygen.
- This oxygen-absorbing medical multi-layer container can absorb oxygen regardless of the presence or absence of moisture in the object to be preserved, and furthermore, since no odor is generated after oxygen absorption, it can be used for various biopharmaceuticals.
- this oxygen-absorbing medical multilayer container has a very small decrease in strength due to oxidation or the like after oxygen absorption, and the strength of the oxygen-absorbing layer is maintained even in long-term use. Therefore, it is possible to realize an oxygen-absorbing medical multilayer container that hardly causes delamination. As a result, the biopharmaceutical can be protected from an external impact or the like over a long period of time.
- Such a storage method using an oxygen-absorbing medical multilayer container is particularly useful in the storage of biopharmaceuticals that are greatly affected by oxygen.
- biopharmaceuticals that can be used in the present embodiment are those created using biotechnology techniques such as cell culture techniques and genetic recombination techniques, and examples include protein drugs, nucleic acid drugs, and peptide drugs. It is done. More specifically, various monoclonal antibodies, various vaccines, interferon, insulin, growth hormone, erythropoietin, colony stimulating factor, TPA, interleukin, blood coagulation factor VIII, blood coagulation factor IX, natriuretic hormone, somatomedin, glucagon , Serum albumin, calcitonin, growth hormone releasing factor, digestive enzyme agent, inflammatory enzyme agent, antibiotics, antisense nucleic acid, antigene nucleic acid, decoy nucleic acid, aptamer, siRNA, microRNA, and biosimilars thereof (biosimilars) However, it is not particularly limited to these.
- these biopharmaceuticals When these biopharmaceuticals are filled in an oxygen-absorbing medical multilayer container, the amount of adsorption of these biopharmaceuticals is small, and they can suppress deterioration due to oxidation and reduction of medicinal effects. Moisture transpiration can also be suppressed.
- the sterilization treatment can be performed by a technique / condition suitable for the biopharmaceutical to be stored.
- sterilization methods for example, hot water treatment at 100 ° C. or lower, pressurized hot water treatment at 100 ° C. or higher, high temperature heat treatment at 121 ° C. or higher, etc., electromagnetic wave sterilization of ultraviolet rays, microwaves, gamma rays, etc., ethylene Examples include gas treatment of oxide and the like, and chemical sterilization such as hydrogen peroxide and hypochlorous acid.
- the oxygen-absorbing medical multilayer container of the first embodiment, the second embodiment, the third embodiment, the fourth embodiment, or the like can be used. Furthermore, in the following, an example of one embodiment of the oxygen-absorbing medical multilayer container used in the storage method of the present embodiment will be described.
- the layer structure in this oxygen-absorbing medical multilayer container is not particularly limited, and the number and types of oxygen-absorbing layers (layer A) and resin layers (layer B) are not particularly limited. For example, an A / B configuration including one layer A and one layer B may be used, or a three-layer configuration including B / A / B including one layer A and two layers B may be used.
- the multilayer injection molded article of the present embodiment may include an arbitrary layer such as an adhesive layer (layer AD) as necessary, for example, seven layers of B1 / AD / B2 / A / B2 / AD / B1. It may be a configuration.
- layer AD adhesive layer
- the oxygen absorbing layer (layer A) includes at least one compound having a tetralin ring represented by the general formula (1) (hereinafter also simply referred to as “tetralin compound”), a transition metal catalyst, and a thermoplastic resin ( It is a layer containing an oxygen-absorbing composition containing a).
- Transition metal catalyst described in the first embodiment can be appropriately used.
- thermoplastic resin (a) described in the first embodiment can be appropriately used.
- the resin layer (layer B) of the oxygen-absorbing medical multilayer container is a layer containing a thermoplastic resin.
- the content of the thermoplastic resin (b1, b2) in the layer B can be appropriately set and is not particularly limited, but is preferably 70 to 100% by mass, more preferably 80 to 100% by mass with respect to the total amount of the layer B. More preferably, it is 90 to 100% by mass.
- the oxygen-absorbing medical multilayer container may have a plurality of layers B, and the configurations of the plurality of layers B may be the same as or different from each other.
- the thickness of the layer B can be appropriately determined according to the application and desired performance, and is not particularly limited, but strength such as drop resistance required for the multilayer body. From the viewpoint of securing various physical properties such as flexibility and flexibility, the thickness is preferably 5 to 1000 ⁇ m, more preferably 10 to 800 ⁇ m, and still more preferably 20 to 500 ⁇ m.
- thermoplastic resin can be used as the thermoplastic resin (b1, b2) of the layer B of the oxygen-absorbing medical multilayer container, and is not particularly limited. For example, it may be the same as or different from the thermoplastic resin (a) used in the layer A described above.
- Layer B preferably contains at least one thermoplastic resin selected from the group consisting of polyolefin, polyester, polyamide, ethylene-vinyl alcohol copolymer, plant-derived resin, and chlorine-based resin.
- the content of the thermoplastic resin (b1, b2) used for the layer B is preferably 50 to 100% by mass, more preferably 70 to 100% by mass, and still more preferably 90 to 100% by mass with respect to the total amount of the layer B. % By mass.
- polyesters, polyamides, ethylene-vinyl alcohol copolymers, plant-derived resins, and chlorine-based resins mentioned as the thermoplastic resins (b1, b2) that can be used for the layer B the heat that can be used for the layer A What was illustrated as a plastic resin can each be used.
- Layer B may contain various additives known in the art in addition to the thermoplastic resins (b1, b2).
- optional components include desiccants, coloring pigments such as titanium oxide, dyes, antioxidants, slip agents, antistatic agents, plasticizers, stabilizers, additives such as lubricants, calcium carbonate, clay, mica, Examples thereof include fillers such as silica, deodorants and the like, but are not particularly limited thereto.
- an antioxidant to the layer B from the viewpoint of recycling and reworking offcuts generated during production.
- the oxygen-absorbing medical multilayer container of the present embodiment may further include an optional layer in addition to the above-described oxygen-absorbing layer (layer A) and resin layer (layer B) depending on the desired performance and the like.
- an optional layer include an adhesive layer, a metal foil, a metal vapor deposition layer, and an organic-inorganic film.
- the adhesive layer preferably contains a thermoplastic resin having adhesiveness.
- a thermoplastic resin having adhesiveness for example, an acid modification in which a polyolefin resin such as polyethylene or polypropylene is modified with an unsaturated carboxylic acid such as acrylic acid, methacrylic acid, maleic acid, maleic anhydride, fumaric acid, itaconic acid, etc.
- the thickness of the adhesive layer is not particularly limited, but is preferably 2 to 100 ⁇ m, more preferably 5 to 90 ⁇ m, and still more preferably from the viewpoint of ensuring molding processability while exhibiting practical adhesive strength. Is 10 to 80 ⁇ m.
- the metal foil is not particularly limited, but an aluminum foil is preferable.
- the thickness of the metal foil is preferably 3 to 50 ⁇ m, more preferably 3 to 30 ⁇ m, still more preferably 5 to 15 ⁇ m, from the viewpoints of gas barrier properties, light shielding properties, bending resistance, and the like.
- a metal vapor deposition layer The resin film etc. in which the metal or metal oxide films, such as aluminum and an alumina, were vapor-deposited are preferable.
- Examples of the method for forming a vapor deposition film include physical vapor deposition methods such as vacuum vapor deposition, sputtering, and ion plating, and chemical vapor deposition methods such as PECVD, but are not particularly limited and are publicly known. This method is applicable.
- the thickness of the deposited film is preferably 5 to 500 nm, more preferably 5 to 200 nm, from the viewpoints of gas barrier properties, light shielding properties, bending resistance, and the like.
- the organic-inorganic film layer is not particularly limited, but a resin film coated with a silica-polyvinyl alcohol hybrid film produced by a sol-gel method or the like is preferable.
- the thickness of the coating film is preferably from 100 nm to 50 ⁇ m, more preferably from 1 to 15 ⁇ m, from the viewpoints of gas barrier properties, light shielding properties, bending resistance, and the like.
- the thickness of the oxygen-absorbing medical multilayer container is not particularly limited, but is preferably 500 to 5000 ⁇ m, more preferably from the viewpoint of enhancing oxygen absorption performance and ensuring various physical properties such as flexibility required as a storage container. Is 700 to 4000 ⁇ m, more preferably 800 to 3000 ⁇ m.
- the production method of the oxygen-absorbing medical multilayer container is not particularly limited, and a known method can be applied according to the properties of various materials, the target shape, and the like.
- an oxygen-absorbing medical multilayer container can be manufactured by applying various injection molding methods.
- the above-mentioned oxygen-absorbing composition is injected from the injection cylinder into the mold cavity through the mold hot runner.
- An injection molded body having a shape corresponding to the cavity shape can be manufactured.
- the mouth-and-neck portion may be heat-treated at this stage for crystallization.
- the crystallinity in this case may be set as appropriate according to the type of resin used and the desired performance, and is not particularly limited, but is generally preferably about 30 to 50%, more preferably 35 to 45. %.
- the shape of the oxygen-absorbing medical multilayer container is not particularly limited as long as it is appropriately set according to the intended use. In the case of performing injection molding using a mold as described above, it can have an arbitrary shape corresponding to the cavity shape of the mold.
- the oxygen-absorbing medical multilayer container When used as a part of the components of the sealing container, it absorbs oxygen in the container, and there is little oxygen that permeates or enters the container wall from outside the container. Can absorb this permeating or penetrating oxygen and prevent alteration of the stored content article (stored object) due to oxygen.
- the injection molded body of this embodiment may itself be molded into a container shape. Moreover, it can also shape
- the aspect of the oxygen-absorbing medical multilayer container used in the biopharmaceutical storage method of the present embodiment is not particularly limited, and can be used in various aspects.
- Preferred examples of usage include, but are not particularly limited to, vials, ampoules, prefilled syringes, vacuum blood collection tubes, and the like.
- the details of the vial, ampoule, prefilled syringe, vacuum blood collection tube, and the like are the same as those described in the first embodiment and the like unless otherwise specified, and redundant descriptions are omitted here. .
- the reaction mixture was cooled to room temperature, released hydrogen, and replaced with 1 MPa of nitrogen twice. Then, the catalyst was filtered off, and the catalyst was washed with 1.0 kg of acetone three times. The solvent was removed from the obtained mother liquor under reduced pressure by an evaporator to obtain a crude product.
- the acid anhydride F was obtained by recrystallizing the obtained composition organism. Using a differential heat / thermogravimetric simultaneous measurement apparatus (manufactured by Shimadzu Corporation, trade name “DTG-60”), the 3% weight reduction temperature of the obtained compound was measured. Table 1 shows the structural formula, molecular weight, and 3% weight loss temperature of the obtained compound.
- the NMR analysis results were as follows.
- Example 1-1 Using a twin screw extruder having two 37 mm diameter screws, 95 parts by mass of an ethylene-vinyl alcohol copolymer (manufactured by Kuraray Co., Ltd., trade name “EVAL L171B”, hereinafter also abbreviated as “EVOH”). On the other hand, 5 parts by mass of the diester compound A and cobalt (II) stearate are melt-kneaded at 220 ° C. so that the amount of cobalt is 0.05 parts by mass, the strand is extruded from the extruder head, cooled, and pelletized. An oxygen-absorbing composition (1) was obtained. Next, as shown below, a vial, which is an oxygen-absorbing medical multilayer molded body, was produced using this oxygen-absorbing composition (1). Then, the performance evaluation of the obtained vial was performed as shown below. The evaluation results are shown in Table 2.
- EVAL L171B ethylene-vinyl alcohol copolymer
- thermoplastic resin constituting the resin layer (layer B) is injected from the injection cylinder, and then the oxygen-absorbing composition (1) constituting the oxygen absorption layer (layer A) is separated from another injection cylinder.
- the thermoplastic resin constituting the layer B is injected from the injection cylinder, and then the oxygen-absorbing composition (1) constituting the oxygen absorption layer (layer A) is separated from another injection cylinder.
- a B / A / B three-layer construction is achieved.
- An injection molded body was obtained. Thereafter, the obtained injection-molded product was cooled to a predetermined temperature, transferred to a blow mold, and blow-molded to produce a vial (bottle part).
- the total mass of the vial was 24 g, and the mass of the layer A was 30% by mass of the total mass of the vial.
- a thermoplastic resin constituting the layer B polypropylene (Nippon Polypro Co., Ltd., trade name “MG03B”) was used.
- Vials oxygen permeability The oxygen permeability on the 30th day from the start of measurement was measured in an atmosphere of 23 ° C., 50% relative humidity outside the molded body, and 100% relative humidity inside the molded body.
- an oxygen permeability measuring device manufactured by MOCON, trade name “OX-TRAN 2-21 ML” was used. It shows that oxygen barrier property is so favorable that a measured value is low.
- the lower limit of detection of the measurement is oxygen permeability 5 ⁇ 10 ⁇ 5 mL / (0.21 atm ⁇ day ⁇ package).
- Example 1-2 A multilayer vial was prepared in the same manner as in Example 1 except that the diester compound A was replaced with the diester compound B, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-3 A multilayer vial was prepared in the same manner as in Example 1-1 except that diester compound A was replaced with diester compound C, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-4 A multilayer vial was prepared in the same manner as in Example 1-1 except that the diester compound A was replaced with the diester compound D, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-5 A multilayer vial was prepared in the same manner as in Example 1-1 except that the diester compound A was replaced with the diamide compound E, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-6 A multilayer vial was prepared in the same manner as in Example 1-1 except that the diester compound A was replaced with the acid anhydride F, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1--7 Polypropylene is replaced with polycarbonate (trade name “Lexan 144R” manufactured by Sabic), and EVOH is also abbreviated as amorphous polyamide (trade name “NOVAMID X21-F07” manufactured by Mitsubishi Engineering Plastics Co., Ltd., hereinafter “6IT”).
- a multilayer vial was produced in the same manner as in Example 1-1 except that the injection cylinder temperature for layer A was set to 260 ° C., and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-8 A multilayer vial was prepared in the same manner as in Example 1-7 except that the diester compound A was replaced with the diester compound B, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-9 A multilayer vial was prepared in the same manner as in Example 1-7 except that the diester compound A was replaced with the diester compound C, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-10 A multilayer vial was prepared in the same manner as in Example 1-7 except that diester compound A was replaced with diester compound D, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-11 A multilayer vial was prepared in the same manner as in Example 1-7 except that the diester compound A was replaced with the diamide compound E, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-12 A multilayer vial was prepared in the same manner as in Example 1-7 except that the diester compound A was replaced with the acid anhydride F, and the same evaluation as in Example 1-1 was performed. The results are shown in Table 2.
- Example 1-1 The same procedure as in Example 1-1 was performed except that 100 parts by mass of polypropylene (trade name “MG03B” manufactured by Nippon Polypro Co., Ltd.) was used as the resin constituting the layer. Layer vials were manufactured. The performance evaluation of the obtained vial was performed in the same manner as in Example 1-1. The evaluation results are shown in Table 2.
- polypropylene trade name “MG03B” manufactured by Nippon Polypro Co., Ltd.
- Example 1-2 The same configuration as in Example 1-1, except that 100 parts by weight of polypropylene (trade name “Lexan 144R”, manufactured by Sabic) was used as the resin constituting the layer. Single-layer vials were prepared. The performance evaluation of the obtained vial was performed in the same manner as in Example 1-1. The evaluation results are shown in Table 2.
- polypropylene trade name “Lexan 144R”, manufactured by Sabic
- Example 1-3 A multilayer vial was prepared in the same manner as in Example 1-1 except that diester compound A and cobalt stearate were not used, and the same evaluation as in Example 1-1 was performed. That is, although it has a three-layer structure, a compound having a tetralin ring and a transition metal were not used (see Table 2). These results are shown in Table 2.
- Example 1-4 A multilayer vial was prepared in the same manner as in Example 1-7 except that diester compound A and cobalt stearate were not used, and evaluation was performed in the same manner as in Example 1-1. That is, although it has a three-layer structure, a compound having a tetralin ring and a transition metal were not used (see Table 2). These results are shown in Table 2.
- the unit is mL / (0.21 atm ⁇ day ⁇ package), and the lower limit of detection is 5 ⁇ 10 -5 mL / (0.21 atm ⁇ day ⁇ package). 2) The lower limit of detection is 0.1 ( ⁇ g / mL).
- each example vial has a reduced oxygen permeability compared to each comparative example vial, has a good oxygen barrier property, and has good strength even after long-term storage. It was confirmed that the contents visibility was ensured and the amount of elution from the container to the contents was low.
- Example 2-1 Using a twin screw extruder having two 37 mm diameter screws, 95 parts by mass of an ethylene-vinyl alcohol copolymer (manufactured by Kuraray Co., Ltd., trade name “EVAL L171B”, hereinafter also abbreviated as “EVOH”). On the other hand, 5 parts by mass of the diester compound A and cobalt (II) stearate are melt-kneaded at 220 ° C. so that the amount of cobalt is 0.05 parts by mass, the strand is extruded from the extruder head, cooled, and pelletized. An oxygen-absorbing composition (1) was obtained. Next, as shown below, a vial, which is an oxygen-absorbing medical multilayer molded body, was produced using this oxygen-absorbing composition (1). Then, the performance evaluation of the obtained vial was performed as shown below. The evaluation results are shown in Table 3.
- EVAL L171B ethylene-vinyl alcohol copolymer
- the polyolefin constituting the polyolefin-containing resin layer (layer B) is injected from the injection cylinder, and then the oxygen-absorbing composition (1) constituting the oxygen-absorbing layer (layer A) is injected into another injection cylinder. From the injection of the polyolefin constituting the layer B at the same time, and then injecting the required amount of the polyolefin constituting the layer B to fill the cavity in the injection mold, B / A / B three-layer injection molding Got the body. Thereafter, the obtained injection-molded product was cooled to a predetermined temperature, transferred to a blow mold, and blow-molded to produce a vial (bottle part).
- the total mass of the vial was 24 g
- the mass of the layer A was 30% by mass of the total mass of the vial.
- a cycloolefin polymer manufactured by Nippon Zeon Co., Ltd., trade name “ZEONEX 690R”, hereinafter also abbreviated as “COP” was used.
- Vials oxygen permeability The oxygen permeability on the 30th day from the start of measurement was measured in an atmosphere of 23 ° C., 50% relative humidity outside the molded body, and 100% relative humidity inside the molded body.
- an oxygen permeability measuring device manufactured by MOCON, trade name “OX-TRAN 2-21 ML” was used. It shows that oxygen barrier property is so favorable that a measured value is low.
- the lower limit of detection of the measurement is oxygen permeability 5 ⁇ 10 ⁇ 5 mL / (0.21 atm ⁇ day ⁇ package).
- Vapor water vapor transmission rate (WVTR) The water vapor transmission rate on the 10th day from the start of measurement was measured in an atmosphere of 40 ° C. and 100% relative humidity outside the molded body.
- a water vapor transmission rate measuring device (trade name “PERMATRAN-W 3 / 33G” manufactured by MOCON) was used. It shows that water vapor
- the lower limit of detection of the measurement is a water vapor transmission rate of 5 ⁇ 10 ⁇ 4 g / (day ⁇ package).
- Example 2-2 A multilayer vial was prepared in the same manner as in Example 2-1, except that the diester compound A was replaced with the diester compound B, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2-3 A multilayer vial was prepared in the same manner as in Example 2-1, except that the diester compound A was replaced with the diester compound C, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2-4 A multilayer vial was prepared in the same manner as in Example 2-1, except that the diester compound A was replaced with the diester compound D, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2-5 A multilayer vial was prepared in the same manner as in Example 2-1, except that the diester compound A was replaced with the diamide compound E, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2-6 A multilayer vial was prepared in the same manner as in Example 2-1, except that the diester compound A was replaced with the acid anhydride F, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2--7 EVOH is replaced with amorphous polyamide (trade name “NOVAMID X21-F07”, hereinafter abbreviated as “6IT”, manufactured by Mitsubishi Engineering Plastics Co., Ltd.), except that the injection cylinder temperature for layer A is 260 ° C.
- a multilayer vial was prepared in the same manner as in Example 2-1, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2-8 A multilayer vial was prepared in the same manner as in Example 2-7 except that the diester compound A was replaced with the diester compound B, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2-9 A multilayer vial was prepared in the same manner as in Example 2-7 except that the diester compound A was replaced with the diester compound C, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2-11 A multilayer vial was prepared in the same manner as in Example 2-7 except that diester compound A was replaced with diamide compound E, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2-12 A multilayer vial was prepared in the same manner as in Example 2-7 except that the diester compound A was replaced with the acid anhydride F, and the same evaluation as in Example 2-1 was performed. The results are shown in Table 3.
- Example 2-1 The same procedure as in Example 2-1 was conducted except that 100 parts by mass of cycloolefin polymer (manufactured by ZEON CORPORATION, trade name “ZEONEX 690R”) was used as the resin constituting the layer. Shaped single layer vials were produced. The performance evaluation of the obtained vial was performed in the same manner as in Example 2-1. The evaluation results are shown in Table 3.
- Example 2-13 The same procedure as in Example 2-1 was performed except that 100 parts by mass of polycarbonate (trade name “Lexan 144R”, manufactured by Sabic) was used as the resin constituting the layer, and a single layer having the same shape as Example 2-1. Vials were manufactured. The performance evaluation of the obtained vial was performed in the same manner as in Example 2-1. The evaluation results are shown in Table 3.
- polycarbonate trade name “Lexan 144R”, manufactured by Sabic
- Example 2-2 A multilayer vial was prepared in the same manner as in Example 2-1, except that the diester compound A and cobalt stearate were not used, and the same evaluation as in Example 2-1 was performed. These results are shown in Table 3.
- Example 2-3 A multilayer vial was prepared in the same manner as in Example 2-7 except that diester compound A and cobalt stearate were not used, and evaluation was performed in the same manner as in Example 2-1. These results are shown in Table 3.
- a vial was produced in the same manner as in Example 2-1, except that this oxygen-absorbing composition (M) was used in place of the oxygen-absorbing composition (1).
- the performance evaluation of the obtained vial was performed in the same manner as in Example 2-1. The evaluation results are shown in Table 3.
- the unit is mL / (0.21 atm ⁇ day ⁇ package), and the lower limit of detection is 5 ⁇ 10 -5 mL / (0.21 atm ⁇ day ⁇ package). 2) The unit is g / (day ⁇ package), and the lower detection limit is 5 ⁇ 10 ⁇ 4 g / (day ⁇ package). 3) The lower limit of detection is 0.1 ( ⁇ g / mL).
- the vials of each example have good oxygen barrier properties and water vapor barrier properties, maintain good strength even after long-term storage, ensure content visibility, and contain the contents from the container.
- the amount of elution into the product was also confirmed to be low.
- Example 3-1 Using a twin screw extruder having two 37 mm diameter screws, 95 parts by mass of an ethylene-vinyl alcohol copolymer (manufactured by Kuraray Co., Ltd., trade name “EVAL L171B”, hereinafter also abbreviated as “EVOH”). On the other hand, 5 parts by mass of the diester compound A and cobalt (II) stearate are melt-kneaded at 220 ° C. so that the amount of cobalt is 0.05 parts by mass, the strand is extruded from the extruder head, cooled, and pelletized. An oxygen-absorbing composition (1) was obtained. Next, as shown below, a vial, which is an oxygen-absorbing medical multilayer molded body, was produced using this oxygen-absorbing composition (1). Then, the performance evaluation of the obtained vial was performed as shown below. The evaluation results are shown in Table 4.
- EVAL L171B ethylene-vinyl alcohol copolymer
- polyester constituting the polyester-containing resin layer (layer B) is injected from the injection cylinder, and then the oxygen-absorbing composition (1) constituting the oxygen-absorbing layer (layer A) is injected into another injection cylinder. Injection of the polyester constituting the layer B, and then injecting a necessary amount of the polyester constituting the layer B to fill the cavity in the injection mold. Got the body. Thereafter, the obtained injection-molded product was cooled to a predetermined temperature, transferred to a blow mold, and blow-molded to produce a vial (bottle part).
- the total mass of the vial was 24 g
- the mass of the layer A was 30% by mass of the total mass of the vial.
- PET polyethylene terephthalate resin
- Vials oxygen permeability The oxygen permeability on the 30th day from the start of measurement was measured in an atmosphere of 23 ° C., 50% relative humidity outside the molded body, and 100% relative humidity inside the molded body.
- an oxygen permeability measuring device manufactured by MOCON, trade name “OX-TRAN 2-21 ML” was used. It shows that oxygen barrier property is so favorable that a measured value is low.
- the lower limit of detection of the measurement is oxygen permeability 5 ⁇ 10 ⁇ 5 mL / (0.21 atm ⁇ day ⁇ package).
- Example 3-2 A multilayer vial was prepared in the same manner as in Example 3-1, except that the diester compound A was replaced with the diester compound B, and the same evaluation as in Example 3-1 was performed. The results are shown in Table 4.
- Example 3-3 A multilayer vial was prepared in the same manner as in Example 3-1, except that the diester compound A was replaced with the diester compound C, and the same evaluation as in Example 3-1 was performed. The results are shown in Table 4.
- Example 3-4 A multilayer vial was prepared in the same manner as in Example 3-1, except that the diester compound A was replaced with the diester compound D, and the same evaluation as in Example 3-1 was performed. The results are shown in Table 4.
- Example 3-5 A multilayer vial was prepared in the same manner as in Example 3-1, except that the diester compound A was replaced with the diamide compound E, and the same evaluation as in Example 3-1 was performed. The results are shown in Table 4.
- Example 3-6 A multilayer vial was prepared in the same manner as in Example 3-1, except that the diester compound A was replaced with the acid anhydride F, and evaluation was performed in the same manner as in Example 3-1. The results are shown in Table 4.
- Example 3--7 EVOH is replaced with amorphous polyamide (trade name “NOVAMID X21-F07”, hereinafter abbreviated as “6IT”, manufactured by Mitsubishi Engineering Plastics Co., Ltd.), except that the injection cylinder temperature for layer A is 260 ° C.
- a multilayer vial was prepared in the same manner as in Example 3-1, and the same evaluation as in Example 3-1. The results are shown in Table 4.
- Example 3-8 A multilayer vial was prepared in the same manner as in Example 3-7 except that diester compound A was replaced with diester compound B, and evaluation was performed in the same manner as in Example 3-1. The results are shown in Table 4.
- Example 3-9 A multilayer vial was prepared in the same manner as in Example 3-7 except that diester compound A was replaced with diester compound C, and evaluation was performed in the same manner as in Example 3-1. The results are shown in Table 4.
- Example 3-10 A multilayer vial was prepared in the same manner as in Example 3-7 except that the diester compound A was replaced with the diester compound D, and the same evaluation as in Example 3-1 was performed. The results are shown in Table 4.
- Example 3-11 A multilayer vial was prepared in the same manner as in Example 3-7 except that the diester compound A was replaced with the diamide compound E, and the same evaluation as in Example 3-1 was performed. The results are shown in Table 4.
- Example 3-12 A multilayer vial was prepared in the same manner as in Example 3-7 except that the diester compound A was replaced with the acid anhydride F, and evaluation was performed in the same manner as in Example 3-1. The results are shown in Table 4.
- Example 3-1 A multilayer vial was prepared in the same manner as in Example 3-1, except that the diester compound A and cobalt stearate were not used, and evaluation was performed in the same manner as in Example 3-1. These results are shown in Table 4.
- Example 3-2 A multilayer vial was prepared in the same manner as in Example 3-7 except that diester compound A and cobalt stearate were not used, and evaluation was performed in the same manner as in Example 3-1. These results are shown in Table 4.
- a vial was prepared in the same manner as in Example 3-1, except that this oxygen-absorbing composition (M) was used instead of the oxygen-absorbing composition (1), and the injection cylinder temperature for layer B was 260 ° C. Manufactured. The performance evaluation of the obtained vial was performed in the same manner as in Example 3-1. The evaluation results are shown in Table 4.
- the unit is mL / (0.21 atm ⁇ day ⁇ package), and the lower limit of detection is 5 ⁇ 10 ⁇ 5 mL / (0.21 atm ⁇ day ⁇ package).
- the lower limit of detection is 0.1 ( ⁇ g / mL).
- the vials of each example can reduce the oxygen transmission rate compared to each comparative example, ensure the visibility inside the container, and maintain good strength even after long-term storage. In addition, it was confirmed that the amount of elution from the container to the contents was also low. Furthermore, it was confirmed that the vials of Examples 3-1 to 3-6, 3-11, and 3-12 were excellent in transparency and had very good contents visibility.
- Example 4-1 Using a twin screw extruder having two 37 mm diameter screws, 95 parts by mass of an ethylene-vinyl alcohol copolymer (manufactured by Kuraray Co., Ltd., trade name “EVAL L171B”, hereinafter also abbreviated as “EVOH”). On the other hand, 5 parts by mass of the diester compound A and cobalt (II) stearate are melt-kneaded at 220 ° C. so that the amount of cobalt is 0.05 parts by mass, the strand is extruded from the extruder head, cooled, and pelletized. An oxygen-absorbing composition (1) was obtained. Next, as shown below, a syringe, which is an oxygen-absorbing medical multilayer molded body, was produced using this oxygen-absorbing composition (1). Performance evaluation of the obtained syringe was performed as shown below. The evaluation results are shown in Table 5.
- EVAL L171B ethylene-vinyl alcohol copolymer
- thermoplastic resin constituting the resin layer (layer B) is injected from the injection cylinder, and then the oxygen-absorbing composition (1) constituting the oxygen absorption layer (layer A) is separated from another injection cylinder.
- the thermoplastic resin constituting the layer B is injected from the injection cylinder, and then the oxygen-absorbing composition (1) constituting the oxygen absorption layer (layer A) is separated from another injection cylinder.
- Oxygen permeability of syringe The oxygen permeability on the 30th day from the start of measurement was measured in an atmosphere of 23 ° C., 50% relative humidity outside the molded body, and 100% relative humidity inside the molded body.
- an oxygen permeability measuring device manufactured by MOCON, trade name: OX-TRAN 2-21 ML was used. It shows that oxygen barrier property is so favorable that a measured value is low.
- the lower limit of detection of the measurement is oxygen permeability 5 ⁇ 10 ⁇ 5 mL / (0.21 atm ⁇ day ⁇ package).
- Example 4-2 A multilayer syringe was produced in the same manner as in Example 4-1, except that the diester compound A was replaced with the diester compound B, and the same evaluation as in Example 4-1 was performed. These results are shown in Table 5.
- Example 4-3 A multilayer syringe was prepared in the same manner as in Example 4-1, except that the diester compound A was replaced with the diester compound C, and the same evaluation as in Example 4-1 was performed. These results are shown in Table 5.
- Example 4-4 A multilayer syringe was produced in the same manner as in Example 4-1, except that the diester compound A was replaced with the diester compound D, and the same evaluation as in Example 4-1 was performed. These results are shown in Table 5.
- Example 4-5 A multilayer syringe was prepared in the same manner as in Example 4-1, except that the diester compound A was replaced with the diamide compound E, and evaluation was performed in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-6 A multilayer syringe was produced in the same manner as in Example 4-1, except that the diester compound A was replaced with the acid anhydride F, and the same evaluation as in Example 4-1. These results are shown in Table 5.
- Example 4-7 EVOH is replaced with amorphous polyamide (trade name “NOVAMID X21-F07”, hereinafter abbreviated as “6IT”, manufactured by Mitsubishi Engineering Plastics Co., Ltd.), except that the injection cylinder temperature for layer A is 260 ° C.
- a multilayer syringe was prepared in the same manner as in Example 4-1, and the same evaluation as in Example 4-1. These results are shown in Table 5.
- Example 4-8 A multilayer syringe was produced in the same manner as in Example 4-7 except that diester compound A was replaced with diester compound B, and evaluation was performed in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-9 A multilayer syringe was produced in the same manner as in Example 4-7 except that the diester compound A was replaced with the diester compound C, and the same evaluation as in Example 4-1 was performed. These results are shown in Table 5.
- Example 4-10 A multilayer syringe was prepared in the same manner as in Example 4-7 except that the diester compound A was replaced with the diester compound D, and the same evaluation as in Example 4-1 was performed. These results are shown in Table 5.
- Example 4-11 A multilayer syringe was prepared in the same manner as in Example 4-7 except that the diester compound A was replaced with the diamide compound E, and the same evaluation as in Example 4-1 was performed. These results are shown in Table 5.
- Example 4-12 A multilayer syringe was prepared in the same manner as in Example 4-7 except that the diester compound A was replaced with the acid anhydride F, and evaluation was performed in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-1 Example 4-1 except that COC was replaced by polypropylene (trade name “MG03B”, hereinafter abbreviated as “PP”, manufactured by Nippon Polypro Co., Ltd.), and the injection cylinder temperature for layer B was 220 ° C. Similarly, a multilayer syringe was produced and evaluated in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-14 A multilayer syringe was prepared in the same manner as in Example 4-13 except that diester compound A was replaced with diester compound B, and evaluation was performed in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-15 A multilayer syringe was produced in the same manner as in Example 4-13 except that diester compound A was replaced with diester compound C, and the same evaluation as in Example 4-1 was performed. These results are shown in Table 5.
- Example 4-16 A multilayer syringe was produced in the same manner as in Example 4-13 except that diester compound A was replaced with diester compound D, and evaluation was performed in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-17 A multilayer syringe was produced in the same manner as in Example 4-13 except that diester compound A was replaced with diamide compound E, and evaluation was performed in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-18 A multilayer syringe was prepared in the same manner as in Example 4-13 except that the diester compound A was replaced with the acid anhydride F, and evaluation was performed in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-1 The same procedure as in Example 4-1 was performed except that COC was used instead of the oxygen-absorbing composition (1) and the injection cylinder temperature for layer A was 280 ° C. A layer syringe was prepared and evaluated in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-2 A single-layer syringe having the same shape as in Example 4-1 was prepared except that PP was used in place of the oxygen-absorbing composition (1), and a single-layer syringe having the same shape as Example 4-1 was prepared. Similar evaluations were made. These results are shown in Table 5.
- Example 4-3 A multilayer syringe was prepared in the same manner as in Example 4-1, except that the diester compound A and cobalt stearate were not used, and the same evaluation as in Example 4-1. These results are shown in Table 5.
- Example 4-4 A multilayer syringe was prepared in the same manner as in Example 4-7, except that diester compound A and cobalt stearate were not used, and evaluation was performed in the same manner as in Example 4-1. These results are shown in Table 5.
- Example 4-1 The same procedure as in Example 4-1, except that this oxygen-absorbing composition (M) was used instead of the oxygen-absorbing composition (1) and the injection cylinder temperature for layer B was 260 ° C. Manufactured. The performance of the obtained syringe was evaluated in the same manner as in Example 4-1. The evaluation results are shown in Table 5.
- the unit is mL / (0.21 atm ⁇ day ⁇ package), and the lower limit of detection is 5 ⁇ 10 -5 mL / (0.21 atm ⁇ day ⁇ package). 2) The lower limit of detection is 0.1 ( ⁇ g / mL).
- the syringe of each example can reduce the oxygen permeability relative to the syringe of each comparative example, the visibility inside the container is ensured, and maintains good strength even after long-term storage, It was confirmed that the amount of elution from the container into the contents was also low. Furthermore, it was confirmed that the syringes of Examples 4-11 and 4-12 were excellent in transparency and the contents visibility was very good.
- Example 5-1 Using a twin screw extruder having two 37 mm diameter screws, 95 parts by mass of an ethylene-vinyl alcohol copolymer (manufactured by Kuraray Co., Ltd., trade name “EVAL L171B”, hereinafter also abbreviated as “EVOH”). On the other hand, 5 parts by mass of the diester compound A and cobalt (II) stearate are melt-kneaded at 220 ° C. so that the amount of cobalt is 0.05 parts by mass, the strand is extruded from the extruder head, cooled, and pelletized. An oxygen-absorbing composition (1) was obtained. Next, as shown below, a vial, which is an oxygen-absorbing medical multilayer molded body, was produced using this oxygen-absorbing composition (1). Then, the performance evaluation of the obtained vial was performed as shown below. The evaluation results are shown in Table 6.
- EVAL L171B ethylene-vinyl alcohol copolymer
- thermoplastic resin constituting the resin layer (layer B) is injected from the injection cylinder, and then the oxygen-absorbing composition (1) constituting the oxygen absorption layer (layer A) is separated from another injection cylinder.
- the thermoplastic resin constituting the layer B is injected from the injection cylinder, and then the oxygen-absorbing composition (1) constituting the oxygen absorption layer (layer A) is separated from another injection cylinder.
- a B / A / B three-layer construction is achieved.
- An injection molded body was obtained. Thereafter, the obtained injection-molded product was cooled to a predetermined temperature, transferred to a blow mold, and blow-molded to produce a vial (bottle part).
- the total mass of the vial was 24 g, and the mass of the layer A was 30% by mass of the total mass of the vial.
- the thermoplastic resin constituting the layer B a cycloolefin polymer (manufactured by Zeon Corporation, trade name “ZEONEX 690R”) was used.
- Vials oxygen permeability The oxygen permeability on the 30th day from the start of measurement was measured in an atmosphere of 23 ° C., 50% relative humidity outside the molded body, and 100% relative humidity inside the molded body.
- an oxygen permeability measuring device manufactured by MOCON, trade name “OX-TRAN 2-21 ML” was used. It shows that oxygen barrier property is so favorable that a measured value is low.
- the lower limit of detection of the measurement is oxygen permeability 5 ⁇ 10 ⁇ 5 mL / (0.21 atm ⁇ day ⁇ package).
- Biopharmaceutical preservation test (binding ratio measurement method) Using an isothermal titration calorimeter (ITC; manufactured by GE Healthcare, “Microcal VP-ITC”), a 5 ⁇ M antigen solution (BIOLOGICAL Industries Ltd., “FGF1-Mouse”) was filled on the cell side, and monoclonal The binding ratio was measured at a measurement temperature of 25 ° C. while dropping 10 ⁇ L of the antibody solution into the cell. (Preservation test) A vial was filled with 1 cc of monoclonal antibody (mAb1) (trade name “ANTI FGF1, Monoclonal Antibody (mAb1)” manufactured by Wako Pure Chemical Industries, Ltd.) adjusted to 50 ⁇ M, and 180 ° C.
- mAb1 monoclonal antibody
- Antibody activity retention rate (%) (Binding ratio of antibody solution after storage for 180 days / Binding ratio of antibody solution before storage) ⁇ 100
- Example 5-2 A multilayer vial was prepared in the same manner as in Example 5-1, except that the diester compound A was replaced with the diester compound B, and the same evaluation as in Example 5-1 was performed. These results are shown in Table 6.
- Example 5-3 A multilayer vial was prepared in the same manner as in Example 5-1, except that the diester compound A was replaced with the diester compound C, and the same evaluation as in Example 5-1 was performed. These results are shown in Table 6.
- Example 5-4 A multilayer vial was prepared in the same manner as in Example 5-1, except that the diester compound A was replaced with the diester compound D, and the same evaluation as in Example 5-1 was performed. These results are shown in Table 6.
- Example 5-5 A multilayer vial was prepared in the same manner as in Example 5-1, except that the diester compound A was replaced with the diamide compound E, and the same evaluation as in Example 5-1 was performed. These results are shown in Table 6.
- Example 5-6 A multilayer vial was prepared in the same manner as in Example 5-1, except that the diester compound A was replaced with the acid anhydride F, and evaluation was performed in the same manner as in Example 5-1. These results are shown in Table 6.
- Example 5-7 A multilayer vial was prepared in the same manner as in Example 5-1, except that EVOH was replaced with amorphous nylon (trade name “NOVAMID X21-F07”, hereinafter abbreviated as “6IT”, manufactured by Mitsubishi Engineering Plastics Co., Ltd.). The same evaluation as in Example 5-1 was performed. These results are shown in Table 6.
- Example 5-8 A multilayer vial was prepared in the same manner as in Example 5-7 except that diester compound A was replaced with diester compound B, and evaluation was performed in the same manner as in Example 5-1. These results are shown in Table 6.
- Example 5-9 A multilayer vial was prepared in the same manner as in Example 5-7 except that the diester compound A was replaced with the diester compound C, and the same evaluation as in Example 5-1 was performed. These results are shown in Table 6.
- Example 5-10 A multilayer vial was prepared in the same manner as in Example 5-7 except that diester compound A was replaced with diester compound D, and evaluation was performed in the same manner as in Example 5-1. These results are shown in Table 6.
- Example 5-11 A multilayer vial was prepared in the same manner as in Example 5-7 except that diester compound A was replaced with diamide compound E, and evaluation was performed in the same manner as in Example 5-1. These results are shown in Table 6.
- Example 5-12 A multilayer vial was prepared in the same manner as in Example 5-7 except that the diester compound A was replaced with the acid anhydride F, and evaluation was performed in the same manner as in Example 5-1. These results are shown in Table 6.
- Example 5 Example 5 except that 100 parts by mass of a cycloolefin polymer (manufactured by Nippon Zeon Co., Ltd., trade name “ZEONEX 690R”, hereinafter also abbreviated as “COP”) was used in place of the oxygen-absorbing composition (1).
- COP cycloolefin polymer
- Example 5-2 A multilayer vial was prepared in the same manner as in Example 5-1, except that the diester compound A was not used, and the same evaluation as in Example 5-1. These results are shown in Table 6.
- Example 5-3 A multilayer vial was prepared in the same manner as in Example 5-8 except that the diester compound A was not used, and the same evaluation as in Example 5-1 was performed. These results are shown in Table 6.
- the unit is mL (0.21 atm ⁇ day ⁇ package), and the lower limit of detection is 5 ⁇ 10 -5 mL / (0.21 atm ⁇ day ⁇ package). 2) The lower limit of detection is 0.1 ( ⁇ g / mL).
- each example was able to reduce the oxygen permeability relative to each comparative example. And it can prevent oxidative degradation of biopharmaceuticals with little permeated oxygen, protect biopharmaceuticals from external impacts even when stored for a long time, and effectively mix impurities into biopharmaceuticals It was confirmed that the decrease in drug efficacy after storage was suppressed.
- Japanese Patent Application filed with the Japan Patent Office on March 6, 2013 Japanese Patent Application No. 2013-04754
- Japanese Patent Application filed with the Japan Patent Office on March 6, 2013 Japanese Patent Application No. 2013-044734
- Japanese Patent Application filed with the Japan Patent Office on March 6, 2013 Japanese Patent Application filed with the Japan Patent Office on March 6, 2013
- Japanese Patent Application filed with the Japan Patent Office on March 6, 2013 Japanese Patent Application No. 2013-044737
- Japanese Patent Application Japanese Patent Application No. 2013-044740
- the oxygen-absorbing medical multilayer container of the present invention has at least an excellent oxygen-absorbing property, it can absorb oxygen regardless of the presence or absence of moisture in the object to be stored, and further, the odor intensity after oxygen absorption. Since the increase is suppressed, it can be used particularly effectively in, for example, pharmaceuticals and health foods. Moreover, since it is not sensitive to metal detectors, it can be used widely and effectively in applications in which metals, metal pieces, etc. are inspected from the outside by metal detectors, such as packaging and containers.
Abstract
Description
本発明の別の目的は、優れた酸素バリア性と水蒸気バリア性を有し、長期保存時でも強度が維持され、不純物の溶出量が少ない酸素吸収性医療用多層容器を提供することにある。
本発明の更に別の目的は、優れた酸素バリア性を有し、長期保存時でも強度が維持され、不純物の溶出量が少なく、層間密着性に優れた酸素吸収性医療用多層容器を提供することにある。
本発明の更に別の目的は、優れた酸素バリア性を有し、好ましくは優れた水蒸気バリア性能をも有し、長期保存時でも強度が維持され、酸素吸収後の低分子量化合物の生成が著しく抑制された酸素吸収性プレフィルドシリンジを提供することにある。
本発明の更に別の目的は、保存時におけるバイオ医薬の酸化劣化を防止でき、外部からの衝撃からバイオ医薬を長期間にわたって保護することができ、バイオ医薬への不純物の混入が抑制でき、保存後のバイオ医薬の薬効の低下を抑制できる、バイオ医薬の保存方法を提供することにある。
<1>
熱可塑性樹脂(b1)を含有する第1の樹脂層と、酸素吸収性組成物を含有する酸素吸収層と、熱可塑性樹脂(b2)を含有する第2の樹脂層との少なくとも3層をこの順に有する、酸素吸収性医療用多層容器であって、
前記酸素吸収性組成物が、下記一般式(1)で表されるテトラリン環を有する化合物を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含む、酸素吸収性医療用多層容器。
<2>
前記一般式(1)で表されるテトラリン環を有する化合物が、2つ以上のカルボニル基を有する、<1>に記載の酸素吸収性医療用多層容器。
<3>
前記一般式(1)において、R1~R12のうち、少なくとも2つ以上が、下記一般式(2)で表される一価の置換基である、<2>に記載の酸素吸収性医療用多層容器。
-C(=O)-X (2)
(式中、Xは、水素原子、ヒドロキシ基、アルキル基、アルコキシ基、モノアルキルアミノ基、及びジアルキルアミノ基からなる群より選ばれる1つであり、複数のXは、同一であってもよいし、異なっていてもよい。)
<4>
前記一般式(1)で表されるテトラリン環を有する化合物が、テトラリン環を2つ以上有する、<1>~<3>のいずれか一項に記載の酸素吸収性医療用多層容器。
<5>
前記酸素吸収性組成物中の、前記一般式(1)で表されるテトラリン環を有する化合物と前記熱可塑性樹脂(a)との総量に対する、前記一般式(1)で表されるテトラリン環を有する化合物の割合が、1~30質量%である、<1>~<4>のいずれか一項に記載の酸素吸収性医療用多層容器。
<6>
前記遷移金属触媒は、マンガン、鉄、コバルト、ニッケル、及び銅からなる群より選ばれる少なくとも1種の遷移金属を含む、<1>~<5>のいずれか一項に記載の酸素吸収性医療用多層容器。
<7>
前記酸素吸収性組成物中、前記遷移金属触媒が、前記一般式(1)で表されるテトラリン環を有する化合物と前記熱可塑性樹脂(a)との総量100質量部に対して、遷移金属量として、0.001~10質量部含まれる、<1>~<6>のいずれか一項に記載の酸素吸収性医療用多層容器。
<8>
前記酸素吸収性組成物の熱可塑性樹脂(a)が、ポリオレフィン、ポリエステル、ポリアミド、エチレン-ビニルアルコール共重合体、植物由来樹脂及び塩素系樹脂からなる群より選択される少なくとも1種以上である、<1>~<7>のいずれか一項に記載の酸素吸収性医療用多層容器。
<9>
前記熱可塑性樹脂(b1)がポリオレフィン(PO1)であり、
前記熱可塑性樹脂(b2)がポリオレフィン(PO2)である、<1>~<8>のいずれか一項に記載の酸素吸収性医療用多層容器。
<10>
前記熱可塑性樹脂(b1)がポリエステル(PES1)であり、
前記熱可塑性樹脂(b2)がポリエステル(PES2)である、<1>~<8>のいずれか一項に記載の酸素吸収性医療用多層容器。
<11>
前記ポリエステル(PES1)と前記ポリエステル(PES2)の少なくともいずれかにおいて、ジカルボン酸単位中の70モル%以上が、テレフタル酸、イソフタル酸、1,3-ナフタレンジカルボン酸、1,4-ナフタレンジカルボン酸、1,5-ナフタレンジカルボン酸、2,6-ナフタレンジカルボン酸、2,7-ナフタレンジカルボン酸、及びこれらのエステル形成性誘導体からなる群より選ばれる1種以上のジカルボン酸に由来する単位である、<10>に記載の酸素吸収性医療用多層容器。
<12>
前記酸素吸収性医療用多層容器が、予め薬剤を密封状態下に収容し、使用に際し前記密封状態を解除して前記薬剤を注出し得るようにされた酸素吸収性プレフィルドシリンジである、<1>~<8>のいずれか一項に記載の酸素吸収性医療用多層容器。
<13>
バイオ医薬を、<1>~<12>のいずれか一項に記載の酸素吸収性医療用多層容器内に保存するバイオ医薬の保存方法。
また、本発明によれば、水蒸気バリア性が良好で、優れた酸素吸収性能を有する優れた酸素バリア性能を有し、長期保存時でも強度が維持され、不純物の溶出量が少ない酸素吸収性医療用多層容器を提供することができる。しかも、本発明の好適態様によれば、容器内部の視認性に優れ、金属探知機に感応しない酸素吸収性多層インジェクション成形体をも実現される。
本発明によれば、優れた酸素吸収性能を有する優れた酸素バリア性能を有し、長期保存時でも強度が維持され、不純物の溶出量が少なく、層間密着性に優れた酸素吸収性医療用多層容器を提供することができる。しかも、本発明の好適態様によれば、容器内部の視認性に優れ、金属探知機に感応しない酸素吸収性多層インジェクション成形体をも実現される。
本発明によれば、優れた酸素バリア性を有し、好ましくは優れた水蒸気バリア性能をも有し、長期保存時でも強度が維持され、酸素吸収後の低分子量化合物の生成が著しく抑制された酸素吸収性プレフィルドシリンジを提供することができる。しかも、本発明の好適態様によれば、容器内部の視認性に優れ、金属探知機に感応しない酸素吸収性プレフィルドシリンジをも実現される。
本発明によれば、保存時におけるバイオ医薬の酸化劣化を防止でき、外部からの衝撃からバイオ医薬を長期間にわたって保護することができ、バイオ医薬への不純物の混入が抑制でき、保存後のバイオ医薬の薬効の低下を抑制できる、バイオ医薬の保存方法を提供することができる。しかも、本発明の好適態様によれば、保存中のバイオ医薬を十分に視認することもでき、金属探知機に感応しない保存方法をも実現される。
[酸素吸収性医療用多層容器]
本実施形態の酸素吸収性医療用多層容器は、熱可塑性樹脂(b)を含有する第1の樹脂層(層B)と、酸素吸収性組成物を含有する酸素吸収層(層A)と、熱可塑性樹脂(b)を含有する第2の樹脂層(層B)との少なくとも3層をこの順に有する、酸素吸収性医療用多層容器であって、
前記酸素吸収性組成物が、下記一般式(1)で表されるテトラリン環を有する化合物を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含む、
酸素吸収性医療用多層容器である。
本実施形態の酸素吸収性医療用多層容器の酸素吸収層(層A)は、上記一般式(1)で表されるテトラリン環を有する化合物(以下、単に「テトラリン化合物」ともいう。)を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含有する酸素吸収性組成物を含む層である。
上記一般式(1)において、R1~R12で示す一価の置換基としては、ハロゲン原子(例えば、塩素原子、臭素原子、ヨウ素原子)、アルキル基(好ましくは炭素数が1~15、より好ましくは炭素数が1~6の直鎖状、分岐状又は環状アルキル基、例えば、メチル基、エチル基、n-プロピル基、イソプロピル基、tert-ブチル基、n-オクチル基、2-エチルヘキシル基、シクロプロピル基、シクロペンチル基)、アルケニル基(好ましくは炭素数が2~10、より好ましくは炭素数が2~6の直鎖状、分岐状又は環状アルケニル基、例えば、ビニル基、アリル基)、アルキニル基(好ましくは炭素数が2~10、より好ましくは炭素数が2~6のアルキニル基、例えば、エチニル基、プロパルギル基)、アリール基(好ましくは炭素数が6~16、より好ましくは炭素数が6~10のアリール基、例えば、フェニル基、ナフチル基)、複素環基(好ましくは炭素数が1~12、より好ましくは炭素数が2~6の5員環或いは6員環の芳香族又は非芳香族の複素環化合物から1個の水素原子を取り除くことによって得られる一価の基、例えば、1-ピラゾリル基、1-イミダゾリル基、2-フリル基)、シアノ基、ヒドロキシ基、カルボキシル基、エステル基、アミド基、ニトロ基、アルコキシ基(好ましくは炭素数が1~10、より好ましくは炭素数が1~6の直鎖状、分岐状又は環状アルコキシ基、例えば、メトキシ基、エトキシ基)、アリールオキシ基(好ましくは炭素数が6~12、より好ましくは炭素数が6~8のアリールオキシ基、例えば、フェノキシ基)、アシル基(ホルミル基を含む。好ましくは炭素数が2~10、より好ましくは炭素数が2~6のアルキルカルボニル基、好ましくは炭素数が7~12、より好ましくは炭素数が7~9のアリールカルボニル基、例えば、アセチル基、ピバロイル基、ベンゾイル基)、アミノ基(好ましくは炭素数が1~10、より好ましくは炭素数が1~6のアルキルアミノ基、好ましくは炭素数が6~12、より好ましくは炭素数が6~8のアニリノ基、好ましくは炭素数が1~12、より好ましくは炭素数が2~6の複素環アミノ基、例えば、アミノ基、メチルアミノ基、アニリノ基)、チオール基、アルキルチオ基(好ましくは炭素数が1~10、より好ましくは炭素数が1~6のアルキルチオ基、例えば、メチルチオ基、エチルチオ基)、アリールチオ基(好ましくは炭素数が6~12、より好ましくは炭素数が6~8のアリールチオ基、例えば、フェニルチオ基)、複素環チオ基(好ましくは炭素数が2~10、より好ましくは炭素数が1~6の複素環チオ基、例えば、2-ベンゾチアゾリルチオ基)、イミド基(好ましくは炭素数が2~10、より好ましくは炭素数が4~8のイミド基、例えば、N-スクシンイミド基、N-フタルイミド基)等が例示されるが、これらに特に限定されない。
-C(=O)X (2)
(式(2)中、Xは、水素原子、ヒドロキシ基、アルキル基、アルコキシ基、モノアルキルアミノ基、及びジアルキルアミノ基からなる群より選ばれる1つであり、複数のXは、同一であってもよいし、異なっていてもよい。)
(A)テトラリン環の芳香族環に上記一般式(2)で表される一価の置換基が1以上結合されており、テトラリン環の脂肪族環に上記一般式(2)で表される一価の置換基が1以上結合されている。
(B)テトラリン環の芳香族環に上記一般式(2)で表される一価の置換基が2以上結合されている。
(C)テトラリン環の脂肪族環に上記一般式(2)で表される一価の置換基が2以上結合されている。
の何れかを満たすものがより好ましい。
酸素吸収性組成物において使用される遷移金属触媒としては、上記のテトラリン環を有する化合物の酸化反応の触媒として機能し得るものであれば、公知のものから適宜選択して用いることができ、特に限定されない。
酸素吸収性組成物は、熱可塑性樹脂(a)を含有する。このとき、酸素吸収性組成物中における前記化合物と遷移金属触媒の含有形態は、特に限定されない。例えば、前記化合物及び遷移金属触媒が熱可塑性樹脂(a)中にそのまま含有されていても、前記化合物及び遷移金属触媒が上述した担体物質に担持された状態で熱可塑性樹脂(a)中に含有されていてもよい。
酸素吸収性組成物に用いられるポリオレフィンとしては、例えば、低密度ポリエチレン、中密度ポリエチレン、高密度ポリエチレン、線状低密度ポリエチレン、線状超低密度ポリエチレン等のポリエチレン、ポリプロピレン、ポリブテン-1、ポリ-4-メチルペンテン-1等のオレフィン単独重合体;エチレン-プロピレンランダム共重合体、エチレン-プロピレンブロック共重合体、エチレン-プロピレン-ポリブテン-1共重合体、エチレン-環状オレフィン共重合体等のエチレンとα-オレフィンとの共重合体;エチレン-(メタ)アクリル酸共重合体等のエチレン-α,β-不飽和カルボン酸共重合体、エチレン-(メタ)アクリル酸エチル共重合体等のエチレン-α,β-不飽和カルボン酸エステル共重合体、エチレン-α,β-不飽和カルボン酸共重合体のイオン架橋物、エチレン-酢酸ビニル共重合体等のその他のエチレン共重合体;環状オレフィン類開環重合体及びその水素添加物;環状オレフィン類-エチレン共重合体;とこれらのポリオレフィンを無水マレイン酸等の酸無水物等でグラフト変性したグラフト変性ポリオレフィン等が挙げられる。
酸素吸収性組成物に用いられるポリエステルとしては、例えば、ジカルボン酸を含む多価カルボン酸及びこれらのエステル形成性誘導体から選ばれる1種又は2種以上とグリコールを含む多価アルコールから選ばれる1種又は2種以上とからなるもの、又はヒドロキシカルボン酸及びこれらのエステル形成性誘導体からなるもの、又は環状エステルからなるもの等が挙げられる。エチレンテレフタレート系熱可塑性ポリエステルは、エステル反復単位の大部分、一般に70モル%以上をエチレンテレフタレート単位が占めるものであり、ガラス転移点(Tg)が50~90℃、融点(Tm)が200~275℃の範囲にあるものが好適である。エチレンテレフタレート系熱可塑性ポリエステルとしてポリエチレンテレフタレートが耐圧性、耐熱性、耐熱圧性等の点で特に優れているが、エチレンテレフタレート単位以外にイソフタル酸やナフタレンジカルボン酸等のジカルボン酸とプロピレングリコール等のジオールからなるエステル単位の少量を含む共重合ポリエステルも使用できる。
酸素吸収性組成物に用いられるポリアミドとしては、例えば、ラクタムもしくはアミノカルボン酸から誘導される単位を主構成単位とするポリアミドや、脂肪族ジアミンと脂肪族ジカルボン酸とから誘導される単位を主構成単位とする脂肪族ポリアミド、脂肪族ジアミンと芳香族ジカルボン酸とから誘導される単位を主構成単位とする部分芳香族ポリアミド、芳香族ジアミンと脂肪族ジカルボン酸とから誘導される単位を主構成単位とする部分芳香族ポリアミド等が挙げられる。なお、ここでいうポリアミドは、必要に応じて、主構成単位以外のモノマー単位が共重合されたものであってもよい。
酸素吸収性組成物に用いられるエチレンビニルアルコール共重合体としては、エチレン含量が15~60モル%であり、且つ、酢酸ビニル成分のケン化度が90モル%以上のものが好適である。エチレン含量は、好ましくは20~55モル%であり、より好ましくは29~44モル%である。また、酢酸ビニル成分のケン化度は、好ましくは95モル%以上である。なお、エチレンビニルアルコール共重合体は、プロピレン、イソブテン、α-オクテン、α-ドデセン、α-オクタデセン等のα-オレフィン、不飽和カルボン酸又はその塩、部分アルキルエステル、完全アルキルエステル、ニトリル、アミド、無水物、不飽和スルホン酸又はその塩等の少量のコモノマーを更に含んでいてもよい。
酸素吸収性組成物に用いられる植物由来樹脂としては、原料として植物由来物質を含む樹脂であればよく、その原料となる植物は特に限定されない。植物由来樹脂の具体例としては、脂肪族ポリエステル系生分解性樹脂が挙げられる。また、脂肪族ポリエステル系生分解性樹脂としては、例えば、ポリグリコール酸(PGA)、ポリ乳酸(PLA)等のポリ(α-ヒドロキシ酸);ポリブチレンサクシネート(PBS)、ポリエチレンサクシネート(PES)等のポリアルキレンアルカノエート等が挙げられる。
酸素吸収性組成物に用いられる塩素系樹脂としては、構成単位に塩素を含む樹脂であればよく、公知の樹脂を用いることができる。塩素系樹脂の具体例としては、ポリ塩化ビニル、ポリ塩化ビニリデン、及び、これらと酢酸ビニル、マレイン酸誘導体、高級アルキルビニルエーテル等との共重合体等が挙げられる。
本実施形態の酸素吸収性医療用多層体の熱可塑性樹脂層(層B)は、熱可塑性樹脂(b)を含有する層である。層B中の熱可塑性樹脂(b)の含有量は、適宜設定でき、特に限定されないが、層Bの総量に対して、70~100質量%が好ましく、より好ましくは80~100質量%であり、更に好ましくは90~100質量%である。
本実施形態の酸素吸収性医療用多層体は、所望する性能等に応じて、上述した酸素吸収層(層A)及び樹脂層(層B)の他に、任意の層を更に含んでいてもよい。そのような任意の層としては、例えば、接着層、金属箔、金属蒸着層及び有機-無機膜等が挙げられる。
本実施形態の酸素吸収性医療用多層容器の製造方法は、各種材料の性状や目的とする形状等に応じて、公知の方法を適用することができ、特に限定されない。各種の射出成形法を適用して、酸素吸収性医療用多層容器を製造することができる。
本実施形態の酸素吸収性医療用多層容器は、バイアルとして使用することができる。一般的には、バイアルは、ボトル、ゴム栓、キャップから構成され、薬液をボトルに充填後、ゴム栓をして、さらにその上からキャップを巻締めることで、ボトル内が密閉されている。このバイアルのボトル部分に、本実施形態の酸素吸収性医療用多層容器を用いることができる。
また、本実施形態の酸素吸収性医療用多層容器は、アンプルとして使用することができる。一般的には、アンプルは、頸部が細く形成された小容器から構成され、薬液を容器内に充填後、頸部の先を熔封することで、容器内が密閉されている。このアンプル(小容器)に本実施形態の酸素吸収性医療用多層容器を用いることができる。本実施形態の酸素吸収性医療用多層容器をアンプルに成形する方法としては、例えば、射出ブロー成形、押出しブロー成形等が好適である。
さらに、本実施形態の酸素吸収性医療用多層容器は、プレフィルドシリンジのバレルとして使用することができる。一般的なプレフィルドシリンジバレルの形状は、注射針を接続することができるオス型ルアーテーパのノズル、ノズル基端から円筒部にかけて肩部が形成され、円筒部基端にフランジが形成されたものである。薬剤収容時には前記ノズルをキャップにより封止し、前記円筒部内にはプランジャーが接続されたガスケットを挿入する。このバレルに本実施形態の酸素吸収性医療用多層容器を用いることができる。
また、本実施形態の酸素吸収性医療用多層容器は、真空採血管として使用することができる。一般的には、真空採血管は、管状体及び栓体から構成されている。この管状体に、本実施形態の酸素吸収性医療用多層容器を用いることができる。
本実施形態の酸素吸収性医療用多層容器に充填される被保存物(充填物)は、特に限定されない。例えば、ビタミンA、ビタミンB2、ビタミンB12、ビタミンC、ビタミンD、ビタミンE、ビタミンK等のビタミン剤、アトロピン等のアルカロイド、アドレナリン、インシュリン等のホルモン剤、ブドウ糖、マルトース等の糖類、セフトリアキソン、セファロスポリン、シクロスポリン等の抗生物質、オキサゾラム、フルニトラゼパム、クロチアゼパム、クロバザム等のベンゾジアゼピン系薬剤等、任意の天然物や化合物を充填可能である。本実施形態の酸素吸収性医療用多層容器は、これらの天然物や化合物を充填した場合、これらの天然物や化合物の吸着量が少なく、またこれらの酸化による変質を抑制することができ、また、溶媒(例えば水分)の蒸散を抑制することもできる。
[酸素吸収性医療用多層容器]
本実施形態の酸素吸収性医療用多層容器は、ポリオレフィン(PO1)を含有する第1の樹脂層(層B)と、酸素吸収性組成物を含有する酸素吸収性層(層A)と、ポリオレフィン(PO2)を含有する第2の樹脂層(層B)との少なくとも3層をこの順に有する、酸素吸収性医療用多層容器であって、
前記酸素吸収性組成物が、下記一般式(1)で表されるテトラリン環を有する化合物を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含む、
酸素吸収性医療用多層容器である。
本実施形態の酸素吸収性医療用多層容器の酸素吸収層(層A)は、上記一般式(1)で表されるテトラリン環を有する化合物(以下、単に「テトラリン化合物」ともいう。)を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含有する酸素吸収性組成物を含む層である。
上記した第1の実施形態で述べたテトラリン環を有する化合物を適宜用いることができる。
上記した第1の実施形態で述べた遷移金属触媒を適宜用いることができる。
上記した第1の実施形態で述べた熱可塑性樹脂(a)を適宜用いることができる。
本実施形態の酸素吸収性医療用多層容器において樹脂層(層B;第1の樹脂層、第2の樹脂層)は、ポリオレフィン(PO1、PO2)を含有する。
本実施形態の層Bで用いられるポリオレフィン(PO1、PO2)の具体例としては、ポリエチレン(低密度ポリエチレン、中密度ポリエチレン、高密度ポリエチレン、直鎖状(線状)低密度ポリエチレン)、ポリプロピレン、ポリブテン-1、ポリ-4-メチルペンテン-1、エチレンとα-オレフィンとの共重合体、プロピレンとα-オレフィン共重合体、エチレン-α,β-不飽和カルボン酸共重合体、エチレン-α,β-不飽和カルボン酸エステル共重合体等が挙げられるが、これらに特に限定されない。これらポリオレフィンの具体例としては、上記した第2実施形態の酸素吸収性多層体の層Bにおいて好適に用いられる熱可塑性樹脂で示したものが挙げられる。とりわけ、ノルボルネンもしくはテトラシクロドデセン又はそれらの誘導体等のシクロオレフィン類開環重合体及びその水素添加物、ノルボルネンもしくはテトラシクロドデセン又はその誘導体等のシクロオレフィンと、エチレン又はプロピレンとの重合により分子鎖にシクロペンチル残基や置換シクロペンチル残基が挿入された共重合体である樹脂がより好ましい。ここで、シクロオレフィンは、単環式及び多環式のものを含む。また、熱可塑性ノルボルネン系樹脂又は熱可塑性テトラシクロドデセン系樹脂もより好ましいものの1つである。熱可塑性ノルボルネン系樹脂としては、ノルボルネン系単量体の開環重合体、その水素添加物、ノルボルネン系単量体の付加型重合体、ノルボルネン系単量体とオレフィンの付加型重合体等が挙げられる。熱可塑性テトラシクロドデセン系樹脂としては、テトラシクロドデセン系単量体の開環重合体、その水素添加物、テトラシクロドデセン系単量体の付加型重合体、テトラシクロドデセン系単量体とオレフィンの付加型重合体等が挙げられる。熱可塑性ノルボルネン系樹脂は、例えば、特開平03-014882号公報、特開平03-122137号公報、特開平04-063807号公報等に記載されている。なお、ポリオレフィン(PO1)とポリオレフィン(PO2)は、同一の種類であってもよいし、異なる種類であってもよい。
本実施形態の酸素吸収性医療用多層体は、所望する性能等に応じて、上述した酸素吸収層(層A)及び樹脂層(層B)の他に、任意の層を更に含んでいてもよい。そのような任意の層としては、例えば、接着層、金属箔、金属蒸着層及び有機-無機膜等が挙げられる。これらは、上記した第1の実施形態で述べた他の層を適宜用いることができる。
本実施形態の酸素吸収性医療用多層容器の製造方法は、各種材料の性状や目的とする形状等に応じて、公知の方法を適用することができ、特に限定されない。各種の射出成形法等を適用して、酸素吸収性医療用多層容器を製造することができる。なお、多層体の射出成形一般についての詳細は上記した第1の実施形態において説明したものと同一であり、ここでの重複した説明は省略する。
本実施形態の酸素吸収性医療用多層容器に充填される被保存物(充填物)は、特に限定されない。なお、被保存物についての詳細は上記した第1の実施形態において説明したものと同一であり、ここでの重複した説明は省略する。
[酸素吸収性医療用多層容器]
本実施形態の酸素吸収性医療用多層容器は、ポリエステル(PES1)を含有する第1の樹脂層と、酸素吸収性組成物を含有する酸素吸収性層と、ポリエステル(PES2)を含有する第2の樹脂層との少なくとも3層をこの順に有する、酸素吸収性医療用多層容器であって、前記酸素吸収性組成物が、一般式(1)で表されるテトラリン環を有する化合物を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂を含む、酸素吸収性医療用多層容器である。
本実施形態の酸素吸収性医療用多層容器の酸素吸収層(層A)は、上記一般式(1)で表されるテトラリン環を有する化合物(以下、単に「テトラリン化合物」ともいう。)を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂を含有する酸素吸収性組成物を含む層である。
上記した第1の実施形態で述べたテトラリン環を有する化合物を適宜用いることができる。
本実施形態の酸素吸収性組成物において使用される遷移金属触媒としては、上記のテトラリン環を有する化合物の酸化反応の触媒として機能し得るものであれば、公知のものから適宜選択して用いることができ、特に限定されない。遷移金属触媒としては、上記した第1の実施形態で述べた遷移金属触媒を適宜用いることができる。なお、本実施形態では、前記化合物、遷移金属触媒及び熱可塑性樹脂(a)は、公知の方法で混合することができるが、好ましくは押出機により混練することにより、分散状態の良好な酸素吸収性組成物として使用することができる。
本実施形態の酸素吸収性組成物は、熱可塑性樹脂を含有する。このとき、酸素吸収性組成物中における前記化合物と遷移金属触媒の含有形態は、特に限定されない。例えば、前記化合物及び遷移金属触媒が熱可塑性樹脂中にそのまま含有されていても、前記化合物及び遷移金属触媒が上述した担体物質に担持された状態で熱可塑性樹脂中に含有されていてもよい。熱可塑性樹脂(a)としては、上記した第1の実施形態で述べた熱可塑性樹脂(a)を適宜用いることができる。
本実施形態の酸素吸収性医療用多層容器において樹脂層(層B)は、ポリエステル(PES1、PES2)を含有する層である。
本実施形態の酸素吸収性医療用多層体は、所望する性能等に応じて、上述した酸素吸収層(層A)及びポリエステルを含有する樹脂層(層B)の他に、任意の層を更に含んでいてもよい。そのような任意の層としては、例えば、接着層、金属蒸着層及び有機-無機膜等が挙げられる。他の層としては、上記した第1の実施形態の他の層を適宜用いることができる。なお、金属蒸着層としては、特に限定されないが、内容物視認性を確保する観点等からシリカやアルミナ等の透明蒸着膜が好ましい。
本実施形態の酸素吸収性医療用多層容器に充填される被保存物(充填物)は、特に限定されない。なお、被保存物についての詳細は上記した第1の実施形態において説明したものと同一であり、ここでの重複した説明は省略する。
[酸素吸収性プレフィルドシリンジ]
本実施形態の酸素吸収性プレフィルドシリンジは、予め薬剤を密封状態下に収容し、使用に際し前記密封状態を解除して前記薬剤を注出し得るようにされた酸素吸収性プレフィルドシリンジであって、
前記プレフィルドシリンジが、熱可塑性樹脂(b1)を少なくとも含有する第1の樹脂層と、酸素吸収性組成物を含有する酸素吸収層と、熱可塑性樹脂(b2)を少なくとも含有する第2の樹脂層の少なくとも3層をこの順に有し、
前記酸素吸収性組成物が下記一般式(1)で表されるテトラリン環を有する化合物を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含有する、
酸素吸収性プレフィルドシリンジである。
本実施形態の酸素吸収性医療用多層容器の酸素吸収層(層A)は、上記一般式(1)で表されるテトラリン環を有する化合物を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含有する酸素吸収性組成物を含む層である。この酸素吸収性組成物は、酸素吸収後の低分子量化合物の生成が著しく抑制することができるものである。その理由は明らかではないが、例えば以下の酸化反応機構が推測される。
上記の一般式(1)で表されるテトラリン環を有する化合物においては、まずテトラリン環のベンジル位にある水素が引き抜かれてラジカルが生成し、その後、ラジカルと酸素との反応によりベンジル位の炭素が酸化され、ヒドロキシ基又はケトン基が生成すると考えられる。そのため、酸素吸収性組成物としては、従来技術のような酸化反応による酸素吸収主剤の分子鎖の切断がなく、酸素吸収主剤である化合物の構造が維持されるため、低分子量の有機化合物の生成が抑制されているものと推測される。
上記した第1の実施形態で述べたテトラリン環を有する化合物を適宜用いることができる。
本実施形態の酸素吸収性組成物において使用される遷移金属触媒としては、上記のテトラリン環を有する化合物の酸化反応の触媒として機能し得るものであれば、公知のものから適宜選択して用いることができ、特に限定されない。遷移金属触媒としては、上記した第1の実施形態で述べた遷移金属触媒を適宜用いることができる。なお、本実施形態では、前記化合物、遷移金属触媒及び熱可塑性樹脂(a)は、公知の方法で混合することができるが、好ましくは押出機により混練することにより、分散状態の良好な酸素吸収性組成物として使用することができる。
本実施形態の酸素吸収性組成物は、熱可塑性樹脂(a)を含有する。このとき、酸素吸収性組成物中における前記化合物と遷移金属触媒の含有形態は、特に限定されない。例えば、前記化合物及び遷移金属触媒が熱可塑性樹脂(a)中にそのまま含有されていても、前記化合物及び遷移金属触媒が上述した担体物質に担持された状態で熱可塑性樹脂(a)中に含有されていてもよい。熱可塑性樹脂(a)としては、上記した第1の実施形態で述べた熱可塑性樹脂(a)を適宜用いることができる。
本実施形態の酸素吸収性プレフィルドシリンジの第1の樹脂層及び第2の樹脂層(層B)は、熱可塑性樹脂(b)を含有する層である。各層B中の熱可塑性樹脂(b)の含有量は、適宜設定でき、特に限定されないが、層Bの総量に対して70~100質量%が好ましく、より好ましくは80~100質量%であり、更に好ましくは90~100質量%である。
本実施形態の酸素吸収性プレフィルドシリンジは、所望する性能等に応じて、上述した酸素吸収層(層A)及び樹脂層(層B)の他に、任意の層を更に含んでいてもよい。そのような任意の層としては、例えば、接着層、金属蒸着層及び有機-無機膜等が挙げられる。
一般的なプレフィルドシリンジバレルの形状は、注射針を接続することができるオス型ルアーテーパのノズル、ノズル基端から円筒部にかけて肩部が形成され、円筒部基端にフランジが形成されたものである。薬剤収容時には前記ノズルをキャップにより封止し、前記円筒部内にはプランジャーが接続されたガスケットを挿入する。上述したバレル形状の酸素吸収性積層体を成形することにより、本実施形態の酸素吸収性プレフィルドシリンジを製造することができる。製造方法は、各種材料の性状や目的とする形状等に応じて、公知の方法を適用することができ、特に限定されないが、射出成形法が好適である。
本実施形態の酸素吸収性プレフィルドシリンジに充填される被保存物(充填物)としては、薬液等の薬剤であればよく、その種類等は特に限定されない。例えば、ビタミンA、ビタミンB2、ビタミンB12、ビタミンC、ビタミンD、ビタミンE、ビタミンK等のビタミン剤、アトロピン等のアルカロイド、アドレナリン、インシュリン等のホルモン剤、ブドウ糖、マルトース等の糖類、セフトリアキソン、セファロスポリン、シクロスポリン等の抗生物質、オキサゾラム、フルニトラゼパム、クロチアゼパム、クロバザム等のベンゾジアゼピン系薬剤等、任意の天然物や化合物を充填可能である。本実施形態の酸素吸収性プレフィルドシリンジは、これらの天然物や化合物を充填した場合、これらの天然物や化合物の吸着量が少なく、またこれらの酸化による変質を抑制することができ、また、溶媒(例えば水分)の蒸散を抑制することもできる。
[バイオ医薬の保存方法]
本実施形態のバイオ医薬の保存方法は、バイオ医薬を、酸素吸収性組成物を含有する酸素吸収層と、熱可塑性樹脂(b)を含有する樹脂層と、を含む酸素吸収性医療用多層容器内に保存するバイオ医薬の保存方法であって、前記酸素吸収性組成物が、下記一般式(1)で表されるテトラリン環を有する化合物を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含む、バイオ医薬の保存方法である。
本実施形態のバイオ医薬の保存方法では、第1の実施形態、第2の実施形態、第3の実施形態、第4の実施形態の酸素吸収性医療用多層容器等を使用することができる。さらに、以下において、本実施形態の保存方法にて使用する酸素吸収性医療用多層容器の一形態例を説明する。この酸素吸収性医療用多層容器における層構成は、特に限定されず、酸素吸収層(層A)及び樹脂層(層B)の数や種類は特に限定されない。例えば、1つの層A及び1つの層BからなるA/B構成であってもよく、1つの層A及び2つの層BからなるB/A/Bの3層構成であってもよい。また、1つの層Aと、2つの層B1及び2つの層B2からなるB1/B2/A/B2/B1の5層構成であってもよく、1層の層A並びに層B1及び層B2の2種2層からなるB1/A/B2の3層構成であってもよい。さらに、本実施形態の多層インジェクション成形体は、必要に応じて接着層(層AD)等の任意の層を含んでもよく、例えば、B1/AD/B2/A/B2/AD/B1の7層構成であってもよい。
酸素吸収層(層A)は、上記一般式(1)で表されるテトラリン環を有する化合物(以下、単に「テトラリン化合物」ともいう。)を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含有する酸素吸収性組成物を含む層である。
上記した第1の実施形態で述べたテトラリン環を有する化合物を適宜用いることができる。
上記した第1の実施形態で述べた遷移金属触媒を適宜用いることができる。
上記した第1の実施形態で述べた熱可塑性樹脂(a)を適宜用いることができる。
酸素吸収性医療用多層容器の樹脂層(層B)は、熱可塑性樹脂を含有する層である。層B中の熱可塑性樹脂(b1、b2)の含有量は、適宜設定でき、特に限定されないが、層Bの総量に対して、70~100質量%が好ましく、より好ましくは80~100質量%であり、更に好ましくは90~100質量%である。
本実施形態の酸素吸収性医療用多層容器は、所望する性能等に応じて、上述した酸素吸収層(層A)及び樹脂層(層B)の他に、任意の層を更に含んでいてもよい。そのような任意の層としては、例えば、接着層、金属箔、金属蒸着層及び有機-無機膜等が挙げられる。
酸素吸収性医療用多層容器の製造方法は、各種材料の性状や目的とする形状等に応じて、公知の方法を適用することができ、特に限定されない。例えば、各種の射出成形法を適用して、酸素吸収性医療用多層容器を製造することができる。
温度計、分縮器、全縮器、撹拌装置を備えた反応器に、1,2,3,4-テトラヒドロナフタレン-2,6-ジカルボン酸ジメチル248g(1.0mol)、n-ヘキシルアルコール409g(4.0mol)、テトラブチルチタネート0.34gを仕込み、窒素雰囲気下で150℃まで昇温し、生成するメタノールを系外へ除きながら反応を行った。メタノールの生成が止まった後、室温まで冷却し、未反応のn-ヘキシルアルコールを減圧除去することにより、ジエステル化合物Aを得た。示差熱・熱重量同時測定装置(株式会社島津製作所製、商品名「DTG-60」)を用いて、得られた化合物の3%重量減少温度を測定した。得られた化合物の構造式及び分子量、3%重量減少温度を表1に示す。なお、NMRの分析結果は下記の通りであった。1H-NMR(400MHz CDCl3)δ7.73-7.79(2H m)、7.16(1H d)、4.29(2H t)、4.10(2H t)、3.01-3.08(2H m)、2.82-2.97(2H m)、2.70-2.78(1H m)、2.18-2.24(1H m)、1.84-1.94(1H m)、1.71-1.79(2H m)、1.58-1.68(2H m)、1.25-1.48(12H m)、0.90(6H t)。
n-ヘキシルアルコールに代えてn-オクチルアルコールを用い、その配合量を521g(4.0mol)とし、反応温度を190℃とすること以外は、合成例1と同様の操作を行い、ジエステル化合物Bを得た。示差熱・熱重量同時測定装置(株式会社島津製作所製、商品名「DTG-60」)を用いて、得られた化合物の3%重量減少温度を測定した。得られた化合物の構造式及び分子量、3%重量減少温度を表1に示す。なお、NMRの分析結果は下記の通りであった。1H-NMR(400MHz CDCl3)δ7.68-7.74(2H m)、7.10(1H d)、4.23(2H t)、4.04(2H t)、2.92-3.00(2H m)、2.72-2.89(2H m)、2.63-2.70(1H m)、2.10-2.18(1H m)、1.76-1.85(1H m)、1.63-1.72(2H m)、1.50-1.59(2H m)、1.09-1.40(20H m)、0.90(6H t)。
1,2,3,4-テトラヒドロナフタレン-2,6-ジカルボン酸ジメチルに代えて1,2,3,4-テトラヒドロナフタレン-1,8-ジカルボン酸ジメチルを用いた以外は、合成2と同様の操作を行い、ジエステル化合物Cを得た。示差熱・熱重量同時測定装置(株式会社島津製作所製、商品名「DTG-60」)を用いて、得られた化合物の3%重量減少温度を測定した。得られた化合物の構造式及び分子量、3%重量減少温度を表1に示す。なお、NMRの分析結果は下記の通りであった。1H-NMR(400MHz CDCl3)δ7.78(1H d)、7.17-7.29(2H m)、4.50(1H t)、4.22(2H t)、3.98-4.12(2H m)、2.76-2.93(2H m)、2.21-2.30(1H m)、1.89-1.99(1H m)、1.67-1.83(4H m)、1.50-1.63(3H m)、1.18-1.44(19H m)、0.89(6H t)。
温度計、分縮器、全縮器、撹拌装置を備えた反応器に、アジピン酸ジメチル108g(0.62mmol)、6-ヒドロキシメチル-1,2,3,4-テトラヒドロナフタレン300g(1.85mmol)を仕込み、130℃まで昇温した。チタンテトラブトキシド0.58gを添加した後に、200℃まで昇温し、生成するメタノールを系外へ除きながら反応を行った。メタノールの生成が止まった後、室温まで冷却し、未反応の6-ヒドロキシメチル-1,2,3,4-テトラヒドロナフタレンを減圧除去した後に、再結晶により、ジエステル化合物Dを得た。示差熱・熱重量同時測定装置(株式会社島津製作所製、商品名「DTG-60」)を用いて、得られた化合物の3%重量減少温度を測定した。得られた化合物の構造式及び分子量、3%重量減少温度を表1に示す。なお、NMRの分析結果は下記の通りであった。1H-NMR(400MHz CDCl3)δ7.00(6H m)、5.02(4H s)、2.70-2.79(8H m)、2.34(4H t)、1.74-1.83(8H m)、1.64-1.70(4H m)。
温度計、撹拌装置を備えた2000mLオートクレーブに1,2,3,4-テトラヒドロナフタレン-2,6-ジカルボン酸ジメチル248g(1.0mol)、n-ヘキシルアミン607g(6.0mol)を仕込み、窒素置換した後、220℃まで昇温し5時間加熱撹拌した。室温まで冷却後、ろ過し、再結晶によりジアミド化合物Eを得た。示差熱・熱重量同時測定装置(株式会社島津製作所製、商品名「DTG-60」)を用いて、得られた化合物の3%重量減少温度を測定した。得られた化合物の構造式及び分子量、3%重量減少温度を表1に示す。なお、NMRの分析結果は下記の通りであった。1H-NMR(400MHz CDCl3)δ7.42(1H s)、7.37(1H d)、7.04(1H d)、5.99(1H m)、5.53(1H m)、3.32-3.41(2H m)、3.15-3.24(2H m)、2.68-3.03(4H m)、2.35-2.43(1H m)、1.97-2.05(1H m)、1.76-1.87(1H m)、1.17-1.58(12H m)、0.83(6H t)。
内容積18Lオートクレーブに、1,8-ナフタル酸無水物1.8kg、5重量%パラジウムを活性炭に担持させた触媒(乾燥品)300g、酢酸エチル7.5kgを仕込んだ。室温で、オートクレーブ内を窒素1MPaで2回置換し、次いで水素1MPaで2回置換した。その後常圧まで落圧した後、内温80℃に昇温し、水素で5MPaまで加圧し、同温度、同圧力で、500rpmで2時間攪拌した。反応後、室温まで冷却し、水素を放出し、窒素1MPaで2回置換した後、触媒を濾別し、触媒をアセトン1.0kgで3回洗浄した。得られた母液から溶媒をエバポレーターにより減圧除去して、粗生成物を得た。得られた組成生物を再結晶することで酸無水物Fを得た。示差熱・熱重量同時測定装置(株式会社島津製作所製、商品名「DTG-60」)を用いて、得られた化合物の3%重量減少温度を測定した。得られた化合物の構造式及び分子量、3%重量減少温度を表1に示す。なお、NMRの分析結果は下記の通りであった。1H-NMR(400MHz CDCl3)δ7.98(1H d)、7.47(1H d)、7.38(1H dd)、3.93(1H t)、2.80-3.00(2H m)、2.55-2.64(1H m)、2.14-2.24(1H m)、1.77-1.94(2H m)。
(実施例1-1)
直径37mmのスクリューを2本有する2軸押出機を用いて、エチレン-ビニルアルコール共重合体(株式会社クラレ製、商品名「エバールL171B」、以下、「EVOH」とも略する。)95質量部に対し、ジエステル化合物A5質量部、及び、コバルト量が0.05質量部となるようステアリン酸コバルト(II)を220℃で溶融混練し、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることで酸素吸収性組成物(1)を得た。次いで、下記に示すとおり、この酸素吸収性組成物(1)を用いて、酸素吸収性医療用多層成形体であるバイアルを製造した。その後、得られたバイアルの性能評価を、以下に示すとおりに行った。評価結果を表2に示す。
下記の条件により、樹脂層(層B)を構成する熱可塑性樹脂を射出シリンダーから射出し、次いで酸素吸収層(層A)を構成する酸素吸収性組成物(1)を別の射出シリンダーから、層Bを構成する熱可塑性樹脂と同時に射出し、次に層Bを構成する熱可塑性樹脂を必要量射出して射出金型内キャビティーを満たすことにより、B/A/Bの3層構成の射出成形体を得た。その後、得られた射出成形体を所定の温度まで冷却し、ブロー金型へ移行し、ブロー成形を行うことで、バイアル(ボトル部)を製造した。ここで、バイアルの総質量は24gとし、層Aの質量はバイアルの総質量の30質量%とした。また、層Bを構成する熱可塑性樹脂としては、ポリプロピレン(日本ポリプロ株式会社、商品名「MG03B」)を使用した。
全長89mm、外径40mmφ、肉厚1.8mmとした。なお、バイアルの製造には、射出ブロー一体型成形機(UNILOY製、型式:IBS 85、4個取り)を使用した。
(バイアルの成形条件)
層A用の射出シリンダー温度:220℃
層B用の射出シリンダー温度:280℃
射出金型内樹脂流路温度 :280℃
ブロー温度 :150℃
ブロー金型冷却水温度 :15℃
得られたバイアルの酸素透過率の測定、成形後の外観評価、落下試験、溶出試験について、以下の方法及び基準にしたがって測定し、評価した。
23℃、成形体外部の相対湿度50%、成形体内部の相対湿度100%の雰囲気下にて、測定開始から30日目の酸素透過率を測定した。測定は、酸素透過率測定装置(MOCON社製、商品名「OX-TRAN 2-21 ML」)を使用した。測定値が低いほど、酸素バリア性が良好であることを示す。なお、測定の検出下限界は酸素透過率5×10-5mL/(0.21atm・day・package)である。
バイアルの内容物視認性を目視にて観察した。内容物の体積、色調確認ができて、視認性に問題ないものを合格とした。
バイアルを40℃、90%RH下にて1カ月保存した後、純水50mLを満杯充填し、その後、ゴム栓及びアルミキャップにて密封した。このようにして得られた密封容器を2mの高さから落下させ、そのときの容器外観を調査した。この密封容器を20個用意して、20個についての容器外観を調査した。
バイアルを40℃、90%RH下にて1カ月保存した後、純水50mLを満杯充填し、その後、ゴム栓及びアルミキャップにて密封した。このようにして得られた密封容器を40℃、60%RH下にて4カ月保存し、その後、純水中のトータルカーボン量(以下、TOC)を測定した。
(TOC測定)
装置 :株式会社島津製作所製 TOC-VCPH
燃焼炉温度 :720℃
ガス・流量 :高純度空気、TOC計部150mL/min
注入量 :150μL
検出限界 :1μg/mL
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例1と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例1-1と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例1-1と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例1-1と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例1-1と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ポリプロピレンをポリカーボネート(Sabic社製、商品名「レキサン144R」)に代え、EVOHを非晶ポリアミド(三菱エンジニアリングプラスチックス株式会社製、商品名「NOVAMID X21-F07」、以下、「6IT」とも略する。)に代え、層A用の射出シリンダー温度を260℃とした以外は、実施例1-1と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例1-7と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例1-7と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例1-7と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例1-7と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例1-7と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。結果を表2に示す。
層を構成する樹脂をポリプロピレン(日本ポリプロ株式会社製、商品名「MG03B」)100質量部を用いたこと以外は、実施例1-1と同様に行い、実施例1-1と同形状の単層のバイアルを製造した。得られたバイアルの性能評価を実施例1-1と同様に行った。評価結果を表2に示す。
層を構成する樹脂として、ポリプロピレンをポリカーボネート(Sabic社製、商品名「レキサン144R」)100質量部を用いたこと以外は、実施例1-1と同様に行い、実施例1-1と同形状の単層のバイアルを製造した。得られたバイアルの性能評価を実施例1-1と同様に行った。評価結果を表2に示す。
ジエステル化合物A及びステアリン酸コバルトを用いなかった以外は、実施例1-1と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。すなわち、3層構造ではあるが、テトラリン環を有する化合物と遷移金属を用いなかった(表2参照)。これらの結果を表2に示す。
ジエステル化合物A及びステアリン酸コバルトを用いなかった以外は、実施例1-7と同様にして多層バイアルを作製して、実施例1-1と同様の評価を行った。すなわち、3層構造ではあるが、テトラリン環を有する化合物と遷移金属を用いなかった(表2参照)。これらの結果を表2に示す。
ナイロンMXD6(三菱瓦斯化学株式会社製、商品名「S7007」)100質量部に対し、ステアリン酸コバルト(II)をコバルト量が0.04質量部となるようドライブレンドして得られた混合物を、直径37mmのスクリューを2本有する2軸押出機に15kg/hの速度で供給し、シリンダー温度280℃の条件にて溶融混練を行い、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることにより、酸素吸収性組成物(M)を得た。酸素吸収性組成物(1)に代えてこの酸素吸収性組成物(M)を用いたこと以外は、実施例1-1と同様に行い、バイアルを製造した。得られたバイアルの性能評価を実施例1-1と同様に行った。評価結果を表2に示す。
上記した合成例1~4にて作製したテトラリン環を有するジエステル化合物A~D、及び合成例5にて作製したテトラリン環を有するジアミド化合物E、及び合成例6にて作製したテトラリン環を有する酸無水物Fを用いた。
直径37mmのスクリューを2本有する2軸押出機を用いて、エチレン-ビニルアルコール共重合体(株式会社クラレ製、商品名「エバールL171B」、以下、「EVOH」とも略する。)95質量部に対し、ジエステル化合物A5質量部、及び、コバルト量が0.05質量部となるようステアリン酸コバルト(II)を220℃で溶融混練し、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることで酸素吸収性組成物(1)を得た。次いで、下記に示すとおり、この酸素吸収性組成物(1)を用いて、酸素吸収性医療用多層成形体であるバイアルを製造した。その後、得られたバイアルの性能評価を、以下に示すとおりに行った。評価結果を表3に示す。
下記の条件により、ポリオレフィンを含有する樹脂層(層B)を構成するポリオレフィンを射出シリンダーから射出し、次いで酸素吸収層(層A)を構成する酸素吸収性組成物(1)を別の射出シリンダーから、層Bを構成するポリオレフィンと同時に射出し、次に層Bを構成するポリオレフィンを必要量射出して射出金型内キャビティーを満たすことにより、B/A/Bの3層構成の射出成形体を得た。その後、得られた射出成形体を所定の温度まで冷却し、ブロー金型へ移行し、ブロー成形を行うことで、バイアル(ボトル部)を製造した。ここで、バイアルの総質量は24gとし、層Aの質量はバイアルの総質量の30質量%とした。また、層Bを構成するポリオレフィンとしては、シクロオレフィンポリマー(日本ゼオン株式会社製、商品名「ZEONEX 690R」、以下、「COP」とも略する。)を使用した。
全長89mm、外径40mmφ、肉厚1.8mmとした。なお、バイアルの製造には、射出ブロー一体型成形機(UNILOY製、型式:IBS 85、4個取り)を使用した。
(バイアルの成形条件)
層A用の射出シリンダー温度:220℃
層B用の射出シリンダー温度:280℃
射出金型内樹脂流路温度 :280℃
ブロー温度 :150℃
ブロー金型冷却水温度 :15℃
得られたバイアルの酸素透過率の測定、成形後の外観評価、落下試験、溶出試験について、以下の方法及び基準にしたがって測定し、評価した。
23℃、成形体外部の相対湿度50%、成形体内部の相対湿度100%の雰囲気下にて、測定開始から30日目の酸素透過率を測定した。測定は、酸素透過率測定装置(MOCON社製、商品名「OX-TRAN 2-21 ML」)を使用した。測定値が低いほど、酸素バリア性が良好であることを示す。なお、測定の検出下限界は酸素透過率5×10-5mL/(0.21atm・day・package)である。
40℃、成形体外部の相対湿度100%の雰囲気下にて、測定開始から10日目の水蒸気透過率を測定した。測定は、水蒸気透過率測定装置(MOCON社製、商品名「PERMATRAN-W 3/33G」)を使用した。測定値が低いほど、水蒸気バリア性が良好であることを示す。なお、測定の検出下限界は水蒸気透過率5×10-4g/(day・package)である。
バイアルの内容物視認性を目視にて観察した。内容物の体積、色調確認ができて、視認性に問題ないものを合格とした。
バイアルを40℃、90%RH下にて1カ月保存した後、純水50mLを満杯充填し、その後、ゴム栓及びアルミキャップにて密封した。このようにして得られた密封容器を2mの高さから落下させ、そのときの容器外観を調査した。この密封容器を20個用意して、20個についての容器外観を調査した。
バイアルを40℃、90%RH下にて1カ月保存した後、純水50mLを満杯充填し、その後、ゴム栓及びアルミキャップにて密封した。このようにして得られた密封容器を40℃、60%RH下にて4カ月保存し、その後、純水中のトータルカーボン量(以下、TOC)を測定した。
(TOC測定)
装置 :株式会社島津製作所製 TOC-VCPH
燃焼炉温度 :720℃
ガス・流量 :高純度空気、TOC計部150mL/min
注入量 :150μL
検出限界 :1μg/mL
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例2-1と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例2-1と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例2-1と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例2-1と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例2-1と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
EVOHを非晶ポリアミド(三菱エンジニアリングプラスチックス株式会社製、商品名「NOVAMID X21-F07」、以下、「6IT」とも略する。)に代え、層A用の射出シリンダー温度を260℃とした以外は、実施例2-1と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例2-7と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例2-7と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例2-7と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例2-7と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例2-7と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。結果を表3に示す。
層を構成する樹脂としてシクロオレフィンポリマー(日本ゼオン株式会社製、商品名「ZEONEX 690R」)100質量部を用いたこと以外は、実施例2-1と同様に行い、実施例2-1と同形状の単層のバイアルを製造した。得られたバイアルの性能評価を実施例2-1と同様に行った。評価結果を表3に示す。
層を構成する樹脂としてポリカーボネート(Sabic社製、商品名「レキサン144R」)100質量部を用いたこと以外は、実施例2-1と同様に行い、実施例2-1と同形状の単層バイアルを製造した。得られたバイアルの性能評価を実施例2-1と同様に行った。評価結果を表3に示す。
ジエステル化合物A及びステアリン酸コバルトを用いなかった以外は、実施例2-1と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。これらの結果を表3に示す。
ジエステル化合物A及びステアリン酸コバルトを用いなかった以外は、実施例2-7と同様にして多層バイアルを作製して、実施例2-1と同様の評価を行った。これらの結果を表3に示す。
ナイロンMXD6(三菱瓦斯化学株式会社製、商品名「S7007」)100質量部に対し、ステアリン酸コバルト(II)をコバルト量が0.04質量部となるようドライブレンドして得られた混合物を、直径37mmのスクリューを2本有する2軸押出機に15kg/hの速度で供給し、シリンダー温度280℃の条件にて溶融混練を行い、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることにより、酸素吸収性組成物(M)を得た。酸素吸収性組成物(1)に代えてこの酸素吸収性組成物(M)を用いたこと以外は、実施例2-1と同様に行い、バイアルを製造した。得られたバイアルの性能評価を実施例2-1と同様に行った。評価結果を表3に示す。
2)単位はg/(day・package)で、検出下限界は5×10-4g/(day・package)である。
3)検出下限界は0.1(μg/mL)である。
上記した合成例1~4にて作製したテトラリン環を有するジエステル化合物A~D、及び合成例5にて作製したテトラリン環を有するジアミド化合物E、及び合成例6にて作製したテトラリン環を有する酸無水物Fを用いた。
直径37mmのスクリューを2本有する2軸押出機を用いて、エチレン-ビニルアルコール共重合体(株式会社クラレ製、商品名「エバールL171B」、以下、「EVOH」とも略する。)95質量部に対し、ジエステル化合物A5質量部、及び、コバルト量が0.05質量部となるようステアリン酸コバルト(II)を220℃で溶融混練し、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることで酸素吸収性組成物(1)を得た。次いで、下記に示すとおり、この酸素吸収性組成物(1)を用いて、酸素吸収性医療用多層成形体であるバイアルを製造した。その後、得られたバイアルの性能評価を、以下に示すとおりに行った。評価結果を表4に示す。
下記の条件により、ポリエステルを含有する樹脂層(層B)を構成するポリエステルを射出シリンダーから射出し、次いで酸素吸収層(層A)を構成する酸素吸収性組成物(1)を別の射出シリンダーから、層Bを構成するポリエステルと同時に射出し、次に層Bを構成するポリエステルを必要量射出して射出金型内キャビティーを満たすことにより、B/A/Bの3層構成の射出成形体を得た。その後、得られた射出成形体を所定の温度まで冷却し、ブロー金型へ移行し、ブロー成形を行うことで、バイアル(ボトル部)を製造した。ここで、バイアルの総質量は24gとし、層Aの質量はバイアルの総質量の30質量%とした。また、層Bを構成するポリエステルとしては、ポリエチレンテレフタレート樹脂(日本ユニペット株式会社製、商品名「RT-553C」、以下「PET」とも略する。)を使用した。
全長89mm、外径40mmφ、肉厚1.8mmとした。なお、バイアルの製造には、射出ブロー一体型成形機(UNILOY製、型式:IBS 85、4個取り)を使用した。
(バイアルの成形条件)
層A用の射出シリンダー温度:220℃
層B用の射出シリンダー温度:280℃
射出金型内樹脂流路温度 :280℃
ブロー温度 :150℃
ブロー金型冷却水温度 :15℃
得られたバイアルの酸素透過率の測定、成形後の外観評価、落下試験、溶出試験について、以下の方法及び基準にしたがって測定し、評価した。
23℃、成形体外部の相対湿度50%、成形体内部の相対湿度100%の雰囲気下にて、測定開始から30日目の酸素透過率を測定した。測定は、酸素透過率測定装置(MOCON社製、商品名「OX-TRAN 2-21 ML」)を使用した。測定値が低いほど、酸素バリア性が良好であることを示す。なお、測定の検出下限界は酸素透過率5×10-5mL/(0.21atm・day・package)である。
バイアルの内容物視認性を目視にて観察した。視認性に問題ないものを合格とした。
バイアルを40℃、90%RH下にて1カ月保存した後、純水50mLを満杯充填し、その後、ゴム栓及びアルミキャップにて密封した。このようにして得られた密封容器を2mの高さから落下させ、そのときの容器外観を調査した。なお、落下試験は、20個の容器を用意し、これらについて同様の条件で試験した。
バイアルを40℃、90%RH下にて1カ月保存した後、純水50mLを満杯充填し、その後、ゴム栓及びアルミキャップにて密封した。このようにして得られた密封容器を40℃、60%RH下にて4カ月保存し、その後、純水中のトータルカーボン量(以下、TOC)を測定した。
(TOC測定)
装置 :株式会社島津製作所製 TOC-VCPH
燃焼炉温度 :720℃
ガス・流量 :高純度空気、TOC計部150mL/min
注入量 :150μL
検出限界 :1μg/mL
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例3-1と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例3-1と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例3-1と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例3-1と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例3-1と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
EVOHを非晶ポリアミド(三菱エンジニアリングプラスチックス株式会社製、商品名「NOVAMID X21-F07」、以下、「6IT」とも略する。)に代え、層A用の射出シリンダー温度を260℃とした以外は、実施例3-1と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例3-7と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例3-7と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例3-7と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例3-7と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例3-7と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。結果を表4に示す。
ジエステル化合物A及びステアリン酸コバルトを用いなかった以外は、実施例3-1と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。これらの結果を表4に示す。
ジエステル化合物A及びステアリン酸コバルトを用いなかった以外は、実施例3-7と同様にして多層バイアルを作製して、実施例3-1と同様の評価を行った。これらの結果を表4に示す。
ナイロンMXD6(三菱瓦斯化学株式会社製、商品名「S7007」)100質量部に対し、ステアリン酸コバルト(II)をコバルト量が0.04質量部となるようドライブレンドして得られた混合物を、直径37mmのスクリューを2本有する2軸押出機に15kg/hの速度で供給し、シリンダー温度280℃の条件にて溶融混練を行い、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることにより、酸素吸収性組成物(M)を得た。酸素吸収性組成物(1)に代えてこの酸素吸収性組成物(M)を用い、層B用の射出シリンダー温度を260℃とした以外は、実施例3-1と同様に行い、バイアルを製造した。得られたバイアルの性能評価を実施例3-1と同様に行った。評価結果を表4に示す。
上記した合成例1~4にて作製したテトラリン環を有するジエステル化合物A~D、及び合成例5にて作製したテトラリン環を有するジアミド化合物E、及び合成例6にて作製したテトラリン環を有する酸無水物Fを用いた。
直径37mmのスクリューを2本有する2軸押出機を用いて、エチレン-ビニルアルコール共重合体(株式会社クラレ製、商品名「エバールL171B」、以下、「EVOH」とも略する。)95質量部に対し、ジエステル化合物A5質量部、及び、コバルト量が0.05質量部となるようステアリン酸コバルト(II)を220℃で溶融混練し、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることで酸素吸収性組成物(1)を得た。次いで、下記に示すとおり、この酸素吸収性組成物(1)を用いて、酸素吸収性医療用多層成形体であるシリンジを製造した。得られたシリンジの性能評価を、以下に示すとおりに行った。評価結果を表5に示す。
下記の条件により、樹脂層(層B)を構成する熱可塑性樹脂を射出シリンダーから射出し、次いで酸素吸収層(層A)を構成する酸素吸収性組成物(1)を別の射出シリンダーから、層Bを構成する熱可塑性樹脂と同時に射出し、次に層Bを構成する熱可塑性樹脂を必要量射出して射出金型内キャビティーを満たすことにより、B/A/Bの3層構成のシリンジを製造した。ここで、シリンジの総重量は1.95gとし、層Aの質量はシリンジの総質量の30質量%とした。また、層Bを構成する熱可塑性樹脂としては、シクロオレフィンコポリマー(Ticona GmbH製、商品名「TOPAS6013」、以下「COC」とも略する。)を使用した。
ISO11040-6に準拠した内容量1cc(スタンダード)とした。なお、シリンジの製造には、射出成型機(日精エー・エス・ビー機械株式会社製、型式:ASB-12N/10)を使用した。
(シリンジの成形条件)
層A用の射出シリンダー温度:220℃
層B用の射出シリンダー温度:280℃
射出金型内樹脂流路温度 :280℃
金型温度 :18℃
得られたシリンジの酸素透過率の測定、成形後の外観評価、耐衝撃試験、溶出試験について、以下の方法及び基準にしたがって測定し、評価した。
23℃、成形体外部の相対湿度50%、成形体内部の相対湿度100%の雰囲気下にて、測定開始から30日目の酸素透過率を測定した。測定は、酸素透過率測定装置(MOCON社製、商品名:OX-TRAN 2-21 ML)を使用した。測定値が低いほど、酸素バリア性が良好であることを示す。なお、測定の検出下限界は酸素透過率5×10-5mL/(0.21atm・day・package)である。
シリンジの内容物視認性を目視にて観察した。視認性に問題ないものを合格とした。
シリンジを40℃、90%RH下にて30日保存した後、50gの金属球をシリンジ胴部に2mの高さから落下させ、このときの破壊の有無を20個のサンプルに対して調査した。なお、落下試験は、20個の容器を用意し、これらについて同様の条件で試験した。
シリンジを40℃、90%RH下にて30日間保存した後、純水1ccを充填し、トップキャップ及びガスケットを装着したプランジャーで密封した。このようにして得られたシリンジを40℃、60%RH下にて120日間保存し、その後、純水中のトータルカーボン量(以下、TOC)を測定した。
(TOC測定)
装置 :株式会社島津製作所製 TOC-VCPH
燃焼炉温度 :720℃
ガス・流量 :高純度空気、TOC計部150mL/min
注入量 :150μL
検出限界 :1μg/mL
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例4-1と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例4-1と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例4-1と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例4-1と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例4-1と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
EVOHを非晶ポリアミド(三菱エンジニアリングプラスチックス株式会社製、商品名「NOVAMID X21-F07」、以下、「6IT」とも略する。)に代え、層A用の射出シリンダー温度を260℃とした以外は、実施例4-1と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例4-7と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例4-7と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例4-7と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例4-7と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例4-7と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
COCをポリプロピレン(日本ポリプロ株式会社製、商品名「MG03B」、以下、「PP」とも略する。)に代え、層B用の射出シリンダー温度を220℃とした以外は、実施例4-1と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行なった。これらの結果を表5に示す。
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例4-13と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例4-13と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例4-13と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例4-13と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例4-13と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
酸素吸収性組成物(1)に代えてCOCを使用し、層A用の射出シリンダー温度を280℃とした以外は実施例4-1と同様に行ない、実施例4-1と同形状の単層シリンジを作製して、実施例4-1と同様の評価を行なった。これらの結果を表5に示す。
酸素吸収性組成物(1)に代えてPPを使用した以外は実施例4-13と同様に行ない、実施例4-1と同形状の単層シリンジを作製して、実施例4-1と同様の評価を行なった。これらの結果を表5に示す。
ジエステル化合物A及びステアリン酸コバルトを用いなかった以外は、実施例4-1と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ジエステル化合物A及びステアリン酸コバルトを用いなかった以外は、実施例4-7と同様にして多層シリンジを作製して、実施例4-1と同様の評価を行った。これらの結果を表5に示す。
ナイロンMXD6(三菱瓦斯化学株式会社製、商品名「S7007」)100質量部に対し、ステアリン酸コバルト(II)をコバルト量が0.04質量部となるようドライブレンドして得られた混合物を、直径37mmのスクリューを2本有する2軸押出機に15kg/hの速度で供給し、シリンダー温度280℃の条件にて溶融混練を行い、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることにより、酸素吸収性組成物(M)を得た。酸素吸収性組成物(1)に代えてこの酸素吸収性組成物(M)を用い、層B用の射出シリンダー温度を260℃とした以外は、実施例4-1と同様に行い、シリンジを製造した。得られたシリンジの性能評価を実施例4-1と同様に行った。評価結果を表5に示す。
上記した合成例1~4にて作製したテトラリン環を有するジエステル化合物A~D、及び合成例5にて作製したテトラリン環を有するジアミド化合物E、及び合成例6にて作製したテトラリン環を有する酸無水物Fを用いた。
直径37mmのスクリューを2本有する2軸押出機を用いて、エチレン-ビニルアルコール共重合体(株式会社クラレ製、商品名「エバールL171B」、以下、「EVOH」とも略する。)95質量部に対し、ジエステル化合物A5質量部、及び、コバルト量が0.05質量部となるようステアリン酸コバルト(II)を220℃で溶融混練し、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることで酸素吸収性組成物(1)を得た。次いで、下記に示すとおり、この酸素吸収性組成物(1)を用いて、酸素吸収性医療用多層成形体であるバイアルを製造した。その後、得られたバイアルの性能評価を、以下に示すとおりに行った。評価結果を表6に示す。
下記の条件により、樹脂層(層B)を構成する熱可塑性樹脂を射出シリンダーから射出し、次いで酸素吸収層(層A)を構成する酸素吸収性組成物(1)を別の射出シリンダーから、層Bを構成する熱可塑性樹脂と同時に射出し、次に層Bを構成する熱可塑性樹脂を必要量射出して射出金型内キャビティーを満たすことにより、B/A/Bの3層構成の射出成形体を得た。その後、得られた射出成形体を所定の温度まで冷却し、ブロー金型へ移行し、ブロー成形を行うことで、バイアル(ボトル部)を製造した。ここで、バイアルの総質量は24gとし、層Aの質量はバイアルの総質量の30質量%とした。層Bを構成する熱可塑性樹脂としては、シクロオレフィンポリマー(日本ゼオン株式会社製、商品名「ZEONEX690R」)を使用した。
全長89mm、外径40mmφ、肉厚1.8mmとした。なお、バイアルの製造には、射出ブロー一体型成形機(UNILOY製、型式:IBS 85、4個取り)を使用した。
(バイアルの成形条件)
層A用の射出シリンダー温度:220℃
層B用の射出シリンダー温度:280℃
射出金型内樹脂流路温度 :280℃
ブロー温度 :150℃
ブロー金型冷却水温度 :15℃
得られたバイアルの酸素透過率の測定、成形後の外観評価、落下試験、溶出試験について、以下の方法及び基準にしたがって測定し、評価した。
得られたバイアルの酸素透過率の測定、成形後の外観評価、落下試験、溶出試験について、以下の方法及び基準にしたがって測定し、評価した。
23℃、成形体外部の相対湿度50%、成形体内部の相対湿度100%の雰囲気下にて、測定開始から30日目の酸素透過率を測定した。測定は、酸素透過率測定装置(MOCON社製、商品名「OX-TRAN 2-21 ML」)を使用した。測定値が低いほど、酸素バリア性が良好であることを示す。なお、測定の検出下限界は酸素透過率5×10-5mL/(0.21atm・day・package)である。
バイアルの内容物視認性を目視にて観察した。内容物の体積、色調確認ができて、視認性に問題ないものを合格とした。
バイアルを40℃、90%RH下にて30日間保存した後、純水50mLを満杯充填し、その後、ゴム栓及びアルミキャップにて密封した。このようにして得られた密封容器を2mの高さから落下させ、そのときの容器外観を調査した。なお、落下試験は、20個の容器を用意し、これらについて同様の条件で試験した。
バイアルを40℃、90%RH下にて30日間保存した後、純水50mLを満杯充填し、その後、ゴム栓及びアルミキャップにて密封した。このようにして得られた密封容器を40℃、60%RH下にて120日間保存し、その後、純水中のトータルカーボン量(以下、TOC)を測定して溶出した不純物の量を測定した。
(TOC測定)
装置 :株式会社島津製作所製 TOC-VCPH
燃焼炉温度 :720℃
ガス・流量 :高純度空気、TOC計部150mL/min
注入量 :150μL
検出限界 :1μg/mL
(結合比測定方法)
等温滴定型熱量計(ITC;GE ヘルスケア社製、「Microcal VP-ITC」)を用い、5μMの抗原溶液(BIOLOGICAL Industries Ltd.社製、「FGF1-Mouse」)をセル側に充填し、モノクローナル抗体溶液を10μLずつセルに滴下しながら、測定温度25℃で、結合比を測定した。
(保存試験)
バイアルに、50μMに調整した、モノクローナル抗体(mAb1)(和光純薬工業株式会社製、商品名「ANTI FGF1, Monoclonal Antibody (mAb1)」)を1cc充填し、8℃、50%RH条件下で180日間保存した。溶媒にはライフテクノロジーズジャパン製、リン酸バッファー(PBS;pH7.4;1倍液体製品)を使用した。保存試験前及び180日保存後の抗体溶液の結合比を上記の方法で測定し、保存前後での抗体活性保持率を次式に基づいて求めた。
抗体活性保持率(%)
=(180日保存後の抗体溶液の結合比/保存前の抗体溶液の結合比)×100
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例5-1と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例5-1と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例5-1と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例5-1と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例5-1と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
EVOHを非晶ナイロン(三菱エンジニアリングプラスチックス株式会社製、商品名「NOVAMID X21-F07」、以下、「6IT」とも略する。)に代えた以外は、実施例5-1と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aをジエステル化合物Bに代えた以外は、実施例5-7と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aをジエステル化合物Cに代えた以外は、実施例5-7と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aをジエステル化合物Dに代えた以外は、実施例5-7と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aをジアミド化合物Eに代えた以外は、実施例5-7と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aを酸無水物Fに代えた以外は、実施例5-7と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
酸素吸収性組成物(1)に代えてシクロオレフィンポリマー(日本ゼオン株式会社製、商品名「ZEONEX690R」、以下、「COP」とも略する。)を100質量部用いたこと以外は実施例5-1と同様に行ない、実施例5-1と同形状の単層バイアルを作製して、実施例5-1と同様の評価を行なった。これらの結果を表6に示す。
ジエステル化合物Aを用いなかった以外は、実施例5-1と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ジエステル化合物Aを用いなかった以外は、実施例5-8と同様にして多層バイアルを作製して、実施例5-1と同様の評価を行った。これらの結果を表6に示す。
ナイロンMXD6(三菱瓦斯化学株式会社製、商品名「S7007」)100質量部に対し、ステアリン酸コバルト(II)をコバルト量が0.04質量部となるようドライブレンドして得られた混合物を、直径37mmのスクリューを2本有する2軸押出機に15kg/hの速度で供給し、シリンダー温度280℃の条件にて溶融混練を行い、押出機ヘッドからストランドを押し出し、冷却後、ペレタイジングすることにより、酸素吸収性組成物(M)を得た。酸素吸収性組成物(1)に代えてこの酸素吸収性組成物(M)を用いたこと以外は、実施例5-1と同様に行い、バイアルを製造した。得られたバイアルの性能評価を実施例5-1と同様に行った。評価結果を表6に示す。
Claims (13)
- 熱可塑性樹脂(b1)を含有する第1の樹脂層と、酸素吸収性組成物を含有する酸素吸収層と、熱可塑性樹脂(b2)を含有する第2の樹脂層との少なくとも3層をこの順に有する、酸素吸収性医療用多層容器であって、
前記酸素吸収性組成物が、下記一般式(1)で表されるテトラリン環を有する化合物を少なくとも1種、遷移金属触媒、及び熱可塑性樹脂(a)を含む、酸素吸収性医療用多層容器。
- 前記一般式(1)で表されるテトラリン環を有する化合物が、2つ以上のカルボニル基を有する、請求項1に記載の酸素吸収性医療用多層容器。
- 前記一般式(1)において、R1~R12のうち、少なくとも2つ以上が、下記一般式(2)で表される一価の置換基である、請求項2に記載の酸素吸収性医療用多層容器。
-C(=O)-X (2)
(式中、Xは、水素原子、ヒドロキシ基、アルキル基、アルコキシ基、モノアルキルアミノ基、及びジアルキルアミノ基からなる群より選ばれる1つであり、複数のXは、同一であってもよいし、異なっていてもよい。) - 前記一般式(1)で表されるテトラリン環を有する化合物が、テトラリン環を2つ以上有する、請求項1~3のいずれか一F項に記載の酸素吸収性医療用多層容器。
- 前記酸素吸収性組成物中の、前記一般式(1)で表されるテトラリン環を有する化合物と前記熱可塑性樹脂(a)との総量に対する、前記一般式(1)で表されるテトラリン環を有する化合物の割合が、1~30質量%である、請求項1~4のいずれか一項に記載の酸素吸収性医療用多層容器。
- 前記遷移金属触媒は、マンガン、鉄、コバルト、ニッケル、及び銅からなる群より選ばれる少なくとも1種の遷移金属を含む、請求項1~5のいずれか一項に記載の酸素吸収性医療用多層容器。
- 前記酸素吸収性組成物中、前記遷移金属触媒が、前記一般式(1)で表されるテトラリン環を有する化合物と前記熱可塑性樹脂(a)との総量100質量部に対して、遷移金属量として、0.001~10質量部含まれる、請求項1~6のいずれか一項に記載の酸素吸収性医療用多層容器。
- 前記酸素吸収性組成物の熱可塑性樹脂(a)が、ポリオレフィン、ポリエステル、ポリアミド、エチレン-ビニルアルコール共重合体、植物由来樹脂及び塩素系樹脂からなる群より選択される少なくとも1種以上である、請求項1~7のいずれか一項に記載の酸素吸収性医療用多層容器。
- 前記熱可塑性樹脂(b1)がポリオレフィン(PO1)であり、
前記熱可塑性樹脂(b2)がポリオレフィン(PO2)である、請求項1~8のいずれか一項に記載の酸素吸収性医療用多層容器。 - 前記熱可塑性樹脂(b1)がポリエステル(PES1)であり、
前記熱可塑性樹脂(b2)がポリエステル(PES2)である、請求項1~8のいずれか一項に記載の酸素吸収性医療用多層容器。 - 前記ポリエステル(PES1)と前記ポリエステル(PES2)の少なくともいずれかにおいて、ジカルボン酸単位中の70モル%以上が、テレフタル酸、イソフタル酸、1,3-ナフタレンジカルボン酸、1,4-ナフタレンジカルボン酸、1,5-ナフタレンジカルボン酸、2,6-ナフタレンジカルボン酸、2,7-ナフタレンジカルボン酸、及びこれらのエステル形成性誘導体からなる群より選ばれる1種以上のジカルボン酸に由来する単位である、請求項10に記載の酸素吸収性医療用多層容器。
- 前記酸素吸収性医療用多層容器が、予め薬剤を密封状態下に収容し、使用に際し前記密封状態を解除して前記薬剤を注出し得るようにされた酸素吸収性プレフィルドシリンジである、請求項1~8のいずれか一項に記載の酸素吸収性医療用多層容器。
- バイオ医薬を、請求項1~12のいずれか一項に記載の酸素吸収性医療用多層容器内に保存するバイオ医薬の保存方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/767,114 US9994382B2 (en) | 2013-03-06 | 2014-03-06 | Oxygen-absorbing medical multilayer container and method for storing biological medicine |
EP14760939.0A EP2965907B1 (en) | 2013-03-06 | 2014-03-06 | Oxygen-absorbing medical multiwall container and biopharmaceutical storage method |
CN201480012172.9A CN105026151B (zh) | 2013-03-06 | 2014-03-06 | 吸氧性医疗用多层容器及生物药物的保存方法 |
KR1020157027458A KR20150128809A (ko) | 2013-03-06 | 2014-03-06 | 산소 흡수성 의료용 다층 용기 및 바이오 의약의 보존 방법 |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-044740 | 2013-03-06 | ||
JP2013-044734 | 2013-03-06 | ||
JP2013044740A JP6086220B2 (ja) | 2013-03-06 | 2013-03-06 | バイオ医薬の保存方法 |
JP2013-044737 | 2013-03-06 | ||
JP2013044755A JP6094940B2 (ja) | 2013-03-06 | 2013-03-06 | 酸素吸収性プレフィルドシリンジ |
JP2013-044754 | 2013-03-06 | ||
JP2013044734A JP6048742B2 (ja) | 2013-03-06 | 2013-03-06 | 酸素吸収性医療用多層容器 |
JP2013044737A JP6048743B2 (ja) | 2013-03-06 | 2013-03-06 | 酸素吸収性医療用多層容器 |
JP2013-044755 | 2013-03-06 | ||
JP2013044754A JP6048746B2 (ja) | 2013-03-06 | 2013-03-06 | 酸素吸収性医療用多層容器 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014136918A1 true WO2014136918A1 (ja) | 2014-09-12 |
Family
ID=51491425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/055877 WO2014136918A1 (ja) | 2013-03-06 | 2014-03-06 | 酸素吸収性医療用多層容器及びバイオ医薬の保存方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9994382B2 (ja) |
EP (1) | EP2965907B1 (ja) |
KR (1) | KR20150128809A (ja) |
CN (1) | CN105026151B (ja) |
TW (1) | TWI632061B (ja) |
WO (1) | WO2014136918A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016193731A (ja) * | 2015-03-31 | 2016-11-17 | 株式会社吉野工業所 | 調湿容器 |
CN108698730B (zh) | 2016-02-16 | 2021-07-13 | 三菱瓦斯化学株式会社 | 多层容器、包含其的注射器和物品、该多层容器的制造方法及其应用 |
ES2602162B1 (es) * | 2016-09-16 | 2017-06-20 | Grifols, S.A. | Contenedor para una solución de proteínas plasmáticas humanas y procedimiento de preparación del mismo |
WO2018091314A1 (en) * | 2016-11-15 | 2018-05-24 | Becton Dickinson France | Assessment of stability of biological product in prefilled syringes |
KR102459001B1 (ko) * | 2017-02-08 | 2022-10-25 | 미츠비시 가스 가가쿠 가부시키가이샤 | 멸균필 산소 흡수성 다층체의 제조 방법 |
WO2019065938A1 (ja) * | 2017-09-29 | 2019-04-04 | 大日本印刷株式会社 | 液体内容物包装用のシーラントフィルムとそれを含む積層体、及び液体内容物用包装材料、液体内容物用包装体 |
PL3804686T3 (pl) * | 2017-10-10 | 2023-12-11 | Sun Pharmaceutical Industries Ltd | Dożylna infuzyjna postać dawkowania dla pemetreksedu |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51136845A (en) | 1975-05-21 | 1976-11-26 | Saito Reisuke | Method of producing oxygen absorbent provided in container for food |
JPH01259870A (ja) | 1987-10-12 | 1989-10-17 | Terumo Corp | 中空糸膜型人工透析器 |
JPH02500846A (ja) | 1987-07-27 | 1990-03-22 | カヌードメタルボックス パブリック リミテド カンパニー | 包装に関する改良 |
JPH031488A (ja) | 1989-05-30 | 1991-01-08 | Toshiba Lighting & Technol Corp | 調光装置 |
JPH03122137A (ja) | 1989-10-06 | 1991-05-24 | Japan Synthetic Rubber Co Ltd | 熱可塑性樹脂成形品 |
JPH0463807A (ja) | 1990-03-06 | 1992-02-28 | Idemitsu Kosan Co Ltd | ノルボルネン系重合体およびその製造方法ならびに該重合体からなるフィルムおよびその製造方法 |
JPH05115776A (ja) | 1991-04-02 | 1993-05-14 | W R Grace & Co | 酸素掃去のための配合物、製品及び方法 |
JPH05300939A (ja) | 1992-02-12 | 1993-11-16 | Daikyo Seiko:Kk | 医療用具品 |
JPH05317411A (ja) | 1992-05-21 | 1993-12-03 | Nippon Zeon Co Ltd | 医療用器材 |
JPH08127641A (ja) | 1994-10-31 | 1996-05-21 | Mitsubishi Rayon Co Ltd | 医療用ポリエステル容器 |
JPH09234832A (ja) | 1995-12-28 | 1997-09-09 | Mitsubishi Gas Chem Co Inc | 酸素吸収多層フィルム及びその製造方法 |
JP2000319207A (ja) * | 1999-05-07 | 2000-11-21 | Nof Corp | テトラリンオリゴマー及びその製造方法 |
JP2001233809A (ja) * | 1999-12-14 | 2001-08-28 | Sumitomo Chem Co Ltd | 炭化水素類の酸化方法 |
JP2001252560A (ja) | 2000-03-14 | 2001-09-18 | Toyobo Co Ltd | 酸素吸収剤 |
JP2003521552A (ja) | 1998-03-25 | 2003-07-15 | シェブロン フィリップス ケミカル カンパニー エルピー | プラスチックフィルムそして飲料および食品の容器で使用するための酸化生成物が減少する酸素スカベンジャー |
WO2004018556A1 (ja) * | 2002-08-23 | 2004-03-04 | Toyo Seikan Kaisha,Ltd. | 酸素吸収性樹脂組成物及び積層体 |
JP2004229750A (ja) | 2003-01-28 | 2004-08-19 | Nipro Corp | プレフィルドシリンジ及びそのバレルの製造方法 |
JP2004323058A (ja) | 2003-04-24 | 2004-11-18 | Daikyo Seiko Ltd | 衛生品用容器及びその製造方法 |
WO2005105887A1 (ja) * | 2004-04-30 | 2005-11-10 | Toyo Seikan Kaisha, Ltd. | 酸素吸収性樹脂、酸素吸収性樹脂組成物及び酸素吸収性容器 |
JP2009108153A (ja) | 2007-10-29 | 2009-05-21 | Nippon Parison Kk | 樹脂組成物、単層樹脂成形品、及び、多層樹脂成形品 |
JP2011212447A (ja) * | 2011-05-23 | 2011-10-27 | Hosokawa Yoko Co Ltd | 医療容器用多層体および医療容器 |
WO2012102086A1 (ja) * | 2011-01-27 | 2012-08-02 | 東洋製罐株式会社 | 酸素吸収性樹脂組成物 |
WO2014034800A1 (ja) * | 2012-08-29 | 2014-03-06 | 三菱瓦斯化学株式会社 | 酸素吸収剤組成物及び酸素吸収剤包装体 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2626482B2 (ja) | 1993-07-29 | 1997-07-02 | 東洋製罐株式会社 | 包装米飯の製造法 |
JPH08133345A (ja) | 1994-11-07 | 1996-05-28 | Toppan Printing Co Ltd | 無菌化米飯包装体とその製造方法 |
US6454965B1 (en) * | 1999-03-24 | 2002-09-24 | Chevron Phillips Chemical Company Lp | Oxygen scavenging polymers in rigid polyethylene terephthalate beverage and food containers |
KR100715637B1 (ko) | 1999-12-14 | 2007-05-08 | 다이셀 가가꾸 고교 가부시끼가이샤 | 케톤, 알코올 및 하이드로과산화물의 제조 방법 |
US6485460B2 (en) * | 2001-01-12 | 2002-11-26 | Bracco Diagnostics, Inc. | Tamper evident syringe barrel |
JP2008050403A (ja) * | 2006-08-22 | 2008-03-06 | Mitsubishi Gas Chem Co Inc | 酸素吸収性樹脂 |
US8110261B2 (en) | 2007-03-29 | 2012-02-07 | Multisorb Technologies, Inc. | Oxygen absorbing plastic structure |
US20090162675A1 (en) | 2007-12-20 | 2009-06-25 | Graham Packaging Co. | Plastic packaging articles for oxygen sensitive products |
US9181414B2 (en) * | 2009-11-13 | 2015-11-10 | Plastipak Packaging, Inc. | Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions |
US11267951B2 (en) * | 2010-12-13 | 2022-03-08 | Cytec Technology Corp. | Stabilizer compositions containing substituted chroman compounds and methods of use |
TWI621529B (zh) | 2013-03-06 | 2018-04-21 | 三菱瓦斯化學股份有限公司 | 氧吸收性多層體、氧吸收性容器、氧吸收性密閉容器、氧吸收性ptp包裝體及使用此等之保存方法 |
-
2014
- 2014-03-06 EP EP14760939.0A patent/EP2965907B1/en not_active Not-in-force
- 2014-03-06 TW TW103107684A patent/TWI632061B/zh not_active IP Right Cessation
- 2014-03-06 WO PCT/JP2014/055877 patent/WO2014136918A1/ja active Application Filing
- 2014-03-06 US US14/767,114 patent/US9994382B2/en not_active Expired - Fee Related
- 2014-03-06 CN CN201480012172.9A patent/CN105026151B/zh not_active Expired - Fee Related
- 2014-03-06 KR KR1020157027458A patent/KR20150128809A/ko not_active Application Discontinuation
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51136845A (en) | 1975-05-21 | 1976-11-26 | Saito Reisuke | Method of producing oxygen absorbent provided in container for food |
JPH02500846A (ja) | 1987-07-27 | 1990-03-22 | カヌードメタルボックス パブリック リミテド カンパニー | 包装に関する改良 |
JPH01259870A (ja) | 1987-10-12 | 1989-10-17 | Terumo Corp | 中空糸膜型人工透析器 |
JPH031488A (ja) | 1989-05-30 | 1991-01-08 | Toshiba Lighting & Technol Corp | 調光装置 |
JPH03122137A (ja) | 1989-10-06 | 1991-05-24 | Japan Synthetic Rubber Co Ltd | 熱可塑性樹脂成形品 |
JPH0463807A (ja) | 1990-03-06 | 1992-02-28 | Idemitsu Kosan Co Ltd | ノルボルネン系重合体およびその製造方法ならびに該重合体からなるフィルムおよびその製造方法 |
JPH05115776A (ja) | 1991-04-02 | 1993-05-14 | W R Grace & Co | 酸素掃去のための配合物、製品及び方法 |
JPH05300939A (ja) | 1992-02-12 | 1993-11-16 | Daikyo Seiko:Kk | 医療用具品 |
JPH05317411A (ja) | 1992-05-21 | 1993-12-03 | Nippon Zeon Co Ltd | 医療用器材 |
JPH08127641A (ja) | 1994-10-31 | 1996-05-21 | Mitsubishi Rayon Co Ltd | 医療用ポリエステル容器 |
JPH09234832A (ja) | 1995-12-28 | 1997-09-09 | Mitsubishi Gas Chem Co Inc | 酸素吸収多層フィルム及びその製造方法 |
JP2003521552A (ja) | 1998-03-25 | 2003-07-15 | シェブロン フィリップス ケミカル カンパニー エルピー | プラスチックフィルムそして飲料および食品の容器で使用するための酸化生成物が減少する酸素スカベンジャー |
JP2000319207A (ja) * | 1999-05-07 | 2000-11-21 | Nof Corp | テトラリンオリゴマー及びその製造方法 |
JP2001233809A (ja) * | 1999-12-14 | 2001-08-28 | Sumitomo Chem Co Ltd | 炭化水素類の酸化方法 |
JP2001252560A (ja) | 2000-03-14 | 2001-09-18 | Toyobo Co Ltd | 酸素吸収剤 |
WO2004018556A1 (ja) * | 2002-08-23 | 2004-03-04 | Toyo Seikan Kaisha,Ltd. | 酸素吸収性樹脂組成物及び積層体 |
JP2004229750A (ja) | 2003-01-28 | 2004-08-19 | Nipro Corp | プレフィルドシリンジ及びそのバレルの製造方法 |
JP2004323058A (ja) | 2003-04-24 | 2004-11-18 | Daikyo Seiko Ltd | 衛生品用容器及びその製造方法 |
WO2005105887A1 (ja) * | 2004-04-30 | 2005-11-10 | Toyo Seikan Kaisha, Ltd. | 酸素吸収性樹脂、酸素吸収性樹脂組成物及び酸素吸収性容器 |
JP2009108153A (ja) | 2007-10-29 | 2009-05-21 | Nippon Parison Kk | 樹脂組成物、単層樹脂成形品、及び、多層樹脂成形品 |
WO2012102086A1 (ja) * | 2011-01-27 | 2012-08-02 | 東洋製罐株式会社 | 酸素吸収性樹脂組成物 |
JP2011212447A (ja) * | 2011-05-23 | 2011-10-27 | Hosokawa Yoko Co Ltd | 医療容器用多層体および医療容器 |
WO2014034800A1 (ja) * | 2012-08-29 | 2014-03-06 | 三菱瓦斯化学株式会社 | 酸素吸収剤組成物及び酸素吸収剤包装体 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2965907A4 |
Also Published As
Publication number | Publication date |
---|---|
KR20150128809A (ko) | 2015-11-18 |
TWI632061B (zh) | 2018-08-11 |
CN105026151A (zh) | 2015-11-04 |
CN105026151B (zh) | 2017-03-22 |
US20150368023A1 (en) | 2015-12-24 |
EP2965907B1 (en) | 2017-04-19 |
EP2965907A4 (en) | 2016-11-02 |
TW201505833A (zh) | 2015-02-16 |
US9994382B2 (en) | 2018-06-12 |
EP2965907A1 (en) | 2016-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2792713B1 (en) | Oxygen-absorbing resin molded article obtained from an oxygen-absorbing resin composition, and multilayer body, container, injection-molded article and medical container using the composition | |
WO2014136918A1 (ja) | 酸素吸収性医療用多層容器及びバイオ医薬の保存方法 | |
DK2784120T3 (en) | OXYGEN-ABSORBING RESIN COMPOSITION, OXYGEN-ABSORBING FORMED USE OF THE SAME, AND MULTIPLE BODIES, CONTAINERS, INJECTED BODIES AND MEDICINAL CONTAINERS, WHICH USES OXYGEN ORGANESE MEDICINE ORMS, OXYGEN ABOUT | |
JP6102234B2 (ja) | 医療用多層容器 | |
JP6048742B2 (ja) | 酸素吸収性医療用多層容器 | |
JP6048743B2 (ja) | 酸素吸収性医療用多層容器 | |
JP6086220B2 (ja) | バイオ医薬の保存方法 | |
JP6048746B2 (ja) | 酸素吸収性医療用多層容器 | |
JP6015322B2 (ja) | 医療用多層容器 | |
JP6094940B2 (ja) | 酸素吸収性プレフィルドシリンジ | |
JP6051896B2 (ja) | バイオ医薬の保存方法 | |
JP6056439B2 (ja) | プレフィルドシリンジ | |
JP6056440B2 (ja) | バイオ医薬の保存方法 | |
JP6015344B2 (ja) | バイオ医薬の保存方法 | |
JP6102229B2 (ja) | 医療用多層容器 | |
JP6020108B2 (ja) | 医療用多層容器 | |
WO2023233984A1 (ja) | 樹脂組成物 | |
JP6098238B2 (ja) | 薬液が充填された容器の保存方法 | |
JP5966852B2 (ja) | プレフィルドシリンジ | |
JP2014171404A (ja) | アルコール飲料の保存方法 | |
JP2018135310A (ja) | アドレナリン含有薬液の保存方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480012172.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14760939 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14767114 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2014760939 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014760939 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20157027458 Country of ref document: KR Kind code of ref document: A |